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General aspects of Lung Cancer
Lung cancer is one of the most commonly occurring cancers in the world, with 
approximately 2 million new patients in 2018 (1). The global epidemic of lung cancer 
is primarily caused by tobacco smoking (2, 3), accounting for 80-90% of lung cancer 
cases (2). Lung cancer has a high mortality rate in the Netherlands; only 19% of the 
patients are alive 5 years after diagnosis (based on the period 2011-2015) (4). In 
2018, 13.800 people were newly diagnosed with lung cancer in the Netherlands (4). 
Lung cancer is generally divided into 2 major subtypes; Non-Small Cell Lung Cancer 
(NSCLC, 80%) and Small Cell Lung Cancer (SCLC, 15%). SCLC-patients have the worst 
prognosis with a 5 year overall survival (OS) of 8% compared to 20% for NSCLC 
(4). Lung cancer is staged based on the TNM principle: extension of the primary 
tumor (T-stage), involved lymph nodes (N-stage) and presence of distant metastasis 
(M-stage) (5). When there is a large primary tumor and/or involvement of mediastinal 
lymph nodes, but without distant metastasis, it is defined as Locally-Advanced Non-
Small Cell Lung Cancer (LA-NSCLC), also known as stage III. About 25% of all NSCLC 
patients present with LA-NSCLC at diagnosis. This stage is often inoperable due to 
local or regional tumor extension. Therefore, these patients are often treated with a 
combination of systemic treatment and radical radiotherapy. This thesis focused on 
studies to optimize radiotherapy for patients with LA-NSCLC.
Treatment of locally advanced NSCLC 
Since the mid-1990s, the standard treatment for LA-NSCLC has been thoracic 
radiotherapy.  After the meta-analysis of the Non-Small Cell Lung Cancer Collaborative 
Group in 1995 (6), the value of additional chemotherapy was established. An absolute 
OS benefit of 10%, 4% and 5% for 1, 2 and 5 years respectively, was reported in this 
meta-analysis in favor of radiotherapy combined with chemotherapy compared to 
radiotherapy alone. In 2010, a meta-analysis (7) showed an absolute OS benefit of 
5.7% and 4.5% at 3 and 5 years for concurrent chemoradiation (CCRT) compared 
to sequential chemoradiation (SCRT). Currently, for patients with LA-NSCLC, the 
treatment of choice is CCRT (7, 8). Nonetheless, with 2-year OS rates ranging between 
44 and 59%, there is certainly room for improvement (9-11). Recently, a phase III 
trial investigating the potential benefits from adjuvant immunotherapy after CCRT in 
LA-NSCLC patients, reported significant improvements of progression free survival 
(PFS) (median PFS 5.6 months versus 17.2 months) and OS ( 2-year OS 55.6% versus 
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66.3%) (12). Therefore, adjuvant immunotherapy after CCRT, in patients without 
tumor progression, is standard of care in the Netherlands since 2019. The studies 
described in this thesis have included patients who were treated between 2008 and 
2017, when CCRT alone was standard of care for LA-NSCLC. 
NSCLC is a heterogeneous disease and together with the increase of treatment 
options such as chemotherapy, molecular targeted agents, immunotherapy, 
optimized radiotherapy schemes/techniques, and new surgery techniques, it is 
important to select the best treatment (or combinations) for each individual patient. 
Moreover, the emergence of novel parameters such as genomics, imaging modalities 
and new biomarkers calls for more innovative models to depict the best treatment 
for each patients, while taking into account several interdependencies between risk 
markers. Current prediction models use baseline characteristics to predict treatment 
outcomes (13). The use of baseline characteristics only, currently limits these models 
to a moderate predictive accuracy. A major improvement might be to incorporate 
novel longitudinal risk parameters into dynamic models that can be updated during 
treatment and/or follow-up. Such dynamic models can serve personalized treatment 
choices, e.g. to distinguish in which patient a resection after CCRT needs to be 
considered. 
Optimization of radiotherapy by dose alteration
With the theory that increasing the radiotherapy dose improves local control and 
OS, dose-escalation is an appealing option (14, 15). The excellent local control and 
OS reported for limited stage NSCLC patients treated with stereotactic ablative 
radiotherapy (SABR) (16) substantiates this theory. Safety and efficacy of dose 
escalation for LA-NSCLC was studied in several studies (9, 14, 17-20). A large phase 
III trial (RTOG-0617) (9) reported worse OS for the high dose arm (74 Gy, 2Gy 
fractions) compared to the standard arm (60 Gy, 2Gy fractions); 20.3 versus 28.7 
months respectively. Furthermore, an increase of acute toxicity was seen in the dose-
escalation arm. A recent Swedish randomized dose escalation phase II trial (19) (68 
Gy versus maximum 84 Gy in 2 Gy per fraction) was prematurely terminated (N=36, 
18 in each arm) due to excessive toxicity; 7 toxicity related death due to esophageal 
perforations and pneumonitis of which 5 in the dose-escalated arm and 2 in the 
standard arm. In both studies, dose escalation was performed by extending the 
overall treatment time. Since the outcomes of these recent trials, there is common 
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opinion that dose escalation with prolonged overall treatment time is not effective. 
Therefore, hypofractionation should be used in further studies focusing on dose-
escalation. In our institute a mildly hypofractionated radiotherapy schedule is used of 
24x2.75 Gy, once daily, 5 times a week (17). Compared to the conventional schedule 
of 60 Gy in 30 fractions, this hypofractionated schedule results in a reduction of more 
than one-week overall treatment time; 32 days versus 40 days. Besides, a higher 
biological effective dose is given, with the expectation of improved local control. The 
type of chemotherapy administered for concurrent chemotherapy varies across 
centers in the Netherlands (21). Due to the advantageous toxicity profile, daily low 
dose Cisplatin is preferred in the Netherlands Cancer Institute. Several studies (10, 
17, 18, 20, 22) reported a high local control and a low toxicity of this CCRT-regime. It 
is well known that local control is associated with OS in lung cancer. Van Diessen et.al 
(22) investigated the pattern of local and regional failure in LA-NSCLC patients treated 
with CCRT. The incidence of local and regional failure as site of first failure was 16% 
and 6%, respectively. This difference was significantly associated with the difference in 
volume of the primary tumor and lymph nodes. The risk of severe pulmonary, cardiac 
and esophageal toxicities induced by CCRT, are mainly determined by the involvement 
of the mediastinal lymph nodes, the size and location of the primary tumor and the 
total radiation dose. Since involved mediastinal lymph nodes have generally a smaller 
volume compared to the primary tumor in the majority of patients, an appealing 
strategy is to prescribe a differentiated dose to the lymph nodes and primary tumor 
to reduce acute and late toxicities in LA-NSCLC patients treated with CCRT.
Patient selection for oligometastatic disease 
When a NSCLC patient is diagnosed with metastases, from a historical point of view, 
the treatment aim is palliative; to prolong PFS or to improve quality of life. In 1995, the 
term ‘oligometastasis’ was introduced by Hellman and Weichselbach (23). This concept 
implies that patients with a limited number of metastases might still achieve long 
term OS if all these metastases are treated with a radical schedule (24-26). With more 
systemic treatment options for NSCLC patients (e.g. molecular targeted therapies and 
immune checkpoint inhibitors) (27), there is an increasing interest in a more radical 
approach for oligometastatic disease (28-30). SABR is a highly advanced radiotherapy 
technique, which is able to deliver very precisely a high biologically effective dose to 
a small tumor (31). SABR is a very effective treatment with few side effects, to treat 
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(oligo) metastases in for example brain, liver, lungs, bone and adrenal glands. Besides 
SABR, radiofrequency ablation and surgery are also frequently used techniques to 
treat (oligo) metastases. Between 2008 and 2016 we performed an observationally 
study in patients that were selected during a tumor board meeting to have a radical 
approach of oligometastatic NSCLC (32). In this time period a radical approach for 
oligo metastatic NSCLC was not standard of care (28, 33). Recent years, evidence is 
growing that a radical treatment for oligometastatic NSCLC is beneficially. Recently 
published phase 2 trials, showed a significantly improved OS in oligometastatic NSCLC 
patients who were treated with a radical treatment on all metastases (26, 30). At the 
moment, phase 3 studies are ongoing (34, 35) to establish the role of such a radical 
approach in NSCLC finally. This will hopefully gather evidence, to confirm the benefit 
seen in randomized phase II trials of this therapeutic approach for oligometastatic 
disease, and will teach us which patient to select. 
Image Guided radiotherapy
The introduction of the 18F-fluorodeoxyglucose positron emission tomography (FDG-
PET) combined with CT, had a major impact on accurate staging of lung cancer 
patients. An FDG-PET is able to differentiate between an elevated glucose metabolism 
in tissues, which is characteristic for cancer and inflammation, and leads to a more 
accurate tumor staging; e.g. a better distinction between tumor and atelectasis or 
detection of distant metastasis (36). By combining the FDG-PET with the RT-planning 
CT, the delineation uncertainties of the gross tumor volume (GTV) are reduced (37). 
To take into account microscopic tumor extension, the GTV is expanded to the clinical 
target volume (CTV). To correct for geometric uncertainties, this CTV is expanded to a 
planning target volume (PTV) (38). In our institute the ‘van Herk’ margin recipe is used 
(39), which corrects for random and systemic errors and incorporates the size of the 
margin on individualized respiratory tumor motion.
Image guide radiotherapy (IGRT) visualizes the tumor and organs at risk (OAR) in 
the treatment room and corrects for differences between treatment planning and 
delivery. In the past, electronic portal imaging devices (EPID) with the use of megavolt or 
kilovolt imaging were used making 2D images. Nowadays most modern radiotherapy 
departments use linear accelerator integrated Cone Beam CT’s (CBCT) for imaging 
during radiotherapy (40). A CBCT is a type of CT-scanner, which can make in-room 3D 
and 4D (kV) images of the patient before, during and after the treatment using a single 
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rotation. The images made by the CBCT are registered to the images of the RT-planning 
CT based on anatomical structures (e.g. vertebrae, carina or the primary tumor). This 
registration can be used for tumor alignment, to observe anatomical changes and for 
dosimetric purposes (41). The accuracy of radiotherapy is affected by a diversity of 
geometrical uncertainties (e.g. set-up errors, baseline shifts and respiratory motion). 
The goal of IGRT is to increase this accuracy during a radiotherapy fraction (intra-
fraction) and between different fractions (inter-fraction). The repetitive CBCT’s made 
us also aware of intra thoracic anatomical changes during treatment in lung cancer. In 
the Netherlands, CBCT’s are typically analyzed by radiation therapy technician (RTT); 
the radiation oncologist is informed in case a change is observed. With the increased 
use of daily CBCT imaging, there was a clinical need for a clear and practical decision 
support system to guide the RTTs in prioritizing the anatomical changes. Since 2012, 
daily CBCT’s with online position verification and correction are made for lung cancer 
patients treated with radical intent in the Netherlands Cancer Institute. Schaake et al. 
(42) demonstrated that the PTV margins can be reduced when this daily online CBCT 
position verification is used. Subsequently, a PTV margin reduction with expected 
decrease in toxicity was clinically introduced in 2015 in our institute.  
These daily CBCT’s also resulted in an increase of imaging data of tumor volume 
changes during treatment. The predictive value of tumor volume changes has 
been studied previously (43-45). These studies hint towards a predictive potential 
for OS, when there was tumor volume change during treatment, but the observed 
associations were inconsistent and the performed studies included few patients. 
Furthermore, the performed analyses could have been too simplistic. For example, 
observed GTV-changes during treatment were dichotomized below or above the 
median (43-45). The assumption that 2 groups (above/below median) represent the 
treatment response of all NSCLC patients might be a misconception (46). In order 
to identify various subgroups of patients with distinct treatment responses, more 
advanced statistical techniques, such as latent class mixed modelling, could be useful 
(47-50). Hence, more research is needed to analyze the predictive potential of tumor 
volume change during radiotherapy for treatment outcome. 
Acute esophagus toxicity
The addition of chemotherapy concurrent with radiotherapy provokes a 
radiosensitizing effect leading to an improved local tumor control and OS, compared 
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to radiotherapy only or sequential chemoradiation (7). However, this comes at the 
cost of radiotherapy induced pulmonary, cardiac and esophageal toxicities. Toxicity in 
radiotherapy can be divided in acute (≤ 90 days after end of treatment) or late toxicity 
(> 90 days after end of treatment). A common radiotherapy induced toxicity is acute 
esophagus toxicity (AET) (51). This leads to decreased intake, weight loss, malnutrition 
and retrosternal pain, requiring analgesics, intravenous hydration, tube feeding, 
dietary supplements, hospitalization or a combination of these. To inform a patient 
thoroughly about the risk on toxicities before start of treatment, it is important that 
the normal tissue complication probability models (NTCP-models) clinically used to 
predict the risk on toxicities, are accurate. Several NTCP-models are used in clinical 
practice to predict the risk of AET (51-56). However, many of these models are based 
on 3D-conformal radiotherapy (3D-CRT) techniques. With the introduction of newer 
radiotherapy techniques like Intensity Modulated Radiotherapy (IMRT) and Volumetric 
Modulated Arc Therapy (VMAT), a more conformal dose distribution can be achieved 
(57, 58). These techniques give the opportunity to irradiate larger tumor volumes and 
increase organ sparing compared to 3D-CRT (59-61). However, this might result in 
dose inhomogeneity, which can lead to e.g. high dose areas in organs at risk, which 
are situated inside the PTV such as the esophagus. In addition, an increase of larger 
low dose areas in healthy tissue is frequently seen with IMRT and/or VMAT. This is due 
to the use of segments and greater amount of beam directions compared to 3D-CRT. 
Hence, patients who were not eligible for a radical radiotherapy schedule because of 
large tumor volumes in the 3D-CRT era, benefit due to IMRT and VMAT, and may be 
able to receive radiotherapy with a curative intent. These improvements in radiation 
dose characteristics have influence on the predictive performance of dose limiting 
toxicities, such as AET, of NTCP models. Therefore, the development of these new 
radiotherapy techniques and schedules requires a constant validation and update of 
the existing NTCP-models.
Purpose and outline of thesis
The primary aim of this thesis is to optimize radiotherapy for LA-NSCLC patients 
further. This aim is achieved by focusing on different aspects of the radiation 
treatment. The first part focused on the effect of margin reduction and dose de-
escalation of the dose on the mediastinal lymph nodes on toxicity and treatment 
outcome. Furthermore, we analyzed patients with oligo metastasized NSCLC that 
qualified for a radical treatment. The second part focused on imaging data of intra 
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thoracic and tumor volume changes collected during treatment on CBCT and its 
association with treatment outcome. In the last part of this thesis the prediction 
models of acute esophagus toxicity after CCRT are optimized. 
Part I Dose prescription and patient selection
Subject of the studies in the first part of this thesis is optimizing the treatment of LA-
NSCLC patients by adapting treatment dose prescription and execution. Since June 
2015, patients with LA-NSCLC are treated in our institute with a differentiated dose 
to the primary tumor and involved mediastinal lymph nodes. Simultaneously, the 
planning margins for both the primary tumor and the lymph nodes are reduced. We 
also changed the patient selection by treating patients with oligometastatic disease 
with a radical irradiation scheme. 
In chapter 2, the treatment outcome of the dose de-escalation and margins 
reductions to the lymph nodes and the effects on the incidence of toxicities of this 
dose de-escalation are studied in a large retrospective cohort. 
In chapter 3, the PFS and OS of oligometastatic NSCLC patients selected for a 
treatment with radical intent are described. 
Part II Image Guided Radiotherapy
With the increasing use of image guided radiotherapy for NSCLC patients, longitudinal 
imaging data of tumor volume reduction during the course of a radiotherapy 
treatment is available and intra thoracic anatomical changes are frequently detected. 
In chapter 4, the incidence of the different intra thoracic anatomical changes 
detected on CBCT during radiotherapy is described and a practical decision support 
system is introduced. 
In chapter 5, the association of tumor volume changes, detected on CBCT during 
concurrent chemoradiation for LA-NSCLC patients, with treatment outcome is 
studied.
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Part III Acute esophagus toxicity
In the last part of this thesis, prediction models for acute esophagus toxicity (AET) 
were analyzed and optimized after CCRT. Toxicity is nowadays scored in an electronic 
toxicity registration in the electronic medical record at the NKI, and with that, the (real 
world) data of treatment related toxicity can accordingly much easier be collected 
compared to the analog medical record. This real world data of toxicity scoring can 
be used for auditing toxicity prediction models.  
In chapter 6, the dose effect relation of AET and dose volume parameters of the 
esophagus for patients treated with CCRT are investigated. In this study, NTCP-models 
of AET of IMRT are compared with 3D-CRT. 
In chapter 7, the validity of real world data derived from an electronic toxicity 
registration is assessed. The electronic toxicity registration of AET before and after 
dose-de-escalation for the 2 cohorts as described in chapter 2 are used to validate 
the NTCP-models of AET for CCRT for NSCLC patients.
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(Chemo)Radiotherapy for locally advanced non-small lung cancer (LA-NSCLC) causes 
severe dysphagia due to the radiation dose to the mediastinal lymphadenopathy. 
Reducing the dose to the mediastinum and the margins to the planning target volume 
(PTV) might reduce severe toxicity rates. The results of both adaptations in LA-NSCLC 
patients receiving (chemo) radiotherapy were analysed.
Materials and methods
Three hundred and eight LA-NSCLC patients were included in an observational study. 
Both cohorts received hypofractionated RT (24x2.75 Gy) of 70 Gy (EQD210) to the 
primary tumour. The reference-cohort (N=170) received the same dose of 70 Gy 
(EQD210) to the involved lymph nodes, while the reduction-cohort (N=138) received 
24x2.42 Gy, biologically equivalent to 60 Gy (EQD210). Furthermore, the patient-specific 
PTV-margins for both the primary tumour and lymph nodes were reduced by 2-3mm 
in the reduction-cohort after implementing a carina based correction strategy. The 
effects on toxicity, regional failure and overall survival (OS) were assessed. 
Results
The acute grade 3 (G3) dysphagia and G3 pulmonary toxicity decreased significantly 
from 12.9% to 3.6% and 4.1% versus 0%, respectively. The regional failures were 
comparable: 5.9% versus 4.3% (p=0.546). The median OS was significantly different: 
26 months (reference-cohort) versus 35 months (reduction-cohort). After correction 
for confounders, the association between the reduction-cohort and OS remained 
significant (HR 0.63 versus HR 0.70).
Conclusion
A reduction in PTV-margins and dose from 70 Gy to 60 Gy to the involved lymph nodes 
in LA-NSCLC patients receiving (chemo) radiotherapy did not result in an increase in 
regional failures. Moreover, significantly lower acute toxicities and an improved OS 
were observed in the reduction-cohort. 




Concurrent chemoradiotherapy (cCRT) for locally advanced non-small cell lung 
cancer (LA-NSCLC) results in a 5-year overall survival (OS) of 32% [1, 2]. Local and 
regional failures as well as severe acute and late toxicities adversely affect OS [1, 3, 
4]. Determining the balance between optimal treatment outcomes and low toxicity 
rates is challenging. The risk of severe pulmonary, oesophageal and cardiac toxicity 
is mainly determined by the involvement of mediastinal lymph nodes, the size and 
location of the primary tumour and the total radiation dose [3, 5-7]. Dose-limiting 
toxicities include radiation pneumonitis, associated with mean lung dose (MLD), and 
severe acute and late dysphagia (grade 3 and higher), associated with the volume 
of the oesophagus receiving >50-60 Gy [8, 9]. Moreover, the RTOG-0617 trial 
demonstrated an association of heart dose and OS [1]. Similar findings were found in 
various other cohorts [10, 11]. The reported incidence of regional failures (RF) after 
radiotherapy for LA-NSCLC was generally lower than local failures (LF), around 10% 
versus 30% after 2 years [12-14]. We reported on prognostic factors predicting LF 
and RF after cCRT in detail, revealing that volume was the only significant factor [12]. 
Since involved mediastinal lymph nodes have a smaller volume compared to the 
primary tumour in the majority of patients, we hypothesized that the dose needed 
to control lymph node metastases might be lower than the dose needed to control 
the primary tumour. A consequence of a lower dose to the mediastinum might also 
induce an efficient reduction of the pulmonary, oesophageal and cardiac toxicity rates. 
Additionally, further decrease of the toxicity rates might be obtained by a margin 
reduction. Previously, Schaake et al. demonstrated that the planning target volume 
(PTV) margins for the tumour and the lymph nodes might be reduced due to a daily 
online carina based correction strategy [15]. Since June 2015, patients with LA-NSCLC 
were treated in our institute to a lower radiotherapy dose to the involved mediastinal 
lymph nodes of 58 Gy (24x2.42 Gy; EQD210=60 Gy), while the primary tumour was 
treated with 66 Gy (24x2.75 Gy; EQD210=70 Gy) by using a simultaneous integrated 
boost technique. Simultaneously, the planning margins for both the primary tumour 
and the lymph nodes were reduced. The aim of this study is to investigate the effects 
of this reduction of dose to the involved lymph nodes and PTV-margins on the 





A sequential design cohort study was performed including 308 patients with LA-
NSCLC between June 2013 and June 2017. All data were analysed retrospectively. 
Patient characteristics, treatment data and medical records were also retrospectively 
retrieved. Standard work-up consisted of a computed tomography (CT)-thorax, a 
total body 18Fluorodeoxyglucose positron emission tomography (FDG-PET)-CT-scan 
(performed within 4-6 weeks before treatment according to the NedPass protocol 
[16]), a contrast enhanced CT-scan or Magnetic Resonance Imaging (MRI)-scan of the 
brain and a pulmonary function test. Pathological confirmation of the primary tumour 
and/or lymph nodes was done. All pre- and post-treatment diagnostic examinations 
were available for all patients. The Institutional Review Board of our institute approved 
the study for retrospective data collection according to the European Privacy Law.
Radiotherapy preparation
Patients were treated with hypofractionated Intensity Modulated Radiotherapy (IMRT) 
of 66 Gy to the primary tumour and mediastinal lymph nodes in 24 fractions (overall 
treatment time 32 days), once daily, 5 times per week from June 2013 till June 2015. 
Following the linear-quadratic model and an α/β-ratio of 10 Gy, an absorbed dose of 
66 Gy in 24 fractions is biologically equivalent to 70 Gy in fractions of 2 Gy (EQD210). 
From June 2015, the dose to the involved mediastinal lymph nodes was reduced from 
66 Gy to 58.08 Gy in 24 fractions, which is equivalent to 60 Gy (EQD210). Therefore, the 
dataset was divided in two cohorts: the reference-cohort versus the reduction-cohort. 
Treatment consisted of sequential chemoradiotherapy (sCRT), cCRT or radiotherapy 
(RT) only. The concurrent regimen consisted of daily low dose Cisplatin intravenous (6 
mg/m², maximum 12 mg) 1-2 hours before each RT fraction. The chemotherapy in sCRT 
consisted of Cis- or Carboplatin combined with Gemcitabin, Etoposide or Pemetrexed 
according to the pathology. A four-dimensional (4D)-CT-scan with intravenous contrast 
was performed, from which a 3D-midposition-CT-scan (MidP) was reconstructed [17]. 
The FDG-PET-CT-scan was registered with the MidP to guide the separate delineation 
of the primary tumour and the involved lymph nodes. The following lymph nodes 
were considered tumour positive in the absence of pathological evidence: higher 
FDG-uptake than the mediastinal blood pool on the FDG-PET-CT-scan or growth on 
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the CT compared to the baseline CT. The gross tumour volume (GTV) of the primary 
tumour as well as the GTV of the lymph nodes were both expanded to a planning 
target volume (PTV). Subsequently, the PTV-margins were individualized according to 
the peak-to-peak respiratory amplitude movement of the tumour and lymph nodes. 
The margins in all directions from GTV to PTV consisted of 12 mm plus ¼ of the 
peak-to-peak amplitude in orthogonal directions as measured in the 4D-CT [18]. 
An isotropic PTV margin of 12 mm was used for the lymph nodes. The PTV-margins 
were adapted from June 2015 when a bony anatomy based correction strategy was 
replaced with a carina based correction strategy on the CBCT [15]. Reduction of the 
PTV-margins was applicable to all directions with a maximum in the cranio-caudal 
direction of 3.8mm for the lymph nodes and 2.1mm for the primary tumour. From 
then on, the PTV-margins varied between 9-11 mm. The following organs at risk (OAR) 
were delineated according to our institutional protocol: heart, spinal cord, lungs and 
oesophagus. For this study, the heart (sub)structures were delineated automatically 
using an automatic segmentation method [10]. The planning constraints were: 
oesophagus Dmax ≤66 Gy and V50Gy ≤50% (EQD210), MLD ≤20 Gy (EQD23), spinal cord 
≤52 Gy (EQD22), total heart ≤40 Gy and ⅔ of the heart ≤50 Gy and ⅓ of the heart 
≤66 Gy (EQD23). IMRT-plans were calculated using 10 MV photons. Dose distributions 
were calculated using collapsed cone inhomogeneity corrections (Pinnacle versions 
9.2-9.10, Philips, Best, The Netherlands). The dose inhomogeneity within the PTV was 
between the 90% and 115%. Treatment verification was done using daily cone beam 
CT-scans (CBCT) according to an on-line setup correction protocol and correction 
was performed immediately before the start of every fraction. Replanning was done 
in case of significant changes of the anatomy with an anticipated clinically relevant 
influence on the dose distribution [19].
Toxicity and follow-up (FU)
Toxicity was scored using the Common Toxicity Criteria for Adverse Events version 
4.0. Acute toxicity was scored from start of RT until 3 months after the last fraction. 
Late toxicity was calculated from 3 months after the last fraction. A CT-thorax 
was performed 6-8 weeks after treatment to evaluate the treatment response. 
Subsequently, FU was performed every 3-6 months with chest X-ray or CT-thorax. 




LF and RF were defined as an in-field failure within the PTV of the primary tumour 
(LF) and the involved lymph nodes (RF). In both cases, pathologic confirmation or an 
increase in tumor diameter of at least 20% compared to the previous CT-scan was 
scored as a failure (according to RECIST) and sometimes confirmed by PET. LF and 
RF were calculated from date of diagnosis until first date of failure, last date of FU or 
death. OS was calculated from the date of pathologically proven diagnosis until last 
date of FU or death. Progression-free survival (PFS) was calculated from the date of 
pathologically proven NSCLC until the date of first failure (local, regional, distant), last 
date of FU or death. LF, RF and PFS were classified based on FU-records, imaging 
reports of tumour progression and repeat CT-scans.
Statistical analysis
Patient and tumour characteristics at baseline are presented as the mean (+standard 
deviation (SD) or the median (+ interquartile range, IQR) and proportions in case of 
a categorical variable. The independent samples T-test was performed to compare 
characteristics in case of a normal distribution (age and OAR dose volume parameters). 
The Mann-Whitney U-test was used to compare continuous variables in non-normal 
distributions (volume of the primary tumour and lymph nodes). The Pearson’s chi-
squared test was performed to compare the patient and tumour characteristics as 
well as the toxicity and failure rates in case of binary, nominal or ordinal variables and 
a non-normal distribution. Kaplan-Meier survival curves for the reference-cohort and 
reduction-cohort were plotted for each endpoint. Log-rank tests were performed to 
assess differences in late toxicity, LF, RF, OS and PFS between the reference-cohort 
and reduction-cohort. Proportional hazards assumptions for each model were 
tested by interpretation of the survival plots. Cox proportional hazards analyses were 
performed to assess the independent effect of dose-reduction on each endpoint. 
First, a univariate model was constructed. Then, we subsequently adjusted for 
possible confounding or mediating variables. The variables included are known to 
be associated with dose-reduction and/or are closely related to outcome. To assess 
improvement of the model, percentage changes in the HR ≥10% were tested [20]. 
Since the toxicity profile of cCRT is different compared to sCRT and RT-only (sCRT/RT), 
a subgroup analysis was performed between cCRT and sCRT/RT [21]. P-values <0.05 
were considered statistically significant. The data were analysed using SPSS software, 
version 25.0, for Windows (IBM).




A total of 308 consecutive patients were included in this study with 170 patients in 
the reference-cohort and 138 patients in the reduction-cohort. The majority of the 
patients (70%) received cCRT in both cohorts. The median follow-up time was: 49 
months (IQR 39-53) 48 months (IQR 42-57) for the reference-cohort and 21 months 
(IQR 15-27) 27 months (IQR 22-34) for the reduction-cohort, respectively. Twenty 
patients were excluded: 3 patients who received 60 Gy (EQD210) before June 2015 
due to a high MLD (>20 Gy) and 17 patients who received 70 Gy (EQD210) to the 
mediastinum after June 2015. The reasons were: individually decided by clinician 
(n=5), inclusion of the hilar nodes within the primary tumour volume (n=7), by mistake 
(n=4) or treated within a study protocol (n=1). Patient and tumour characteristics are 
shown in Table 1; no significant differences were observed between the 2 cohorts, 
except T-stage: the patients with T0-X and T3 were unevenly distributed favouring the 
reference-cohort. However, the volume of the primary tumour was comparable. For 
both cohorts, the median GTV of the primary tumour was three-times larger than the 
GTV of the involved lymph nodes. The median radiation doses to the OAR are shown 
in Table 2. 









Median age (IQR) 65 (59-72) 65 (59-70) 65 (59-71) 0.192
Gender 0.188
Male 58.2% (99) 50.7% (70) 54.9% (169)
Female 41.8% (71) 49.3% (68) 45.1% (139)
Performance status 0.584
WHO 0 38.8% (66) 34.1% (47) 36.7% (113)
WHO 1 53.5% (91) 59.4% (82) 56.2% (173)



































































































































GTV = gross tumour volume; PTV = planning target volumes; IQR = interquartile range; RT = 
radiotherapy
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Table 2: The mean dose and standard deviation (SD) of the organs at risk stratified for the 
reference-cohort and reduction-cohort. 
























Spinal cord Dmax (Gy) 41.6 (7.9) 37.7 (9.9) <0.001
All doses are normalized total dose (EQD2) for spinal cord and plexus α/β=2 Gy; for lungs, heart 
and mediastinal envelope α/β=3 Gy and for the oesophagus α/β=10 Gy. SD = standard deviation; 
Heart V2=volume of the heart receiving ≥2 Gy; Oesophagus V50=volume of the oesophagus receiving 
≥50 Gy (EQD210); Lung V5=volume of the lungs receiving ≥5 Gy; MLD=mean lung dose; Spinal cord 
Dmax=maximum dose to 0.1cc of the volume.L
The overall ≥ grade 2 (G2) acute toxicity rates were significantly lower in the reduction-
cohort (Table 3A). G2 and G3 pulmonary toxicity, consisting of cough, dyspnea and 
radiation pneumonitis, was significantly lower in the reduction-cohort (20.6% versus 
4.3%; 1.8% versus 0.0%). G2 and G3 dysphagia was also significantly lower in the 
reduction-cohort: 48.2% vs. 37.0% and 12.9% versus 3.6%, respectively. However, 
the reduction in dose and margins did not result in a decreased late toxicity (Table 
3B). Late toxicity rates were comparable between the 2 cohorts, except G2 cough 
(7.1% versus 1.4%). An additional comparison between the 2 cohorts treated with 
cCRT or sCRT/RT regarding the acute toxicity rates showed significant differences of 
dysphagia and cough (supplemental Table S1a-b). This demonstrated the beneficial 
effect of the reduction-cohort independent of chemoradiotherapy-schedule. In total, 
13 patients (4.2%) died due to a G5 adverse event. In 5 patients, an acute G5 toxicity 
was reported, all were treated in the reference-cohort: 1 (0.6%) patient died due to 
a pulmonary haemorrhage and 4 (2.4%) patients died because of pneumonitis. Eight 
patients died due to a possible G5 late toxicity, of which 5 patients (2.9%) were treated 
in the reference-cohort: an oesophageal fistula (n=1), a pulmonary haemorrhage 
(n=1), pneumonitis (n=3) and respiratory insufficiency (n=1). In the reduction-cohort, 
3 patients (2.2%) died due to a possible G5: a fatal haemorrhage (n=1) and radiation 
pneumonitis (n=2). The proportion of patients that died due to an acute G5 adverse 
event was lower in the reduction-cohort (p=0.042), however, the incidence of late G5 
adverse events did not differ (p=0.668). 
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The LF and RF rates were not significantly different (Table 4 and Fig. 1a-b). The 
median PFS was not significantly different as well (supplementary material, Fig. S1b). 
However, a significant difference was found between the OS of the 2 cohorts (P=0.006, 
HR 0.63, 95%CI 0.45-0.88; Fig 1C). The median OS was 26 months (IQR 11-56) for 
the reference-cohort versus 35 months (IQR 19 – N.A.) for the reduction-cohort, 
respectively. The 1-, 2- and 3- year OS was 70.6%, 51.8% and 38.1% for the reference-
cohort and 87.6%, 66.8% and 49.4% for the reduction-cohort, respectively. Table 5 
represents a Cox proportional hazards model for OS in the reduction-cohort. MLD 
and pulmonary toxicity influenced the association to some extent, but not entirely. 
No differences were found in the association between the reduction-cohort and OS 
for cCRT or sCRT/RT (HR 0.67; HR 0.83).
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4: Local and regional failures (crude incidence and the 1- and 2-year rates) in relative 
and absolute number of the 308 patients for the 2 cohorts receiving 70 Gy (N=170) and 60 Gy 
(N=138) to the involved lymph nodes, while prescribing the tumor 70 Gy (EQD210). 
Failures Reference Reduction Total P
LF only 7.1% (12) 10.9% (15) 8.8% (27) 0.129
RF only 5.9% (10) 4.3% (6) 5.2% (16) 0.719
Both LF and RF 7.1% (12) 3.6% (5) 5.5% (17) 0.375















LF: local failure; RF: regional failure.
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▲Figure 1:Kaplan-Meier curves of the regional control (a), local control (b) and overall survival (c) 
compared between the reference-cohort (N = 170) and the reduction-cohort (N = 138)
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Table 5: Association Cox proportional hazards analysis to test the association for overall survival 
between the reduction-cohort and patient, tumour, treatment characteristics and toxicity.
HR (95% CI) P Relative HR 
change 
Reduction 0.63 (0.45, 0.88) 0.007 -
+ MLD 0.70 (0.50, 0.98) 0.039 11.1%
+ Heart V2 0.61 (0.43, 0.86) 0.004 3.2%
+ Mean heart dose 0.64 (0.45, 0.90) 0.011 1.6%
+ Oesophagus V50 0.67 (0.48, 0.94) 0.021 6.3%
+ Acute toxicity ≥G3 0.67 (0.47, 0.94) 0.019 6.3%
+ Acute pulmonary toxicity ≥G3 0.68 (0.48, 0.95) 0.024 7.9%
+ Acute dysphagia ≥G3 0.63 (0.45, 0.89) 0.008 -
+ Late toxicity ≥G3 0.64 (0.46, 0.90) 0.010 1.6%
+ Late pulmonary toxicity ≥G3 0.64 (0.46, 0.89) 0.009 1.6%
+ Late dysphagia ≥G3 0.62 (0.44, 0.87) 0.005 1.6%
MLD=mean lung dose; Heart V2=volume of the heart receiving ≥2 Gy; Oesophagus V50 =volume 
of the oesophagus receiving ≥50 Gy (EQD210); Pulmonary toxicity=cough, dyspnea and radiation 
pneumonitis.
Discussion
Previously, we published the results of a differential analysis of local and regional 
control after chemoradiotherapy, demonstrating that lymph nodes recur less often 
than the primary tumor due to a lower volume [12]. The current analysis in LA-
NSCLC patients compared 70 Gy (EQD210) versus 60 Gy (EQD210) to the mediastinal 
lymph nodes while treating the primary tumour to 70 Gy (EQD210) using IMRT. 
Simultaneously, the PTV-margins were reduced following the implementation of daily 
image guidance with online carina registration replacing a bony anatomy registration. 
Comparison with a historical cohort, treated with 70 Gy (EQD210) to both the primary 
tumour and the lymph nodes, was performed to determine the safety of this new 
treatment strategy in terms of toxicity and RF. The reduction-cohort demonstrated 
significantly lower acute toxicity rates, a comparable incidence of LF and RF as well as 
a significantly improved OS. 
Since the RTOG-0617, dose-escalation while increasing the overall treatment time 
in lung cancer, is regarded with restraint. This phase 3-trial reported an increased 
acute toxicity as well as a worse OS in the conventionally fractionated 74 Gy-arm 
compared to the 60 Gy-arm of 20.3 vs 28.7 months, respectively, in patients treated 
with concurrent chemotherapy (weekly Paclitaxel and Carboplatin +/- Cetuximab) [1]. 
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Heart dose parameters (V5 and V30) and the presence of dysphagia were associated 
with OS. In addition to the RTOG-0617, Hallqvist et al. recently published their toxicity 
results of a randomized phase II-trial [22]. Thirty-six patients were treated with an 
escalated dose up to 84 Gy to the tumour and involved mediastinum concurrently 
with 3-weekly Cisplatin-Vinorelbin. Seven patients died due to a possible G5 toxicity 
(pneumonitis and oesophageal fistulae) of which 5 patients were included in the 84 
Gy-arm. The study was stopped after this pre-planned safety analysis. The conclusion 
of the RTOG-0617 and the Hallqvist-trial was that the acute and late toxicities were 
at least partly responsible for the negative results. It should be emphasized that the 
primary tumour as well as the involved lymph nodes were exposed to the escalated 
dose. In the current study, we reduced the total dose to the mediastinum, but not 
the primary tumour. Combining a lower mediastinal dose with a reduction of the PTV-
margins resulted in a significantly lower exposure of the OAR (Table 2), a significantly 
lower incidence of severe ≥G3 acute dysphagia and acute pulmonary toxicity as well 
as an improved OS. 
The lower toxicity rates favoured the reduction-cohort, but the safety of this regimen 
also depends on the RF rate. No increase in RF with or without LF was observed 
(Table 4). A previously published study by Van den Bosch et al. supported our results 
by demonstrating that an increased RT dose was not associated with a lower RF rate 
[23]. Seventy-five stage IIB-IV NSCLC patients were treated with a dose between 42-
66 Gy (EQD210) to the tumour as well as the lymph nodes, of which 63% received 
sCRT. The RF rate was not different between lower and higher radiation dose to 
involved lymph nodes and varied between 6-8%. However, the primary tumour did 
show a dose-effect relationship. Several papers showed similar results, although the 
RTOG-0617 did not reveal lower LF rates [1, 13]. In addition to the already mentioned 
potential causes of the detrimental outcome of the 74Gy-arm, the extended overall 
treatment time probably resulted in reduced effectiveness. This disadvantage may 
be countered by hypofractionated RT with a positive effect on OS [3, 24]. However, 
the hypofractionated schedule used in the current analysis differs from the 
conventionally fractionated schedule and could potentially increase the toxicity. Since 
the introduction of our hypofractionated schedule, after being tested within a phase 
II and III EORTC-trial, we have monitored the toxicity closely and published about the 
acute and long term outcome [25-28]. The acute and late toxicity rates are favorable 




The patients treated in the reduction-cohort revealed a better median OS than the 
reference-cohort. It is unclear whether there is an independent association between 
dose-reduction and OS. MLD was found to influence the association between dose-
reduction and OS. However, the reduced dose to the mediastinum could potentially 
have the greatest impact, which might also explain the negative outcome of the 
RTOG-0617. The great advantage of a differential dose-prescription to the primary 
tumour and involved lymph nodes is the balance between maximizing the local 
control (high dose to the primary tumour) while the toxicity rates decrease because of 
a less intense dose to the mediastinum. Due to this favourable profile many patients, 
including the elderly and the patients with considerable co-morbidity, can benefit 
from this intensive treatment with curative intent. 
We acknowledge that the observational nature of this study has its limitations. First, 
this is a retrospective analysis. Second, since heart toxicity is insufficiently recognized 
during FU, we were not able to report on the acute and late heart toxicity in detail. 
Third, the median FU differed between the 2 cohorts. Nevertheless, with a median 
FU of 27 months in the reduction-cohort, we are confident that the majority of the 
local and regional failures have developed already. Also, to compare the two cohorts 
with a similar FU, we censored the reference-cohort after 27 months. No different 
outcomes were observed (supplementary material, Fig.S2a-c ). Fourth, 17 patients 
who received 70 Gy (EQD210) to the mediastinum due to a protocol violation and 
were excluded. The median OS between these 17 patients and the reduction-cohort 
was comparable; therefore we believe that excluding these patients did not influence 
outcome. Last, we simultaneously implemented 2 treatment adaptations resulting 
in a lower dose to the OARs followed by a decrease in the acute toxicity rates. To 
distinguish the contribution of each adaptation is challenging. We have calculated 
within a subset of the patients the effect of the reduced margins as well as the dose 
reduction to the lymph nodes on the MLD and other dose parameters (supplementary 
material, Table S3A-C).
In conclusion, this observational study compared dose-reduction to the lymph nodes 
as well as a margin reduction in 2 consecutive LA-NSCLC cohorts +/- concurrent 
or sequential chemotherapy. With 60 Gy (EQD210) instead of 70 Gy (EQD210) to the 
involved mediastinal lymph nodes of LA-NSCLC patients, the acute toxicity rates 
decreased significantly while the RF rates were comparable. Furthermore, OS 
improved significantly. A differentiated dose to primary tumour and lymph nodes 
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using a hypofractionated regimen is a safe treatment strategy with very low toxicity 
for LA-NSCLC patients.
Acknowledgement




1. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose 
versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin 
plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-
cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet 
Oncol. 2015;16:187-99.
2. Bradley JD, Hu C, Komaki RU, Masters G, Blumenschein GR, Schild SE, et al. Long-Term 
Results of RTOG 0617: A Randomized Phase 3 Comparison of Standard Dose Versus High 
Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC. International 
Journal of Radiation Oncology • Biology • Physics. 2017;99:S105.
3. Kaster TS, Yaremko B, Palma DA, Rodrigues GB. Radical-intent hypofractionated 
radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the 
literature. Clin Lung Cancer. 2015;16:71-9.
4. Koning CC, Wouterse SJ, Daams JG, Uitterhoeve LL, van den Heuvel MM, Belderbos JS. 
Toxicity of concurrent radiochemotherapy for locally advanced non--small-cell lung 
cancer: a systematic review of the literature. Clin Lung Cancer. 2013;14:481-7.
5. Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB. Radiation dose-volume effects in the 
esophagus. Int J Radiat Oncol Biol Phys. 2010;76:S86-93.
6. [6] Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al. Radiation 
dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76:S70-6.
7. Tucker SL, Liu A, Gomez D, Tang LL, Allen P, Yang J, et al. Impact of heart and lung dose 
on early survival in patients with non-small cell lung cancer treated with chemoradiation. 
Radiother Oncol. 2016;119:495-500.
8. Kwint M, Uyterlinde W, Nijkamp J, Chen C, de Bois J, Sonke JJ, et al. Acute esophagus 
toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent 
chemotherapy. Int J Radiat Oncol Biol Phys. 2012;84:e223-8.
9. Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, et al. Predicting 
esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual 
patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87:690-6.
10. Stam B, van der Bijl E, van Diessen J, Rossi MMG, Tijhuis A, Belderbos JSA, et al. Heart 
dose associated with overall survival in locally advanced NSCLC patients treated with 
hypofractionated chemoradiotherapy. Radiother Oncol. 2017;125:62-5.
11. Ferris MJ, Zhong J, Switchenko JM, Higgins KA, Cassidy RJ, 3rd, McDonald MW, et al. 
Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer 
radiation therapy. Radiother Oncol. 2018;126:100-6.
12. van Diessen JN, Chen C, van den Heuvel MM, Belderbos JS, Sonke JJ. Differential analysis 
of local and regional failure in locally advanced non-small cell lung cancer patients treated 
with concurrent chemoradiotherapy. Radiother Oncol. 2016;118:447-52.
13. Schytte T, Nielsen TB, Brink C, Hansen O. Pattern of loco-regional failure after definitive 
radiotherapy for non-small cell lung cancer. Acta Oncol. 2014;53:336-41.
14. Jouglar E, Isnardi V, Goulon D, Segura-Ferlay C, Ayadi M, Dupuy C, et al. Patterns 
of locoregional failure in locally advanced non-small cell lung cancer treated with 
definitive conformal radiotherapy: Results from the Gating 2006 trial. Radiother Oncol. 
2018;126:291-9.
Safety and efficacy of reduced dose and margins
43 
2
15. Schaake EE, Rossi MM, Buikhuisen WA, Burgers JA, Smit AA, Belderbos JS, et al. Differential 
motion between mediastinal lymph nodes and primary tumor in radically irradiated lung 
cancer patients. Int J Radiat Oncol Biol Phys. 2014;90:959-66.
16. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The 
Netherlands protocol for standardisation and quantification of FDG whole body PET 
studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320-33.
17. Wolthaus JW, Schneider C, Sonke JJ, van Herk M, Belderbos JS, Rossi MM, et al. Mid-
ventilation CT scan construction from four-dimensional respiration-correlated CT 
scans for radiotherapy planning of lung cancer patients. Int J Radiat Oncol Biol Phys. 
2006;65:1560-71.
18. van Herk M, Remeijer P, Lebesque JV. Inclusion of geometric uncertainties in treatment 
plan evaluation. Int J Radiat Oncol Biol Phys. 2002;52:1407-22.
19. Kwint M, Conijn S, Schaake E, Knegjens J, Rossi M, Remeijer P, et al. Intra thoracic 
anatomical changes in lung cancer patients during the course of radiotherapy. Radiother 
Oncol. 2014;113:392-7.
20. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J 
Epidemiol. 1993;138:923-36.
21. O’Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in 
non-small cell lung cancer. Cochrane Database Syst Rev. 2010:CD002140.
22. Hallqvist A, Bergstrom S, Bjorkestrand H, Svard AM, Ekman S, Lundin E, et al. Dose 
escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively 
toxic: Results from a prematurely terminated randomized phase II trial. Lung Cancer. 
2018;122:180-6.
23. Agrawal V, Coroller TP, Hou Y, Lee SW, Romano JL, Baldini EH, et al. Lymph node 
volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC. PLoS One. 
2017;12:e0174268.
24. Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, et al. Long-
term follow-up of patients with locally advanced non-small cell lung cancer receiving 
concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother 
Oncol. 2016;118:442-6.
25. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, et al. 
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with 
inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007;43:114-
21.
26. Uyterlinde W, Belderbos J, Baas C, van Werkhoven E, Knegjens J, Baas P, et al. Prediction 
of acute toxicity grade >/= 3 in patients with locally advanced non-small-cell lung cancer 
receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. Clin Lung 
Cancer. 2013;14:541-8.
27. Chen C, Uyterlinde W, Sonke JJ, de Bois J, van den Heuvel M, Belderbos J. Severe late 
esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. 
Radiother Oncol. 2013;108:337-41.
28. Dieleman EMT, Uitterhoeve ALJ, van Hoek MW, van Os RM, Wiersma J, Koolen MGJ, et al. 
Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III 




▲Figure S1a: Kaplan-Meier curves of the locoregional control rate compared between the 
reference-cohort (N=170) and the reduction-cohort (N=138). 
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▲Figure S1b: Kaplan-Meier curves of the progression-free survival compared between the 
reference-cohort (N=170) and the reduction-cohort (N=138). 
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 Table S2.: Univariate Cox proportional hazards analysis for overall survival.
HR (95% CI) P
Reduction 0.63 (0.45, 0.88) 0.007
MLD 1.11 (1.06, 1.16) <0.001
Heart V2 1.01 (1.00, 1.01) 0.002
Mean heart dose 1.04 (1.02, 1.06) <0.001
Oesophagus V50 1.01 (1.00, 1.02) 0.016
Acute toxicity ≥G3 1.60 (1.08, 2.37) 0.019
Acute pulmonary toxicity ≥G3 10.03 (4.60, 21.88) <0.001
Acute dysphagia ≥G3 1.10 (0.68, 1.80) 0.694
Late toxicity ≥G3 1.32 (0.84, 2.10) 0.223
Late pulmonary toxicity ≥G3 1.78 (1.06, 2.98) 0.026
Late dysphagia ≥G3 0.83 (0.34, 2.02) 0.681
MLD=mean lung dose; Heart V2=volume of the heart receiving ≥2 Gy; Oesophagus V50   
=volume of the heart receiving ≥50 Gy (EQD210); Pulmonary toxicity=cough, dyspnea and radiation 
pneumonitis.
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Table S3A-C. The dose to the organs at risk specified to 4 different radiotherapy conditions 
(A-D) of the involved lymph nodes in 10 patients to gain more insight in the toxicity profile of 
the reduction of the mediastinal dose and the margins, separately. A and D are the conditions 
of the reference-cohort and the reduction-cohort, respectively. The difference of the mean (Δ 
Mean) between A and the three other conditions are specified as well as the standard deviation 
(SD). Comparing margin reduction (B) and dose reduction (C) indicates that the contribution of 
these strategies for the mean lung dose and mean heart dose to the overall exposure reduction 
is comparable, while for the V50 of the esophagus the contribution of C dominates over the 
contribution of B.
A=Dose of 70 Gy (EQD2) and margins using a bone anatomy based correction strategy.
B= Dose of 70 Gy (EQD2) and margins using a carina based correction strategy.
C= Dose of 60 Gy (EQD2) and margins using a bone anatomy based correction strategy.
D= Dose of 60 Gy (EQD2) and margins using a carina based correction strategy.
Table S3A. Mean Lung Dose (Gy)
1 2 3 4 5 6 7 8 9 10 Δ 
Mean
SD
A 15.8 19.2 12.3 12.2 16.8 12.2 11.6 10.5 14.3 18.7
B 15.5 19.0 11.7 12.3 16.1 11.5 11.2 10.4 13.5 16.4 0.6 0.63
C 14.7 17 11.5 12.1 15.2 11.4 10.8 9.6 13.6 17.5 1.0 0.54
D 13.9 15.5 10.7 11.8 14.9 11.2 10.6 9.2 12.9 14.2 1.9 1.21
Table S3B. Mean Heart Dose (Gy)
1 2 3 4 5 6 7 8 9 10 Δ 
Mean
SD
A 10.2 9.3 4.0 1.5 11.7 14.8 5.7 2.5 3.8 10.4
B 8.1 8.8 3.6 1.5 11.3 13.6 5.5 2.6 3.9 9.7 0.5 0.65
C 9.2 9.1 3.3 1.8 11.1 12.4 5.0 2.4 4.0 9.6 0.6 0.73
D 8.7 8.3 3.6 1.9 11.2 12.2 5.2 2.5 4.2 8.4 0.8 0.95
Table S3C. The volume of the oesophagus receiving ≥50 Gy (%)
1 2 3 4 5 6 7 8 9 10 Δ 
Mean
SD
A 18.9 30.8 8 0 29.6 32.3 22.3 10.4 40.3 18.4
B 17.6 30.5 8.4 0 25.7 32.2 21.3 10.3 37.7 16.6 1.1 1.3
C 15.7 26.1 5.2 0.9 13.3 31.0 18.9 5.2 36.8 14.9 4.3 4.3
D 13.9 23.0 1.0 1.2 10.0 31.3 17.5 2.2 36.1 11.2 6.4 5.3

CHAPTER 3
OUTCOME OF RADICAL 
LOCAL TREATMENT OF NON-
SMALL CELL LUNG CANCER 
PATIENTS WITH SYNCHRONOUS 
OLIGOMETASTASES
Margriet Kwint, Iris Walraven, Sjaak Burgers, Koen Hartemink, 
Houke Klomp, Joost Knegjens, Marcel Verheij, José Belderbos 




Patients with stage IV non-small cell lung cancer (NSCLC) are considered incurable and 
are mainly treated with palliative intent. This patient group has a poor overall survival 
(OS) and progression free survival (PFS). The purpose of this study was to investigate 
PFS and OS of NSCLC patients diagnosed with synchronous oligometastatic disease 
who underwent radical treatment of both intrathoracic disease and metastases.
Materials and methods
Patients with NSCLC and oligometastatic disease at diagnosis, who were treated with 
radical intent between 2008 and 2016, were included in this observational study. 
Treatment consisted of systemic treatment and radical radiotherapy or resection 
of the intrathoracic disease. Treatment of the metastases consisted of radical or 
stereotactic radiotherapy, surgical resection or radiofrequency ablation. 
Results
Ninety-one patients (52% men, mean age 60 years) in good performance status were 
included. Thirty-eight patients (42%) died during follow-up (median follow-up 35 
months). The cause of dead was lung cancer in all patients, except one. Sixty-three 
(69%) patients developed recurrent disease. Eleven recurrences (17%) occurred 
within the irradiated area. For the whole group, the median PFS was 14 months 
(range 2-89, 95%CI 12-16) and the median OS was 32 months (range 3-89, 95%CI 25-
39). The 1- and 2-year OS rates were 85% and 58% and the 1- and 2-year PFS rates 
were 55% and 27%, respectively. 
Conclusions
Radical local treatment of a selected group of NSCLC patients with good performance 
status presenting with synchronous oligometastatic disease resulted in favorable 
long-term PFS and OS.




Lung cancer is the leading cause of cancer death, with 1.59 million deaths annually 
worldwide [1]. More than half of the patients with non-small cell lung cancer (NSCLC) 
are diagnosed with metastatic disease [2].
According to current treatment guidelines, stage IV NSCLC patients are considered 
incurable and are mainly treated with palliative intent [3]. Nonetheless, the treatment 
options of stage IV NSCLC patients have increased with a tendency towards a 
more personalized treatment approach. When a patient has a limited number of 
metastases (also called ‘oligo metastasis’ [4,5]), a more radical treatment regime 
instead of palliative treatment may be beneficial with respect to progression free and/
or overall survival [6]. 
Hellman and Weichselbaum first described the term ‘oligometastasis’ in 1995 [4,5]. 
According to this concept, radical/aggressive local cancer treatments might be 
curative in a proportion of patients with a limited amount of metastases. However, 
the existing literature is seriously flawed by the lack of a general consensus on the 
definition of oligometastatic disease. A commonly used definition in the literature is 
‘metastases limited in number and destination organ’. However, the specific number 
is not consistently formulated. Often a maximum of 2 metastases are referred to as 
oligometastatic disease, and treated accordingly [7,8].  In contrast, ≤5 metastases 
are also mentioned as oligometastatic disease and considered for radical treatment 
[7] . Considering the lack of a proper definition for oligometastatic disease, there is a 
need to investigate the association between the number of metastases and survival 
in stage IV NSCLC patients. Limited retrospective data are available in literature on 
oligometastatic NSCLC, both on synchronous and metachronous metastases and 
on heterogeneous treatments including surgery, stereotactic ablative radiotherapy 
and radical radiotherapy [7-27]. In a recent systematic review on the evidence for 
the oligometastatic theory in NSCLC, Ashworth et.al. [7] concluded that: “Long-term 
survivors do exist. Radical treatment of the primary lung tumor and metastases are 
strongly associated with improved long-term survival”.  Gomez et.al [14] reported the 
outcome of a prematurely terminated phase II randomized trial. In this trial, patients 
with oligometastatic NSCLC without progression after first line systemic therapy 
were randomized between local consolidative therapy versus maintenance therapy 
or observation. The outcome showed improved progression free survival for those 
patients treated with local consolidative therapy. 
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Hence, radical local treatment on the primary tumor and the metastases seems to 
improve survival in oligometastatic NSCLC disease [7,8,11,13-15,18-20]. Since a radical 
treatment approach for synchronous oligometastatic NSCLC is not standard of care 
according to current treatment guidelines, more evidence is needed to confirm the 
benefit of this therapeutic approach.  
Therefore, the purpose of this observational study was to determine the progression 
free survival (PFS) and overall survival (OS) of NSCLC patients with good performance, 
diagnosed with synchronous oligometastatic (<5 metastases) disease treated with 
curative intent of the intrathoracic disease and the metastases.
Materials and methods
Patients diagnosed with synchronous oligometastatic NSCLC who were treated 
between July 2008 and August 2016 were included in this observational study. 
Patients were selected during the multidisciplinary tumor board meeting for thoracic 
cancer in our institute. When radical local treatment for oligometastatic disease 
was considered, patients were registered in a database between 2008 and 2016. 
Details of all patients were retrospectively retrieved using this registration database, 
with subsequent review of all the patients’ charts. Patients who had progressive 
disease before they finished their radical local treatment were not registered in the 
database. The Institutional Review Board of our institute waived review because of 
the retrospective nature of the study.
Inclusion criteria for this analysis included histological or cytological proven NSCLC and 
less than 5 synchronous metastases at the time of diagnosis. Patients were excluded 
if they had other uncontrolled malignancies. Staging was done for all patients by 
fluorodeoxyglucose-positron-emission-tomography-(FDG-PET)-scan, CT-thorax and 
for the brain a contrast-enhanced magnetic resonance imaging (CE-MRI) or a CT of 
the brain with intravenous contrast. Ideally, metastatic disease was pathologically 
proven but this was not mandatory. Different types of local therapies were allowed. 
Systemic therapy was not mandatory.
For the primary tumor, treatment was considered radical if the patient underwent 
surgery or if a radical radiotherapy dose was given (≥55 Gy biological equivalent dose 
(EQD2) / α/ß=10). For the treatment of the metastases, sometimes a lower radiation 
dose was prescribed (stereotactic radiation for brain metastasis: 1x15 up to 1x24 Gy 
Outcome of treatment of synchronous oligometastases
53 
 3
(N=25), adrenal gland: 3x8 up to 3x12.5 Gy (N=11), or bone: 3x8 Gy up to 3x15 Gy 
or 5x7 Gy (N=9)). Other treatment modalities such as radiofrequency ablation (RFA 
(N=1)) were considered radical as well.
In general, the clinical outcome of the treatment was evaluated 8 weeks after treatment 
by clinical consultation and repeat CT. Subsequently, follow-up was performed every 
3 months by the pulmonologist and radiation oncologist or surgeon. After 2 years, 
follow-up was performed every 6 months. In case of brain metastases, a MRI-brain 
was performed every 3 months. 
Primary endpoints were progression free survival (PFS) and overall survival (OS). 
Survival was calculated from date of pathologically proven diagnosis until the last date 
of follow-up or death. PFS was calculated from date of pathologically proven NSCLC 
until the date of first progression (local, regional, distant) or death. Progressive disease 
was scored based on available clinical data or imaging report of tumor progression. 
Statistical analysis 
Descriptive statistics were used for patient, tumor and treatment characteristics. 
Median OS and PFS were calculated using the Kaplan-Meier method. Median follow-
up was calculated using the reverse Kaplan-Meier method. Univariate Cox regression 
analysis was done on patient, tumor and treatment characteristics to identify 
predictors of OS and PFS. P-Values were used to quantify degree of association 
between each of the factors and the survival-based endpoints. Multivariate Cox 
regression analysis was performed for OS and PFS, based on selected variables from 
univariate analysis (p < 0.10). Multivariate analysis was done by backward selection, 
based on p-value with a removal criterion of p=0.10. Statistical analysis was carried 
out by using SPSS (version 22).
Results
Patient selection and treatment variables
Table 1 presents the baseline patient and tumor characteristics. Between July 2008 
and August 2016, 91 patients with a mean age of 60 years (range 35-86) were treated 
and registered in the database and eligible for this analysis. Seventy-seven (85%) 
patients had a solitary metastasis, 9 (10%) patients had 2 metastases, 2 (2%) patients 
had 3 metastases and 3 (3%) patients had 4 metastases.  The most frequent location 
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of the metastasis was the brain (42%) followed by bone (30%) and adrenal glands 
(18%). A mutation analysis was not mandated at the time of diagnosis in our institute. 
Therefore, Epidermal Growth Factor Receptor (EGFR) was only determined in 57% of 
the cases. In 11 patients (21%) an EGFR mutation was found. Other mutations were 
not analyzed since they were reported in a small minority of patients, and no statically 
power remained to test for this subgroup analysis. 
Treatment of the primary tumor consisted of (chemo) radiation (N= 81, 89%) in most 
patients. The other patients had a surgical intervention (N= 8, 9%) and 2 patients 
(2%) had no local treatment except systemic therapy. One of these 2 patients had an 
occult primary tumor and the other patient had a complete response of the primary 
tumor after targeted therapy. 
Seventy-five patients (82%) received systemic treatment (Table 2). Nine patients (10%) 
received concurrent chemo- radiotherapy and 60 patients (66%) received sequential 
chemo- radiotherapy. Six patients (7%) received targeted therapy. 
The fractionation schedule for the radiotherapy was determined by a team of 
radiation oncologists, with the aim to achieve a radical regime. The most frequently 
used radiotherapy schedules were 24x2.75 Gy (48%), followed by 17x3 Gy (26%) and 
in 13% of the patients the primary tumor was treated with an ablative stereotactic 
radiotherapy schedule.  Stereotactic radiotherapy to the lung tumor was chosen if the 
tumor was located peripheral (< 5 cm) and there were no lymph nodes involved (N0 
disease).  For 78 patients (86%) who received thoracic radiotherapy for the primary 
tumor in our institute (3 patients received the radiotherapy in another institute), the 
mean Gross Tumor Volume (GTV) for the primary tumor was: 71.2 +/- 114, 0 cm³ (min/
max: 0.3 - 741,5 cm³) (median 28.5 cm³). The mean total GTV (primary including lymph 
nodes) was 83.8 +/- 117.8 cm³ (min/max: 1.4 – 741.5 cm³) (median 45.8 cm³). Further 
treatment characteristics of the treatment of the primary tumor and lymph nodes are 
shown in Table 2.
In 48% of the patients, the metastases were treated with stereotactic radiotherapy. 
In 22% of the patients the metastases were in close proximity of the primary tumor 
or pathological lymph nodes and irradiated within the thoracic radiotherapy field (for 
example a rib metastasis or neck/axillary lymph nodes). Treatment modality for the 
brain metastases (surgery or stereotactic radiotherapy) was discussed and approved 
in a neuro-oncology tumor board. 
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Four out of six patients, who did not receive local therapy for the metastasis, had 
brain metastases which were considered too small for stereotactic radiotherapy after 
response to systemic therapy. The other 2 patients (1 liver and 1 bone metastasis) 
had a complete response after systemic treatment for the metastasis and only 
received radical treated for the primary tumor.  Further treatment characteristics of 
the treatment of the metastases are shown in Table 3. 
Table 1: patients and tumor characteristics. WHO = world health organization, NOS: not 
otherwise specified. TNM 7th edition was used for staging. * within brackets number of metastasis.





























Large cell neuro-endocrine carcinoma 6 (6.6%)








Patient and tumor characteristics N (%)
Location metastases
Brain (1)* 29 (31.9%)
Brain (2) 3 (3.3%)
Brain (3) 1 (1.1%)
Brain (4) 3 (3.3%)
Bone 23 (25.3%)
Bone (2) 1 (1.1%)
Adrenal gland 13 (14.3%)
Lymph node 6 (6.6%)
Liver 2 (2.2%)
Soft tissue 1 (1.1%)
Pulmonary 1 (1.1%)
Thyroid Gland 1 (1.1%)
Breast 1 (1.1%)
Liver and bone 1 (1.1%)
Pleural and bone 1 (1.1%)
Brain and bone 1 (1.1%)
Adrenal gland and pulmonary 1 (1.1%)
Adrenal gland and brain 1 (1.1%)
Adrenal gland (2) and lymph node 1(1.1%)
Table 2: treatment characteristics of the primary tumor and lymph nodes. RT= Radiotherapy, 
* 1 patient with an occult primary tumor and 1 patient with complete response after targeted 
therapy of the primary tumor. 
Treatment primary tumor and lymph nodes N (%)
Local treatment
Radiotherapy 81 (89.0%)
Radiotherapy only conventional RT 3 
Radiotherapy only stereotactic RT 7
Sequential + conventional RT 56
Sequential + stereotactic RT 4
Concurrent fulldose +conventional RT 3
Concurrent lowdose +  conventional RT 6
Targeted therapy + conventional RT 1




Sequential chemo + lobectomy 2
Systemic only* 2 (2.2%)
Targeted therapy 1
Chemotherapy 1





Daily lowdose Cisplatin (Concurrent) 6 (6.6%)
Cisplatin-Etoposide (Concurrent) 2 (2.2%)










Table 3: treatment characteristics of the metastases. RT= Radiotherapy, RFA = Radio Frequency 
Ablation 
Treatment of the metastases N (%)




Brain & bone 1
Brain & adrenal gland 1






Bone & Pleura 1





Systemic therapy only 6 (6.6%)
brain 4
Adrenal gland 1
Liver & bone 1




Treatment of the metastases N (%)
Bone 1








Overall survival and progression free survival
After a median follow-up of 35 months (range 3-89, 95%CI 23-47), 42% (N=38) of 
the patients died. Sixty-nine percent (N=63) of the patients developed recurrence 
disease of whom 59% died. One patient died without any recurrence detected after 
15 months. Most recurrences where within the thorax (N=28, 44%), brain (N=22, 
35%) and adrenal gland (N=8, 13%). Eleven (12%) recurrences occurred within the 
irradiated area, of which 6 (7%) were within the thorax and 5 recurrences occurred 
at the location of the metastasis (5%). Thirty-nine patients (43%) had a recurrence 
in same organ which was affected at diagnosis. At the time of analysis, 58% (N=53) 
patients were alive, with a median follow-up of 18 months (range 3-89, 95% CI 12-24). 
Twenty-seven (51%) of those had no recurrence after a median active follow-up of 10 
months (range 3-89, 95% CI 5-15). 
For the whole group, the median PFS was 14 months (range 2-89, 95% CI 12-16) and 
the median OS was 32 months (range 3-89, 95% CI 25-39). The 1- and 2-year OS were 
85% and 58%, respectively. The 1- and 2-year PFS were 55% and 27%, respectively 
(Figure 1 and 2). 
Univariate Cox proportional hazard analyses showed that squamous cell carcinoma 
(HR: 3.21, 95%CI: 1.26 – 8.14) and WHO-PS 1-2 (HR: 2.25, 95%CI: 1.15 – 4.40) were 
significantly associated with a lower OS. With respect to PFS, a higher T-stage (HR: 2.75, 
95%CI: 1.25 – 6.08) was significantly associated with lower PFS (Table 4). In multivariate 
analyses, squamous cell carcinoma (HR: 3.63, 95%CI: 1.42 – 9.28) and WHO PS (HR: 
2.51, 95%CI: 1.25 - 5.05) remained significant predictors for OS. For PFS, a higher 
T-stage (HR: 2.75, 95%CI: 1.25 – 6.08) remained as the only significant parameter 
in multivariate analyses (Table 4). There were no significant correlations between a 
higher T-stage and the development of distant metastasis or local recurrences. 
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▲Figure 1:Progression free survival from time of diagnosis
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▲Figure 2: Overall Survival from time of diagnosis
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Table 4: Univariate and multivariate Cox regression analysis for Progression Free Survival (PFS) 
and Overall Survival (OS) . HR = Hazard Ratio, EGFR= epidermal growth factor receptor, NOS= 
not otherwise specified. WHO PS: World Healthcare Organization Performance Score. GTV = 
Gross Tumor Volume. * For GTV total volume the patients were ranked in 3 equal groups.





















Female 0.710 0.305 1.031 0.904
Age
< 57 1.000 1.000
57-65 0.568 0.180 0.993 0.984
65< 1.242 0.572 1.271 0.454
WHO
WHO PS 0 1.000 1.000 1.000
WHO PS 1-2 0.667 0.018 2.512 0.010 0.812 0.105
Pathology 
Adenoca 1.000 1.000 1.000
Squamousca 3.207 0.014 3.630 0.007 2.042 0.087
NOS 1.109 0.812 0.974 0.952 0.866 0.667
Neuro-en-
dodrinee




EGFR+ 1.356 0.558 1.285 0.512
EGFR - 2.148 0.135 1.093 0.822
Thoracic 
stage
Stage I&II 0.976 0.943 1.051 0.851
Stage III 1.000 1.000
T-stadium 
T0-1 1.000 1.000 1.000
T2 1.947 0.146 2.070 0.037 2.070 0.037
T3 1.097 0.868 0.871 0.750 0.871 0.750
T4 2.509 0.084 2.753 0.012 2.753 0.012
N-stage 
N0 1.000 1.000






1.746 0.259 1.317 0.450





>1 0.684 0.603 0.975 0.954
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Concurrent 0.847 0.785 1.791 0.131
No systemic 
treatment
0.957 0.927 1.031 0.934
Discussion
This observational study showed the results of 91 consecutive NSCLC patients 
diagnosed with oligometastatic disease who were selected for a radical treatment 
of the primary tumor and the metastasis. Stage IV NSCLC patients are considered 
incurable and are mainly treated with palliative intent. With the introduction of 
oligometastatic NSCLC disease as a separate entity, a more radical treatment 
approach is increasingly applied in current medical practice. However, the literature 
on outcome of patients with synchronous oligometastatic NSCLC treated radically is 
scarce. To our best knowledge this is one of the largest studies analyzing the outcome 
of a radical treatment with synchronous oligometastatic NSCLC patients. 
The OS of 32 months and 1- and 2-year OS rates of 85% and 58% and a PFS of 
14 months illustrate the favorable outcome in this patient group [3]. Compared to 
stage IV NSCLC patients who were treated with palliative chemotherapy (1-year OS 
of 29%) [3], OS is considerably better, which is at least in part due to the favorable 
prognostic profile of patients with oligometastatic disease [28].Uyterlinde et.al. 
[29] published the treatment outcome of locally advanced NSCLC patients treated 
with concurrent chemoradiation in our institute; the 2-year OS was 52% and PFS 
was 18.1 months. Although results may be confounded by selection bias, our 
current results show that the outcome of radical treatment of a selected population 
oligometastatic NSCLC patients is comparable with the treatment of locally advanced 
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NSCLC. De Ruysscher et al. [11] reported a prospective single arm phase III study for 
synchronous oligometastatic disease. The median OS and PFS in this study were 13.5 
months and 12.1 months, respectively. The PFS is comparable to our results. The OS 
reported by De Ruysscher et al. is considerably lower. A possible explanation for this 
difference may be the time cohort  2008 to 2016 as compared to 2006-2010 in the 
study of De Ruysscher, as 2nd line systemic treatment in stage IV NSCLC patients has 
changed over recent years. Next to that, only 10% of our patient group received best 
supportive care (after progression), compared to 23% in the study by the Ruysscher 
et.al. The randomized study of Gomez et al. [14] reported a PFS of 12 months in 
the experimental arm (treatment with local consolidative therapy in patients without 
progression after first line chemotherapy) which is similar to our results. In our study 
population, at time of analysis, 5 patients (5%) were still alive 3 years after treatment 
without any signs of recurrence. De Ruysscher et al. observed that 15% of the patients 
did not show disease progression after 24 months. These data support the concept 
of oligometastatic disease in NSCLC and emphasize that these patients may be cured 
or have a favorable PFS.
In the literature different patient and tumor related prognostic factors are described 
for prolonged OS. We found that a good performance score and non-squamous cell 
carcinoma are favorable prognostic factors of OS. These results are in accordance 
with the results of Griffioen et al [15] and Flannery et al. [13]. Griffioen reported a 
better OS in patients who underwent surgery of the primary tumor, a smaller PTV of 
the primary tumor and non-squamous cell carcinoma. Flannery reported a better OS 
in patients with a Karnofsky performance score ≥ 90. 
We acknowledge that the observational nature of this study has limitations. First, 
observational studies carry the risk of selection bias. There is a clear patient selection 
bias due to the procedure by selecting patients in a multidisciplinary tumor board 
meeting in a tertiary reference center which is obviously limiting the generalizability 
of our data. Only patients with favorable risk factors, like good performance score, 
no weight loss, few comorbidities and fit enough for chemotherapy, were selected 
for radical treatment. The majority of patients within our study population presented 
with adenocarcinoma (64%) and a single metastasis (85%). These are known favorable 
prognostic factors for oligometastatic NSCLC [7,9,15] and might have contributed to 
the favorable OS and PFS.
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Although all of our patients had synchronous oligometastatic NSCLC at diagnosis, our 
study population remains heterogeneous since we included patients with different 
types of NSCLC histology, metastases in different organs and allowed different 
treatment regimens. Therefore, the statistical power of this analysis is too low to 
identify subgroups of patients who will benefit from a radical treatment.  
In conclusion, radical local treatment of a selected group of NSCLC patients with good 
performance presenting with synchronous oligometastatic stage IV disease resulted 
in favorable long-term PFS and OS. Radical local treatment strategies should be part 
of future prospective studies and compared with standard therapy. 
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Conebeam-CT (CBCT) guidance is often used for setup verification of lung cancer 
patients treated with radiotherapy. The purpose of this study was to quantify intra-
thoracic anatomical changes (ITACs) during the radiotherapy treatment and to hand 
over a decision support system to guide the radiation therapy technologist and 
radiation oncologist in prioritizing these changes.
Materials and Methods 
1793 CBCT-scans of 177 lung cancer patients treated in 2010 in our institute with 
radical radiotherapy were evaluated. Our decision support system: “the traffic-light 
protocol”, was retrospectively applied to these CBCT-scans. The protocol has four 
levels: red (immediate action before treatment), orange (action before next fraction), 
yellow (no action required) and green (no change). 
Results
In 128 patients (72%), 210 ITACs were observed with a maximum level of red, orange 
and yellow in 12%, 36% and 24% respectively. Types of observed ITACs were, tumor 
regression (35%), tumor baseline shift (27%), changes in atelectasis (19%), tumor 
progression (10%), pleural effusion (6%) and infiltrative changes (3%). 
Conclusions
ITACs have been observed in 72% of all lung cancer patients during the course of 
radical radiotherapy. The clinical relevance of the proposed ITAC classification in lung 
radiotherapy needs to be validated in a prospective analysis.




In the Netherlands, about 12000 new lung cancer patients are diagnosed annually. 
80% of these patients are medically or technically inoperable at diagnosis [1]. 
Patients with inoperable locally advanced lung cancer are often treated with radical 
radiotherapy and depending on physical condition and/or tumor stage with or 
without chemotherapy. The overall treatment time of the radiotherapy courses in our 
clinic is 5/6 weeks and it is generally assumed that the anatomy of the patient is stable 
during this treatment. However, during this course of radiotherapy several anatomical 
changes may occur, such as atelectasis, infiltrative changes, tumor progression or 
regression and pleural effusion [2-14]. 
With the introduction of advanced image-guided systems like kilovoltage (kV) cone-
beam computed tomography (CBCT), megavoltage (MV) CBCT, and tomotherapy, we 
have the ability to visualize the tumor and organs at risk (OAR) in 3D [15,16]. These 
modalities primarily minimize target misalignment and setup-error [9]. Many studies 
investigate setup precision in lung radiotherapy [17,18]. However, only a few studies 
reported anatomical changes during the course of lung radiotherapy [9,11,19]. In 
clinical practice repetitive CBCT’s make us aware of intra thoracic anatomical changes 
(ITACs) during the course of a radical treatment. In the Netherlands, CBCT’s are typically 
analyzed by radiation therapy technologists (RTTs), the radiation oncologist is only 
informed when a change is observed. In our institute, we developed an action level 
protocol as a decision support system to guide the RTT in prioritizing these changes. 
In this study, we quantified ITACs during radiotherapy and present a decision support 
system (Traffic Light Protocol). 
Methods and materials
Patient selection
The Traffic Light Protocol was introduced clinically in our institute in 2011. All CBCT’s 
of lung cancer patients radically treated with radiotherapy or chemo-radiotherapy 
(≥44Gy) in our institute in 2010, were retrospectively analyzed based on this Traffic 
Light Protocol.
Patients treated with stereotactic radiotherapy were excluded as they had a different 
decision protocol. Inclusion criteria for this study were radical treatment with 
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radiotherapy (>44 Gy), histology or cytology proven lung cancer and image guided 
radiotherapy (IGRT) with the use of 3 or 4D-CBCT. All CBCT-scans were available for 
all patients. Several radiotherapy regimens, all planned with Intensity Modulated 
Radiotherapy (IMRT) and concurrent or sequential chemotherapy or radiotherapy 
alone were included.
Radiotherapy preparation
A 3D-midventilation-CT (MidV-CT) was selected for all patients from a respiration 
correlated 4DCT, in which the moving tumor was closest to its time-averaged 
mean position [20]. The gross tumor volume (GTV) and pathological lymph nodes 
were delineated on the MidV-CT. A recent flu-deoxyglucose-positron-emission-
tomography-(FDG-PET)-scan was registered to the MidV-CT[21]. The GTV was 
expanded to a planning target volume (PTV) using margins of 12 mm +¼ of the 4DCT 
peak-to-peak tumor amplitude in orthogonal directions. A uniform PTV margin of 12 
mm was used for the lymph nodes [22] according to our institutional protocol. The 
planning-constraints used for the OAR were; esophagus V35<65% (physical dose), 
Mean Lung-Dose ≤20Gy (EQD2 α/β=3Gy), spinal cord ≤50Gy (EQD2 α/β=2Gy), total 
heart ≤40Gy, ⅔ of the heart ≤50Gy and ⅓ of the heart ≤66Gy (physical dose). Equally 
spaced, 7-field IMRT-plans were designed using 6/10 MV photons and direct machine 
parameter optimization (Pinnacle version 9.0, Philips, Best, the Netherlands) on the 
homo-lateral lung [23]. The prescription-dose was specified at a representative point 
in the PTV. The dose distribution within 99% of the PTV was >90% and <115% of the 
prescribed dose.
Setup correction protocol
An off-line shrinking action level setup correction protocol was used for all patients 
[24] with Nmax=3 and α=9mm. For this off-line shrinking action level setup correction 
protocol, CBCT’s were acquired the first three fractions using Elekta Synergy 4.2 (Elekta 
Oncology Systems Ltd., Crawley, UK). If no correction was necessary (average setup 
error over 3 fractions <5.2mm in each direction) then weekly follow-up scans were 
acquired. If a correction was required, the protocol restarted with three fractions 
with CBCT verification. This resulted in a minimum of 7 CBCT’s per patient. 4D-CBCT 
were acquired if the motion of the tumor, measured on the 4DCT, was ≥8 mm. The 
CBCT’s were registered, by two RTTs, to the MidV-CT based on the bony anatomy of 
the vertebrae [25]. 




A team of dedicated CBCT RTTs, radiation oncologists and physicists evaluated 
examples of collected ITACs. Four types of urgency levels were defined (figure 1): A 
protocol for communication and/or consultation was defined for each urgency level.
1. Action level red: The GTV is outside the PTV due to ITACs. The radiation oncologist 
is called immediately and treatment is only given when approved by the radiation 
oncologist. 
2. Action level orange: The GTV is just inside the PTV due to ITACs. The radiation 
oncologist is notified by email and has to respond before the next fraction. 
Further diagnostics are considered as a result of the ITAC.
3. Action level yellow: There is an ITAC visible but the GTV is well inside the PTV. 
The radiation oncologist is notified by email about the ITAC but no response is 
necessary and treatment may continue. 
4. Action level green: No change visible. No action needed. 
The Traffic Light Protocol is practical guideline to the RTTs visual inspection of the 
patients CBCT in the absence of the possibility to quantify the dosimetric influence 
of ITACs immediately after a CBCT is made. Note that a CBCT is not of diagnostic 
quality. A visual assessment that the CBCT visualized GTV is (well) within the PTV gives 
confidence but no guarantees that the tumor receives adequate dose. The traffic 
light color therefore reflects a risk assessment of the occurrence of clinically relevant 
dosimetric changes. In case of an ITAC, the RTT informs the radiation oncologist. 
The radiation oncologist and clinical physicist make an estimation of the dosimetric 
influence of the ITAC on the tumor and/or OAR. When is estimated that the dosimetric 
influence is relevant for treatment outcome, a new planning-CT and possibly adaptive 
treatment plan will be made. 
 Chapter 4
74
Intra anatomical changes during radiotherapy
75 
 4
◀Figure 1: Four examples of the traffic light protocol. left: planning CT (pCT), right: cone beam CT 
(CBCT). Purple: planning target volume (PTV); Red: gross tumor volume (GTV). First row: example 
of level red change; this patient had cT4N2M0 NSCLC and was treated with 24x 2.75 Gy. This 
is the CBCT of week 3, the atelectasis resolved and this resulted in a tumor shift outside PTV. 
Second row: example of level orange change; this patient had cT4N2M0 NSCLC and was treated 
with 24x 2.75 Gy. In week 1 the CBCT showed development of atelectasis without a tumor shift. 
Third row: example level yellow change; this patient had cT4N2M0 NSCLC and was treated with 
17x 3Gy. This CBCT shows regression in week 3 of the treatment. Fourth row: example level 
green, no change. Recurrence, the patient was treated with 17x 3Gy. The image is the CBCT of 
fraction 15.
Intra Thoracic Anatomical Changes
All CBCT’s were added to a database. All CBCT’s were scored retrospectively and 
compared to the planning-CT (bony anatomy, carina, trachea and mediastinal 
contour were used to compare the CBCT with the planning-CT). Two IGRT-specialists 
independent of each other visually evaluated every CBCT. For each CBCT, the observed 
ITACs were scored: changes in atelectasis, infiltrative changes, pleural effusion, 
considerable tumor baseline shift, tumor regression and tumor progression. If an 
ITAC was detected, the date of the first occurrence of the highest level (red, orange, 
yellow or green) of each ITAC was compiled. Furthermore, subsequent actions, e.g. a 
repeat radiotherapy planning-CT-scan or re-planning were scored. 
Statistical analysis
To evaluate the ITACs during the course of radiotherapy SPSS for windows software, 
version 20, was used for statistical analysis. Firstly, descriptive statistics were used 
to analyze the number of ITACs. Thereafter Spearman’s rank correlation coefficients 
were used to analyze if there were any significant correlations between progression 
and an adaptive treatment plan with the following parameters: tumor regression, 
tumor baseline shift, changes in atelectasis, pleural effusion, infiltrative changes, 
traffic light level of changes, changes in the first week, patient characteristics, tumor 
stage, tumor location, type of treatment and time interval between planning-CT and 





Between January 2010 and December 2010, 226 patients were treated with a radical 
radiotherapy scheme for lung cancer. A group of 177 patients with complete data 
were selected (Table 1). Mean age was 66 years (range 32-87). A total of 1793 CBCT-
scans from these 177 patients were evaluated. Ninety-seven (55%) patients were 
treated with concurrent chemoradiation (CCRT), 57 (32%) with radiotherapy only 
(RT), 23 (13%) received sequential chemoradiation (SeqCRT) and 17 patients were 
irradiated after surgery. 
Table 1: Patient characteristics



















Right upper lob 58 33
Right middle lob 13 7
Right lower lob 18 10
Left upper lob 49 28





Large cell/not specified 70 39
Small cell lung cancer 21 12
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Characteristic No patients (N=177) %
RT-schedule
24x2.75 Gy 113 64
17x3 Gy 31 18
25x2 Gy 25 14
30x2 Gy 3 1.5
30x2.25 Gy 2 1
30x1,5 Gy (2 times a day) 1 0.5
25x1.8 Gy 1 0.5
33x2 Gy 1 0.5
Intra thoracic anatomical changes
ITACs were observed in 128 patients (72%). In total 200 ITACs were scored (Table 2). 
Sixty patients (47%) had 1 ITAC, 46 patients (36%) 2 ITACs and in 22 patients (17%) >2 
ITACs were observed. The highest ITAC scored per patient was level red, orange and 
yellow in 12%, 36% and 24% respectively. 28% off the patients had no observed ITACs 
(level green). Sixteen patients (9%) required an adapted treatment plan to account 
for the changed anatomy, for which 14 received a new plannings-CT-scan (8%). It took 
1 to 3 working days to generate and implement the adapted plan (mean 2.2 working 
days). Most ITACs occurred in the first week (55%). In week 2, 3, 4 and 5, in 16%, 15%, 
8% and 6% ITACs were observed respectively. Types of ITACs scored were evident 
regression (35%), tumor baseline shift (27%), changes in atelectasis (19%), tumor 
progression (10%), pleural effusion (6%) and infiltrative changes (3%) (total N=210 
ITACs in 177 patients).
The incidence of ITACs was higher in the CCRT- (77%) and SeqCRT-group (74%) 
compared to the RT-group (52 %) (p=.265). Similarly, the incidence of level red 
changes was higher in the CCRT- (16%) and SeqCRT-group (12%) compared to the 
RT-group (0%) (p=.204).
In 28(16%) patients atelectasis developed (N=16) or increased (N=12). This occurred 
mainly in the first week (N=25, 89%). In the other 3 patients atelectasis developed in 
week 2 (N=2) or week 3 (N=1). These ITACs had mostly level red (N=10, 36%) and level 
orange (N=15, 53%), the other 3 (11%) were level green. 
Decrease or resolving of atelectasis occurred in 12 patients (7%). This ITAC was not 
typically scored in a specific week; N=3 in week 1 and 2 (25%), N=5 in week 3 (42%) 
and N=1 in week 5 (8%). Level red was observed in 5 patients (42%), level orange in 4 
patients (33%) and level yellow in 3 patients (25%).
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Infiltrative changes were rarely seen as ITACs during the radiotherapy course. This 
appeared in 5 patients (3%) and disappeared in 2 patients (1%) during treatment. This 
was observed in 4 patients in week 1 (57%), 2 patients in week 2 (29%) and in 1 patient 
in week 3 (14%). The urgency levels of these changes were; level red in 1 patient 
(14%), level orange (43%) in 3 patients and level yellow in 3 patients (43%). These level 
red and orange changes were all associated with regression.
Pleural effusion was observed in 24 patients (14%). In 20 patients, pleural effusion 
appeared or increased and in 4 patients pleural effusion disappeared or decreased. 
These changes were mainly seen in week 1 (N=9,38%), thereafter in 6 (25%), 4 (17%), 
3 (13%), and 2 (8%) patients in week 2,3,4 and 5 respectively. The levels corresponding 
with these changes were level red in 5 patients (21%), level orange in 14 patients 
(58%) and level yellow in 5 patients (21%). 
A tumor baseline shift is a visual difference in the tumor position between the 
planning-CT and CBCT after a bony anatomy match[26]. In 56 patients (32%), a 
tumor baseline shift was observed. These baseline shifts remained within the PTV 
(level orange, N=46, 82%) while in 10 patients (18%) the tumor had moved outside 
the PTV (level red). The onset of these tumor baseline shifts were mainly observed 
in the first week (48%). Some of these tumor baseline shifts were combined with 
regression (N=24), atelectasis (N=19) and/or progression (N=8) of the tumor, which in 
turn, themselves may cause a tumor baseline shift.
Tumor progression was observed in 22 patients (12%). This occurred in week 1 for 21 
patients (95%) and in 1 patient (5%) in week 2. This was level red in 9 patients (41%), 
level orange in 9 patients (41%) and level green in 4 patients (18%). In the 22 patients 
with tumor progression, subsequent tumor regression was seen in 16 patients at a 
later stage during the radiotherapy course.
Tumor regression was observed in 73 patients (41%). The onset of the observed 
regression started in week 1 in 3 patients (2%) and in week 2 for a further 10 patients 
(14%). All of these patients were treated with CCRT, except for one patient who only 
received RT. Most regression cases was first observed in week 3 (N=27, 37%) and 
week 4 (N=23, 32%), while in 10 patients (14%) regression started in week 5. The 
levels corresponding to regression were mainly level yellow (N=35, 48%), thereafter 
level orange (N=26, 15%) and level red (N=12, 16%). Remarkably, in the 12 patients 
with a level red change, 8 patients had a change in atelectasis (4x increase and 4x 
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decrease) and in 5 of these 8 patients, a baseline tumor shift was also seen. In total 7 
tumor baseline shifts were scored in patients with a level red regression. Therefore, 
regression was not always the sole cause of level red. Level red was scored due to 
changes in atelectasis and tumor baseline shifts in 10 patients, which was a result of 
regression. 
The median time interval between planning-CT and start of the treatment (first CBCT) 
was 10 days (range 2-20 days). No significant correlation was found between this 
time interval and tumor progression (p=.270), level red change (p=.783) and new 
radiotherapy treatment plans (p=.744). Patients with stage III lung cancer (N=134) had 
a significantly higher chance of receiving a repeat treatment plan if the time interval 
between the planning-CT and start of treatment was more than one week (p=.040; 
correlation coefficient=.178). Tumor progression had a higher chance of a level red 
change (p=.001; correlation coefficient=.286) and development of this change in the 
first week (p=<.001; correlation coefficient=.431). There was also a higher chance of 
developing atelectasis (p=.028; correlation coefficient=.165) and tumor regression 
(p=.001; correlation coefficient=.241) observed in patients with tumor progression. 
The decision for a new treatment plan correlated significantly with tumor progression 
(p=.001), atelectasis (p=.006), tumor baseline shift (p=.005), an ITAC in the first week 
(p=.012) and level red change (p=<.001). There was no significant correlation found 
with patient characteristics (mentioned in Table 1), and ITACs.
Table 2: Intra thoracic anatomical changes (N=210) in 128 patients
ITACs N
Atelectasis developing/increasing 28 (13%)
Atelectasis resolving/decreasing 12 (6%)
Tumor baseline shift 56 (27%)
Infiltrative changes 6 (3%)
Tumor regression 73 (35%)
Tumor progression 22 (10%)





To the best of our knowledge, this is the first study where ITACs observed on the CBCT 
have been systematically analyzed and a decision protocol implemented on how to 
deal with these changes. This study showed that ITACs frequently occurred during 
radical radiotherapy of lung cancer patients. During radiotherapy, it is important 
to have knowledge of and act accordingly to these changes. Many studies have 
described set-up errors, changes in tumor volume or regression during treatment 
[2-13,17,18]. We observed ITACs in 72% (N=128) of all lung cancer patients during 
the radical radiotherapy course. Regression during treatment was described by 
several groups [2-14,18]. Knap et.al.[5] reported that ⅓ of lung cancer patients 
undergoing (chemo-) radiotherapy achieved significant tumor shrinkage at the end 
of radiotherapy. This is in accordance with our findings that in 36% of the patients 
regression was visible on the CBCT during treatment. Siker et.al. [8] studied tumor 
volume change on MV-CT and found similar results; in 32% of the patients, regression 
was visible. Bosmans et.al. [2] studied tumor volume changes in 23 patients in the 
first two weeks of a course of accelerated RT and reported a variation in tumor 
volume change: a 30% increase and 30% decrease. Decreased volume was observed 
from week 2 onwards. This is in accordance with our findings, where only in 2% of 
patients demonstrated regression in week 1. In our experience, informing the patient 
about tumor regression seen during treatment, helps them to cope with their side-
effects during radiotherapy. Bosman et.al. found in 17% (4/23) of the patients an 
increase in tumor volume, mainly seen in week 1. This corresponds with our findings 
that in 12% of patients, tumor progression was visible on CBCT, mainly scored in 
week 1. It is possible that tumor progression may occur between the planning-CT 
and start of irradiation. The initial volume increase may be due to tumor progression, 
edema or inflammation. This study did not show a significant relationship in the time 
interval between planning-CT and start of treatment and tumor volume increase in 
the whole group. However, in stage III patients there was a significantly higher chance 
of adapting a treatment plan due to ITACs, if the time interval between the planning-
CT and start of the treatment is more than one week. Therefore, it is necessary to 
keep this time interval as short as possible. Tumor progression correlated highly 
with the development of atelectasis and tumor regression. This could be explained 
if atelectasis developed due to progression. Progressive tumors may have a higher 
proliferation rate and therefore be more radiosensitive, which could explain the 
correlation with regression[27]. In our study, the CBCT’s were scored visually. This 
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may have caused a bias in the observation of progression and regression because 
this could be more pronounced in larger tumors. 
Besides tumor progression and regression, there was a high incidence of other 
ITACs during treatment. Møller et. al. [19] found in 23% of 163 lung cancer patients 
changes in lung density on CBCT due to atelectasis, pleural effusion or infiltrative 
changes. Tumor volume changes were excluded in this study. This is in accordance to 
our findings, with an incidence of 28% ITACs due to atelectasis, pleural effusion and 
infiltrative changes.
Due to the high incidence and large variability of ITACs it is therefore important that 
repeated (CB) CT’s are made during the course of radiotherapy and that RTTs are 
well trained to evaluate these scans. In current clinical practice, more and more 
radiotherapy departments are implementing CBCT’s. A clear decision protocol could 
be helpful in guiding the radiation oncologists and RTTs in evaluating changes visible 
on CBCT. The decision protocol that was implemented in our institute, contains 
illustrative examples of each of the four urgency levels (figure 1)[28]. All RTTs are 
trained in using these urgency levels. There are no practical limitations to implement 
this protocol in other radiotherapy centers. 
This study is based on weekly CBCT-imaging. In this study, we were unable to 
distinguish whether the ITAC occurred on the first day following the weekly CBCT or 
almost a week later before the next weekly CBCT. From January 2012 on, we have 
implemented daily CBCT guidance for lung cancer patients in our institute in order to 
assess ITACs as soon as possible and for accurate patient alignment. 
This is the first investigation on ITAC during RT on CBCT. This study was done 
retrospectively with weekly CBCT’s. The results of this study needs to be validated in 
a prospective study to find out if CBCT’s needs to be part of routine clinical practice 
in radical irradiated lung cancer patients. The dosimetric impact of ITACs on the dose 
distribution is subject of further research. 
In conclusion, ITACs have been observed in 72% of all lung cancer patients during 
the course of radical radiotherapy. In 12% of the patients, the radiation oncologist 
was required to respond immediately and in 8% of the patients, a new planning-CT-
scan was made to mitigate the risk of tumor under dosage. The clinical relevance of 
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 The aim of this study was to identify subgroups of locally advanced NSCLC patients 
with a distinct treatment response during concurrent chemoradiotherapy (CCRT). 
Subsequently, we investigated the association of subgroup membership with 
treatment outcomes.
Methods
 Three hundred and ninety four NSCLC-patients treated with CCRT between 2007-
2013 were included. Gross Tumor Volume (GTV) during treatment was determined 
and relative GTV-volume change from the planning-CT was subsequently calculated. 
Latent Class Mixed Modeling (LCMM) was used to identify subgroups with distinct 
volume changes during CCRT. The association of subgroup membership with overall 
survival (OS), progression free survival (PFS) and local regional control (LRC) was 
assessed using cox regression analyses. 
Results
 Three subgroups of GTV-volume change during treatment were identified, with 
each subsequent subgroup showing a more profound reduction of GTV during 
treatment. Surprisingly, no associations between subgroup membership and OS, PFS 
nor LRC were observed. Nonetheless, baseline GTV (HR 1.42; 95%CI 1.06–1.91) was 
significantly associated with OS. 
Conclusions
 Three different subgroups of GTV-volume change during treatment were identified. 
Surprisingly, these subgroups did not differ in their risk of treatment outcomes. Only 
patients with a larger GTV at baseline had a significantly worse OS. Therefore, risk 
stratification at baseline might already be accurate in identifying the best treatment 
strategy for most patients. 




Patients with locally advanced non–small cell lung cancer (LA-NSCLC) are preferably 
treated with concurrent chemoradiation (CCRT). Although this treatment has 
a curative intent, overall survival (OS) is poor with 44-59% surviving at 2 years (1-
3). In order to distinguish patients with better or worse OS, it is important to build 
accurate prediction models for individual treatment outcomes. Current prediction 
models mainly use baseline characteristics to predict treatment outcomes (4-11). 
An important step to improve these prediction models might be to incorporate 
longitudinal data of tumor volume change derived during treatment. 
The predictive value of tumor volume changes during treatment has been studied 
previously (12-15). Although these studies hinted towards a predictive potential, the 
observed associations were inconsistent and the performed studies were of limited 
quality due to small sample sizes. Furthermore, the performed analyses could have 
been too simplistic. For example, observed GTV-changes during treatment were 
dichotomized below or above the median (13-15). The assumption that 2 groups 
(above/below median) represent the treatment response of all NSCLC patients might 
be a misconception (16). In order to identify various subgroups of patients with 
distinct treatment responses, more advanced statistical techniques, such as latent 
class mixed modelling, could be useful (17-20). The use of image guided radiotherapy 
(IGRT) (e.g. Cone Beam-CT(CBCT)), resulted in an increase of readily available imaging 
data of tumor volume during radiation treatment(21). Consequently, this data could be 
used as a longitudinal parameter for treatment outcomes. Subgroups with particular 
tumor volume changes could have worse/better outcomes compared to others. The 
addition of this more dynamic information might improve the prognostic accuracy 
of the current baseline prediction models (4-10). Therefore, the aim of this study is 
to identify subgroups of LA-NSCLC patients showing distinct treatment responses 




Materials and Methods 
Patient selection
An observational study was performed, including 394 consecutive patients treated 
with CCRT for cytologically or histologically proven LA-NSCLC in our institute between 
2007 and 2013. Medical records and treatment characteristics of these patients 
were registered. The concurrent chemotherapy regimen consisted of daily low-dose 
cisplatin intravenous (6 mg/m²) 1-2h before irradiation. All patients were treated with 
intensity modulated radiotherapy (IMRT) to 66Gy/24 fractions to the primary tumor 
and the involved mediastinal lymph nodes in, 5 times per week on a linear accelerator 
equipped with a CBCT. Exclusion criteria were: other CCRT schedules or the absence 
of available CBCT-data. The Institutional Review Board of our institute approved the 
study for retrospective data collection according to the European Privacy Law
Radiotherapy preparation
A 3D-midposition-CT (MidP-CT) was selected for all patients from a respiration 
correlated 4D-planning-CT, in which the moving tumor was reconstructed at time 
average mean position (22). A recent FDG-PET-scan was registered to the MidP-CT, and 
the gross tumor volume (GTV) and all pathological lymph nodes were delineated on 
the MidP-CT. The GTV was expanded to a planning target volume (PTV) using margins 
of 12 mm+¼ of the 4DCT peak-to-peak tumor amplitude in orthogonal directions. A 
uniform PTV margin of 12 mm was used for the lymph nodes (23) according to our 
institutional protocol. Organs at risk were delineated according to the institutional 
protocol: heart, spinal cord, lungs and esophagus. Equally spaced, 7-field IMRT-plans 
were designed using 6 or 10 MV photons and direct machine parameter optimization 
(Pinnacle, Philips, Best, the Netherlands) (24). The prescription-dose was specified at 
a representative point in the PTV. The dose distribution within 99% of the PTV was 
>90% and <115% of the prescribed dose.
Setup correction protocol
From January 2007 to December 2012 an off-line shrinking-action level setup 
correction protocol was used (25). In this protocol CBCT’s were acquired during the 
first three fractions, using Elekta Synergy 4.6 (Elekta Oncology Systems Ltd., Crawley, 
UK) augmented with in-house developed software. If no correction was necessary 
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(average setup error over 3 fractions <5.2mm in each direction), then weekly CBCTs 
were acquired for the remainder of the treatment fractions. If a correction was 
executed, the shrinking action protocol restarted with three fractions including CBCT 
verification. This resulted in a minimum of 7 CBCT’s per patient. Between January 
2013 to December 2013 an online action protocol was used; where daily CBCT’s were 
acquired, and a daily set-up correction was performed immediately before the start of 
radiation. The CBCT’s were registered to the MidP-CT based on the vertebrae, carina 
and\or the primary tumor. The CBCT registrations were performed by at least two 
trained technicians.
Follow-up and endpoint definition
Primary endpoints were overall survival (OS), progression free survival (PFS) and local 
regional control (LRC). OS was calculated from the start of treatment until the last 
date of follow-up or death. PFS was calculated until the date of first progression (local, 
regional or distant) or last date of follow-up or death. LRC was calculated until the date 
when a recurrence occurred within the primary tumor or in the irradiated mediastinal 
lymph nodes region (outfield mediastinal recurrence was considered as progressive 
disease but not as local recurrence). Progressive disease was scored based on 
available clinical data or imaging report of tumor progression. After treatment, 
follow-up was performed every 3 months alternating between the pulmonologist and 
radiation oncologist. After 2 years, follow-up was performed every 6 months. 
Deformable image registration and contouring
Since all CBCT’s of all patients consisted of very much data, manual delineation was 
not possible. Therefore, the volume change of the GTV of the primary tumor was 
defined with deformable image registration (DIR). DIR is a process of defining a map 
with deformations between two images in a nonlinear way, providing a voxel to voxel 
mapping between 2 scans. One image is considered the fixed image (CBCT), and the 
other one the moving image (MidP-CT) (26-28). DIR was performed with in-house 
developed software (Match42). First a clip box was defined encompassing the PTV, in 
which the DIR of the MidP-CT to the CBCT was performed using a B-splines algorithm 
(29). The GTV of the MidP-CT was deformed onto the CBCT using the deformation 





Tumor and patient characteristics at baseline are presented as proportions, mean 
(+standard deviation (SD)) or median (+ interquartile range (IQR)) in case of a not 
normally distributed variable. 
Quality of Deformable Registration
To test the reliability of the DIR, we performed a sensitivity analysis in 66 patients 
for whom we manually delineated the GTV of the primary tumor on the CBCTs of 
the first and last fraction and compared this with the deformable GTV. (These 66 
patients were used in a pilot study, in which we delineated manually the GTVs on the 
CBCTs). The quality of the deformable GTVs was subsequently assessed based on the 
correlation between the manual and the deformable relative GTV using the Pearson 
correlation coefficient. Further, a Bland Altman plot was used to further investigate 
the agreement between the manual and the deformable relative GTV.
Latent Class Mixed Modelling
Latent Class Mixed Modelling (LCMM) was used to identify subgroups with distinct 
treatment responses (16-19), specifically, relative GTV-change during CCRT. LCMM 
assumes a heterogeneous population of subjects with each subgroup having a 
specific average profile of the longitudinal marker. The GTV on the MidP-CT was 
regarded as baseline volume (100%) and the relative volume compared to baseline 
was calculated at each CBCT. To best reflect the shape of trajectories observed within 
the data and the distribution of GTV-change, a class-specific quadratic trajectory over 
time was assumed and a normalization of GTV-change was simultaneously done by 
splines (quadratic I-splines with 3 internal knots placed at the quantiles). Intra-patient 
correlation was captured by correlated individual Gaussian random effects on the 
intercept, time and time squared. To determine the optimal number of subgroups, 
a stepwise forward approach was used. First, a model with one subgroup was 
constructed (one average trajectory applying for all patients), and step by step, an 
additional subgroup, with a conceivably distinct trajectory from the already identified 
subgroups was added. For each model, a grid of initial values (20 departures) was 
also considered to ensure the convergence toward the global maximum. The optimal 
number of subgroups was chosen, based on a combination of (i) goodness-of-fit 
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with the lowest Bayesian Information Criterion (BIC) (where a difference of at least 
10 points is regarded as a sufficient improvement), (ii) discriminatory power with the 
best mean posterior probabilities of class-membership (mean probability >0.80) and 
(iii) clinically relevant differences between the subgroups (where subgroups with <5% 
of patients were considered clinically irrelevant). The Grolts-checklist was followed as 
much as possible to report on the LCMM (30). 
Differences in baseline characteristics between the subgroups were tested using 
Pearson Chi Square tests (categorical variables), Kruskal-Wallis tests (non-parametric 
and >2 groups) or ANOVA (parametric and >2 groups).
To test the potential benefit of adding tumor response to a baseline prediction model, 
we compared the baseline model and the baseline+LCMM tumor-volume change 
model using the Harrell’s c-statistic. 
Sensitivity analyses
To validate current literature (13-15) on the prognostic potential of GTV changes 
during treatment, we performed supplementary analyses in which similar definitions, 
as used in this literature, of relative tumor volume change between first and last 
fraction were considered:
 (14). 
(In patients for whom no CBCT was available of the last fraction, the CBCT made in the 
last week was used.)  
And the relative tumor volume change of the GTV between fraction 11 and 21:
 (15).
To replicate the analyses done in the literature, these relative changes were then 
dichotomized according to the median value of the group and the association 
with treatment outcome was subsequently tested using Cox regression analyses. 
Multivariate cox regression analyses were then performed to investigate the 
independent association of the GTV-change parameters with OS, PFS and LRC. 
Furthermore, univariate cox regression analyses were performed to associate the 
median cut-off values from literature with treatment outcome, namely; 39.3 % (rel_
GTVfirst-last) and 22.8% (rel_GTV11-21) (14, 15). Finally, the influence of pathology was also 
assessed by stratifying for; AC or SCC and NSCLC-not otherwise specified (NOS) (13). 
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Baseline analyses and cox proportional hazard analyses were performed in SPSS 
version 22.0 for Windows. LCMM was performed in R version 3.4.1. with package 
LCMM (lcmm function)(31). A p-value of ≤ 0.05 was regarded as statistically significant. 
Results
In this study, 394 patients were included. Patient and tumor characteristics are shown 
in Table 1. The median follow-up was 63 months (IQR 48-83), median OS was 23 
months (IQR 11-67), median PFS was 17 months (IQR 7-66) and the median LRC was 
63 months (IQR 17-NA) (Supplement Figure 1). In total, 288 patients died (73.1%) 
before the end of study of whom 221 (56.1%) had lung cancer related mortality. 
Progressive disease was observed for 259 patients (66%) of whom 113 (29%) had 
local or regional infield recurrence. 
The Pearson correlation coefficient between the manually delineated GTV and 
the deformable GTV was very high, 0.978 (p=0.001) for the first fraction and 0.951 
(p=0.001) for the last CBCT, respectively. The Bland Altman plot (Supplement Figure 
2) further showed a good agreement (B-value of 0.008 (p=0.767)) for the first fraction 
and 0.037 (p=0.393) for the last CBCT, respectively). 
In general, the majority of patients (93%) had tumor volume reduction of the primary 
tumor during treatment (Figure 1). Seven percent (N=26) of the patients showed 
a stable volume or progression during treatment. Using LCMM, 3 subgroups with 
distinct trajectories of relative GTV-change during CCRT were identified (Figure 2). 
Addition of a 4th subgroup did not result in an improvement of fit, included a subgroup 
containing only 12 patients (3%), and was therefore considered clinically irrelevant. 
The first, and largest subgroup showed limited progression between the MidP-CT 
and start of treatment and showed limited tumor volume reduction during CCRT 
(subgroup 1, N=327, 83%), the second subgroup showed more progression between 
MidP-CT and start of treatment and a more profound tumor reduction during CCRT 
(subgroup 2, N=39, 10%). The third subgroup showed the most progression between 
MidP-CT and start, followed by the steepest tumor volume reduction during CCRT 
(subgroup 3, N=28, 7%). 
Subgroup 1 and 2 contained significantly more males compared to subgroup 
3 (p=0.014) (Table 1). No significant differences in other patient and tumor 
characteristics were observed. Although not significant, a tendency towards a higher 
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median GTV-volume at baseline and a lower proportion of adenocarcinomas was 
seen in subgroup 3. 
In multivariate Cox analyses, WHO-PS (HR:2.93), age (HR:1.56) and GTV-volume of 
the primary tumor (HR:1.42) were significantly associated with OS, and WHO-PS 
(HR:2.12), nodal-stage (HR:1.85) and GTV-volume of the primary tumor (HR:1.47) 
were significantly associated with PFS (Table 2). Surprisingly none of GTV-change 
parameters were significantly associated with treatment outcome. When the 
3-subgroup classification derived from LCMM  was added to the multivariate baseline 
model for OS, the Harrell’s c-statistic did not substantially change (baselinemodel 
c-statistics = 0.624; baselinemodel+ LCMM subgroup c-statistics = 0.628). Kaplan 
Meier plots of OS, PFS and LRC of the subgroups are shown in Supplement Figure 3.
In our cohort, the median decrease of tumor volume was 18.5% (IQR 8.9 - 32.5) for 
rel_GTVfirst-last and 11.9% (IQR 4.4-18.2) for rel_GTV11 -21. No significant different OS, PFS 
and LRC rates were found for rel_GTVfirst-last or_ rel_GTV11-21 (Table 2).
Median cut-off values of tumor volume change from literature were higher; 39.3% 
(22) and 22.8% (23), respectively. Nonetheless, no significant OS differences were 
found for those cut-off values either (HR: 1.10, p-value 0.571 & HR: 1.32, p-value 0.227 
respectively).
Within the pathology subgroup analysis a borderline significant association was found 
only for rel_GTVfirst-last in the AC-subgroup (HR:1.50, p-value:0.064). None of the other 




Table 1: patient and tumor characteristics from the total group and the 3 subgroup model 
identified by Latent Class Growth Modelling. 















Male 233 (59.1%) 203 (62.1%) 20 (51.3%) 10 (35.7%)




0 137 (34.8%) 106 (32.4%) 18 (46.2%) 13 (46.4%)
1 242 (61.4%) 209 (63.9%) 19 (48.7%) 14 (50%)
2 15   (3.8%) 12 (3.7%) 2 (5.1%) 1 (3.6%)
Stage 0.759
1&2 26 (6.6%) 26 (8.0%) 0 (0%) 0 (0%)
3A 212 (53.8%) 166 (50.8%) 26 (66.7%) 20 (71.4%)
3B 156 (39.6%) 135 (41.3%) 13 (33.3%) 8 (28.6%)
Tumor-stage 0.199
Tx-T1 70 (17.8%) 57 (17.4%) 7 (17.9%) 6 (21.4%)
T2 113 (28.7%) 88 (26.9%) 16 (41%) 9 (32.1%)
T3 85 (21.6%) 71 (21.7%) 6 (15.4 %) 8 (28.6%)
T4 126 (32%) 111 (33.9%) 10 (25.6%) 5 (17.9%)
Nodal stage 0.315
N0-1 81 (20.6%) 74 (22.6%) 5 (12.8%) 2 (7.1%)
N2 232 (58.9%) 186 (56.9%) 26 (66.7%) 20 (71.4%)
N3 81 (20.6%) 67 (20.5%) 8 (20.5%) 6 (21.4%)
Pathology 0.119
Adenocarcinoma 127 (32.2%) 104 (31.8%) 17 (43.6%) 6 (21.4%)
Squamous cell carci-
noma
132 (33.5%) 114 (34.9%) 10 (25.6%) 8 (28.6%)
Non-small-cell lung 
cancer NOS
135 (34.3%) 109 (33.3%) 12 (30.8%) 14 (50%)
GTV 0.669
Median GTV 77.1 cc 76.7 cc 75.3 cc 101.1 cc
Age 0.314
Mean age 62 year 62 year 63 year 60 year 
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Table 2: Univariate and multivariate Cox regression analysis for Overall Survival (OS), Progression 
Free Survival (PFS) and Local Regional Control (LRC). HR = Hazard Ratio, NOS = not otherwise 
specified, WHO PS: World Healthcare Organization Performance Score, GTV = Gross Tumor 
Volume, LCGM = Latent Class Growth Modelling. * GTV of the patients was ranked in 3 equal 
groups.
Variable HR P-value HR P-value HR P-value HR P-value HR P-value 
OS uni OS multi PFS uni PFS multi LRC uni
Sex 
Male 1.000 1.000 1.000 1.000
Female 0.695 0.003 0.790 0.063 0.850 0.198 0.895 0.561
Age
≤62 1.000 1.000 1.000 1.000
62< 0.638 0.001 1.560 0.001 1.216 0.118 1.320 0.145
WHO PS
WHO PS 0 1.000 1.000 1.000 1.000 1.000
WHO PS 1 1.374 0.015 1.258 0.085 1.249 0.096 1.286 0.065 1.349 0.139
WHO PS 2 2.911 0.001 2.933 0.001 2.069 0.039 2.120 0.036 1.798 0.330
Pathology 
Adenoca 1.000 1.000 1.000 1.000
Squamousca 1.521 0.004 1.315 0.071 1.000 1.000 1.212 0.395
NSCLC NOS 1.130 0.414 1.085 0.592 0.932 0.644 0.845 0.479
Thoracic 
stage
Stage I&II 1.000 1.000 1.000
Stage IIIA 1.346 0.272 1.238 0.433 0.888 0.741
Stage IIIB 1.526 0.123 1.514 0.132 1.164 0.676
T-stadium 
Tx-1 1.000 1.000 1.000
T2 1.095 0.619 1.421 0.069 2.026 0.019
T3 1.153 0.464 1.415 0.092 1.544 0.191
T4 1.251 0.208 1.316 0.157 1.466 0.220
N-stage 
N0-1 1.000 1.000 1.000 1.000
N2 1.256 0.147 1.274 0.141 1.412 0.040 1.036 0.878
N3 1.409 0.068 1.553 0.024 1.847 0.002 1.378 0.259
GTV primary*
GTV-small 1.000 1.000 1.000 1.000 1.000
GTV-interme-
diate
1.268 0.107 1.181 0.271 1.145 0.379 1.232 0.183 1.157 0.518
GTV-large 1.505 0.005 1.424 0.019 1.430 0.019 1.474 0.013 1.184 0.476
3 subgroup model 
LCMM
Subgroup 1 1.000 1.000 1.000
Subgroup 2 1.111 0.592 1.131 0.555 1.188 0.626
Subgroup 3 1.020 0.934 0.950 0.839 0.810 0.649
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Variable HR P-value HR P-value HR P-value HR P-value HR P-value 
OS uni OS multi PFS uni PFS multi LRC uni
rel_GTV-
first-last
≤median 1.000 1.000 1.000
>median 1.084 0.515 1.058 0.662 0.961 0.840
rel_GTV11-
21 
≤median 1.000 1.000 1.000
>median 1.231 0.163 1.142 0.438 1.010 0.967
Table 3: Univariate and multivariate Cox regression analysis for Overall Survival (OS) for 
the subgroup analysis (adenocarcinoma (AC), squamous cell carcinoma (SCC) and NSCLC-
not otherwise specified (NOS)). HR = Hazard Ratio, WHO PS: World Healthcare Organization 
Performance Score, GTV = Gross Tumor Volume LCGM = Latent Class Growth Modelling.  * GTV 
of the patients was ranked in 3 equal groups.
Variable HR P-value HR P-value HR P-value HR P-value HR P-value HR P-value
(OS AC) uni (OS AC) multi (OS SCC) uni (OS SCC) multi (OS NOS) uni (OS NOS) multi
Sex 
Male 1.000 1.000 1.000
Female 0.740 0.168 0.786 0.280 0.714 0.111
Age
≤62 1.000 1.000 1.000 1.000
62< 1.421 0.110 1.745 0.008 1.860 0.004 1.349 0.148
WHO
WHO PS 0 1.000 1.000 1.000 1.000
WHO PS 1 1.052 0.828 1.244 0.349 1.535 0.053 1.535 0.053
WHO PS 2 0.946 0.927 1.926 0.377 8.936 0.000 8.936 0.000
Stage
Stage I&II 1.000 1.000 1.000
Stage IIIA 4.044 0.053 0.761 0.525 1.098 0.817
Stage IIIB 4.028 0.056 0.978 0.959 1.254 0.583
T-stage
Tx-1 1.000 1.000 1.000
T2 0.963 0.899 0.851 0.661 1.219 0.519
T3 0.938 0.854 0.435 0.417 1.520 0.183
T4 0.913 0.782 0.998 0.996 1.267 0.417
N-stage 
N0-1 1.000 1.000 1.000 1.000 1.000
N2 2.467 0.025 2.467 0.025 1.078 0.749 1.081 0.739 1.212 0.466
N3 2.452 0.044 2.452 0.044 2.050 0.018 2.273 0.007 1.222 0.515
GTV primary*
GTV-small 1.000 1.000 1.000
GTV-inter-
mediate
1.028 0.917 1.151 0.604 1.282 0.336
GTV-large 1.260 0.389 1.453 0.184 1.407 0.161
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Variable HR P-value HR P-value HR P-value HR P-value HR P-value HR P-value








1.256 0.467 1.124 0.737 1.109 0.782
Subgroup 
3
1.416 0.557 0.919 0.841 0.990 0.976
rel_GTV-
first-last
≤median 1.000 1.000 1.000
>median 1.503 0.064 0.989 0.953 0.943 0.773
rel_GTV 
11-21
≤median 1.000 1.000 1.000
>median 1.794 0.110 1.577 0.338 1.311 0.471
▲Figure 1: Distinct relative tumor volume change trajectories during concurrent chemoradiation 
treatment for NSCLC patients identified with Latent Class Mixed Modelling. Subgroup 1 
(red, N=327), subgroup 2 (green, N=39), subgroup 3 (black, N=28).  Time=0 is the date of the 
RTplanning-CT and time =1 is the first date of the treatment. The GTV-change between time=0 
and time =1 is the progression of the GTV between RTplanning-CT and start of treatment. The 










▲Figure 2: (A) Individual observed trajectories of GTV volume change for the total cohort (N= 
394). (B) Individual observed trajectories of GTV volume change for subgroup 1(N= 327). (C) 
Individual observed trajectories of GTV volume change for subgroup 2 (N= 39). (D) Individual 
observed trajectories of GTV volume change for subgroup 1(N= 28). Day 0 is planning CT scan 




In this study, we identified 3 subgroups with distinct GTV-changes during treatment. 
The identified subgroups each showed an increasingly steep volume reduction 
during CCRT. However, no associations of membership of a particular subgroup with 
outcomes were observed. 
Recent literature (13-15) suggested associations between tumor volume change and 
OS. In our present study, we could not validate any of the published associations of 
tumor volume changes and OS, either by considering Latent Class Mixed Modelling 
or by replicating the original analyses. An explanation for this might be that these 
previous studies of Brink et al.(13) Jabbour et al.(14) and Wald et al.(15) were very 
small studies (99, 38 and 52 patients, respectively). As Wald et.al.(15, 32) already 
emphasized, those studies can only be considered as hypothesis generating rather 
than conclusive. Since our large study could not validate these results, the observed 
association could be clarified due to a power problem in those smaller studies (13-
15). 
In coherence with previous studies (4-11), a large baseline GTV of the primary tumor 
remained a significant predictor for worse OS and PFS. This remained not significant 
in the pathology subgroup analysis, probably due to a power problem, but the same 
tendency in the strength of association was observed. Although we identified 3 
different subgroups with distinct volume changes, most patients (83%) were grouped 
into the same subgroup with limited tumor volume regression during treatment. 
When looking at the individual patterns of treatment response (Figure1), one might 
acknowledge that the assumption of heterogeneity in treatment response could not 
be confirmed. Moreover, Wald et al.(32) did not observe heterogeneity in treatment 
response either. Therefore, the addition of longitudinal data of tumor volume change 
during treatment might not improve the current risk models based on baseline 
information (4-11). Nevertheless, using longitudinal parameters to improve the 
predictive accuracy of outcome models are an important topic of ongoing research 
(33-35). Novel longitudinal parameters such as imaging features, circulating tumor 
DNA and molecular tumor profiling might be relevant in developing more accurate 
dynamic prediction models for a more personalized treatment and follow-up care 
approach.  
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The median GTV-volume at start of treatment was comparable to the median GTV 
published in literature (13-15), however we observed a lower GTV-volume reduction 
compared to other studies (13-15). The reason for this might be our reduced overall 
treatment time (OTT), since patient were treated with a hypofractionated CCRT regime 
with an OTT of 32 days (24x2.75Gy) compared to an OTT between 40-51 days (60-74 
Gy in 1.8-2Gy/fraction)) in the literature(13-15). Furthermore, different chemotherapy 
regimens were used. In our institute, daily low-dose Cisplatin is administered as a radio 
sensitizer, while conventionally weekly or three weekly administrations of high dose 
chemotherapy are applied and sometimes combined with induction chemotherapy. 
Moreover, different chemotherapy regimens, radiotherapy-schedules and OTT could 
have influenced the onset of the DNA damage response system (36, 37). The DNA 
damage response system determines the radio sensitivity, type and timing of cell 
death. The vast majority of proliferating tumor cells die at a relatively long interval 
after irradiation, usually after attempting mitosis 1 or 2 times. Therefore, this could 
have affect the GTV- change, which could explain the observed differences.
In patients with AC and more than the median GTV-change, a tendency towards a 
worse OS compared to other pathology groups was found. In the LCMM subgroups, 
the same tendency in association was found; subgroup 3 (the subgroup with the 
sharpest decrease in volume) showed worse OS compared to the other subgroups. 
However, this was not statistically significant, probably due to the small number of 
patients in this subgroup (N=6). This association is in accordance with the study of 
Brink et al.(13), who found that patients with more GTV-change during treatment 
showed worse treatment outcomes. Treatment guidelines for CCRT for LA-NSCLC 
patients are currently based on ‘one-size-fits-all’ standards and there is no risk based 
distinction on pathology. Previously published literature already reported higher 
incidences of brain metastases in AC (38-41), a higher incidence of distant metastases 
in AC and that loco regional failures are more common in SCC (11), underlining that 
AC and SCC might be two different entities. A possible explanation could be that more 
aggressive tumors have a higher mitotic rate and are therefore more radiosensitive 
tumors, resulting in increased tumor regression during treatment. This is comparable 
to small-cell lung cancer, which is in general very radiosensitive due to the higher 
mitotic count (rapid growth) and has a poor treatment outcome (42). Therefore, 
response monitoring during treatment within adenocarcinoma patients might be 
beneficial and further investigation is needed.  
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To conclude, 3 different subgroups of GTV-volume change during treatment were 
identified with LCMM. In contrast with previous results, suggesting an association 
between GTV-change and overall survival, membership of a distinct subgroup of 
GTV-change during treatment did not result in different risks of outcomes whereas 
baseline GTV of the primary tumor was significantly associated with OS. Therefore, 
risk stratification at baseline might already be accurate enough in identifying the best 
treatment strategy for most patients. In patients with adenocarcinoma, and a steep 
decrease of GTV during treatment did show a tendency towards a worse OS.  
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▲Supp fig 1: Kaplan Meier curves for Overall Survival, Progression Free Survival and Local 
Regional Control for the total cohort (N=394)
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▲Supp fig 2: Bland Altman Plot: Plot of the difference against the mean of the absolute GTV 
volume by manually and deformable registration for the first and last CBCT.





▲Supp Fig 3: Kaplan Meier curves for Overall Survival, Progression Free Survival and Local 
Regional Control for the 3 Subgroups identified with Latent Class Mixed Modelling. Subgroup 1 
(N=327), subgroup 2 (N=39), subgroup 3 (N=28).
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The purpose of this study is to investigate the dose-effect-relation between acute 
esophageal toxicity (AET) and dose-volume-parameters of the esophagus after 
Intensity Modulated Radiotherapy (IMRT) and concurrent chemotherapy for Non-
Small Cell Lung Cancer (NSCLC) patients.
Methods and materials
One hundred thirty nine inoperable NSCLC patients treated with IMRT and concurrent 
chemotherapy were prospectively analyzed. The fractionation scheme was 24 x 2.75 
Gy. All patients received concurrent a daily dose Cisplatin (6 mg/m²). Maximum AET 
was scored according to CTC 3.0. Dose-volume-parameters V5 to V70, Dmean and Dmax 
of the esophagus were calculated. A logistic regression analysis was performed to 
analyze the dose-effect relation between these parameters and grade ≥2 and grade 
≥3 AET. The outcome was compared to the clinically used esophagus V35 prediction 
model for grade ≥2 after radical 3D conformal radiotherapy (3DCRT) treatment.
Results
In our patient group 9% did not develop AET, 31% developed grade 1, 38% grade 2 
and 22% grade 3 AET. The incidence of grade 2 and 3 AET was not different compared 
to patients treated with CCRT using 3DCRT. The V50 turned out to be the most 
significant dosimetric predictor for grade ≥3 AET (p=0.012). The derived V50-model 
was shown to predict grade ≥2 significantly better compared to the clinical V35-model 
(p<0.001). 
Conclusions
 For NSCLC patients treated with IMRT and concurrent chemotherapy, the V50 was 
identified as most accurate predictor of grade ≥3 AET. There is no difference in 
the incidence of grade ≥2 AET between 3DCRT and IMRT in patients treated with 
concurrent chemoradiotherapy. 




Concurrent chemoradiotherapy (CCRT) has become the treatment of choice in locally 
advanced non-small cell lung cancer (NSCLC). A recent meta-analysis showed that for 
patients with NSCLC, treatment with CCRT significantly improved local control and 
survival compared to sequential chemoradiotherapy (SCRT) [1]. However, this is at the 
cost of more side-effects; CCRT results in more acute esophagus toxicity (AET) than 
RT-only or SCRT [2-7].
A part of the esophagus is often irradiated due to overlap with the planning target 
volume because of involvement of mediastinal lymph nodes or mediastinal tumor 
invasion. The mucosal layer of the esophagus is sensitive to irradiation induced 
damage [2-7]. Patients with insufficient intake due to radiation esophagitis are at risk 
for premature discontinuation of therapy. Predicting the risk of AET makes it possible 
to take appropriate precautions, such as individualized patient information, dietary 
guidance, hydration or tube feeding. Identifying the low-risk patients of AET gives the 
opportunity to escalate the dose of radiotherapy to improve tumor control. 
Intensity Modulated Radiotherapy (IMRT) facilitates a more conformal dose distribution 
leading to increased organ sparing compared to 3D-conformal-radiotherapy (3DCRT) 
[8-10]. In a previous study, with mainly RT-only and SCRT treatments, we reported 
the V35 (relative volume of the esophagus receiving more than 35 Gy), as the best 
predictor of AET grade ≥2 after radical 3DCRT-treatment [2]. The treatment-planning 
esophagus constraint for 3DCRT at that time was length of the esophagus ≤12 cm and 
elective nodal irradiation was given [2]. In this historical dataset the incidence of grade 
2 (54%) and grade 3 (27%) AET was higher in a subset of 37 patients treated with CCRT 
[2]. The derived V35 model was therefore scaled to cover the higher incidence of AET 
for CCRT, but due to the small sample size, evaluation of the best predictor for AET 
in CCRT was not feasible. Other studies revealed several dose-volume-parameters 
to predict AET [2-7]. One specific dose-volume-parameter was not designated yet as 
most reliable predictor of AET. All studies were based on 3DCRT. However, with IMRT 
dose-distributions and dose-volume-parameters for the esophagus have changed, 
which might reveal other predictors for AET. 
The purpose of this study is to investigate the dose-effect-relation between acute 
esophagus toxicity and dose-volume-parameters of the esophagus after IMRT and 





Between January 2008 and November 2010, patients with locally advanced NSCLC 
treated with CCRT in our institute were prospectively followed. Inclusion criteria for 
this study were treatment with CCRT, histology or cytology proven NSCLC, WHO≤2, 
adequate renal and hepatic functions and life expectancy >6 months. The clinical AET 
grades as well as the dose-volume-parameters of the esophagus were available for all 
patients. Former studies reported different dosimetric predictors for AET for SCRT and 
RT-only, compared to CCRT [6,7]. Therefore only patients were selected who received 
at least 50% of the planned chemotherapy dose and 100% of the radiotherapy dose. 
All patients were treated with IMRT of 66 Gy in 24 fractions, once daily, 5 times per 
week. The concurrent chemotherapy regimen consisted of daily low dose Cisplatin 
intravenous (6 mg/m²) 1-2h before irradiation.
Radiotherapy preparation
For all patients a 3D-midventilation-CT (MidV-CT) was selected out of a respiration 
correlated 4DCT, in which the moving tumor was closest to its time-averaged mean 
position [11]. The gross tumor volume (GTV) and all pathological lymph nodes were 
delineated on the MidV-CT which was also registered with a recent fludeoxyglucose-
positron-emission-tomography-(FDG-PET)-scan. Delineations were discussed in a 
multidisciplinary meeting. The GTV was expanded to a planning target volume (PTV) 
using margins of 12 mm +¼ of the 4DCT peak-to-peak tumor amplitude in orthogonal 
directions. For the lymph nodes a uniform PTV margin of 12 mm was used [12]. 
Critical organs were delineated according to a written protocol: heart, spinal cord, 
lungs and esophagus (from cricoïd to gastro-esophageal-junction). The planning-
constraints used for the organs at risk were; esophagus V35<65%, mean lung-dose 
≤20 Gy, spinal cord ≤50 Gy, total heart ≤40 Gy and ⅔ of the heart ≤50 Gy and ⅔ 
of the heart ≤66 Gy. Equally spaced, 7-field IMRT-plans were calculated using 10 or 
6 MV photons and direct machine parameter optimization in the homo-lateral lung 
(Pinnacle version 9.0, Philips, Best, the Netherlands) [10]. The prescription-dose was 
specified at a representative point in the PTV. The dose inhomogeneity within the PTV 
was >90% and <115%.
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Scoring of acute esophagus toxicity
AET was scored using the Common Toxicity Criteria 3.0 from start of treatment, 
until 3 months after. Grade 2 was scored in case of symptomatic and altered eating 
and intravenous fluids indicated for a period shorter than 24 hrs. Grade 3 included 
symptomatic and severely altered eating/swallowing and intravenous fluids, tube 
feedings, or total parenteral nutrition indicated ≥24 hrs; and grade 4 included life-
threatening consequences. The patients were examined and toxicity was scored at 
baseline and weekly during treatment, until 3 weeks after treatment by the treating 
physician. Thereafter the patients were followed with 2 months intervals or more 
frequently if indicated. All patients consulted a dietician at least twice during treatment. 
Dosimetric analysis
The physical RT-dose was converted to Normalized Total Dose (NTD) for 2 Gy per 
fraction with an α/β-ratio of 10 Gy for acute toxicity. With the NTD corrected dose, 
esophageal dose-volume-histograms (DVH) were computed and dose-volume-
parameters were derived in steps of 5 Gy from V5 to V70, as well as the Dmean and 
Dmax. For comparison with 3DCRT, DVH parameters of the current study using IMRT 
were compared to the data of 36 of the 37 patients treated with CCRT in the historical 
dataset (data for 1 patient was missing) [2].
Statistical analysis
To evaluate the introduction of IMRT in the CCRT-protocol, we compared the incidence 
of grade 2 and 3 AET with the historical patient data [2] using a chi-squared test.
The statistical analysis of AET predictability was performed in two steps. First, the V5-
V70, Dmean and Dmax were analyzed for correlation with the AET grade using Spearman’s 
rank correlation coefficients. In the second step, the best dosimetric predictors for 
grade ≥2 and ≥3 AET were estimated, using a stepwise logistic regression method. The 
stepwise regression was done in a forward selection fashion, which involves starting 
with all candidate variables and testing them one by one for statistical significance, 
deleting variables that were least significant until the best predictor remained. The 




Where β0 and β1 are the estimated coefficients and Vx is the most significant 
dosimetric parameter. The new model was then compared with the currently used 
constraint of the V35 [2] using chi-square distribution with 3 degrees of freedom (β0, 
β1, Vx) . The dose-volume-parameters of the current IMRT-patients were compared 
to the historical 3DCRT-data using a 2-sided student t-test.  The data was analyzed by 
SPSS for Windows software, release 15.0 and graphs were generated by Matlab for 
Windows software, release R2009a.
Results
Patients
Between January 2008 and November 2010, 139 consecutive NSCLC patients treated 
with IMRT and concurrent chemotherapy were selected (Table 1). Median age was 
63 years (range 38-85 years).  A total of 109 (78%) patients received all 24 doses 
of chemotherapy. Due to decreasing renal function (N=20), gastro-intestinal (N=6), 
hematological (N=2) or cardiovascular (N=2) side effects, the Cisplatin stopped early 
after 13 up to 23 administrations (mean 19) in 22% of the patients.
From the 139 patients the incidences of AET were, 12 (9%), 43 (31%), 53 (38%) and 31 
(22%) for grade 0, 1, 2 and 3 AET respectively. No grade 4 and 5 AET was observed. In 
analogy to the historical data, current AET was increased compared to the historical 
data for RT-only and SCRT [2] (p<0.0002). The current incidences using IMRT were not 
significantly different from the historical CCRT data with 3DCRT-treatment (p=0.4832 
for AET grade ≥2 and p=0.5457 for AET grade ≥3).   
Dosimetric variables 
With the use of IMRT the relative volume of the esophagus receiving dose levels 
ranging from 5–40 Gy were significantly lower compared to 3DCRT, while the volume 
receiving 70 Gy was significantly increased (Figure 1).   
The esophageal V65 turns out to have the highest correlation with AET with a 
correlation coefficient of 0.300 (p<0.001), although V25-V70, Dmax and Dmean all 
significantly correlated with AET (Table 2). Additionally, correlations between 
dosimetric variables (e.g. with V50 shown in Table 2) indicate high mutual correlation 
with each other. This indicates that a wide range of dose-volume-parameters are 
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predictive of AET. For this reason, in building the logistic model, we only selected the 
most significant parameter to predict grade ≥2 and ≥3 AET, as can be achieved with 
the forward conditional selection logistic regression method. For prediction of grade 
3 AET, the V50 was shown to be the most significant (p=0.013) parameter with a β0 
of -2.486 and a β1 of 0.032 (Table 3). For grade 2 AET, the Dmax was the remaining 
parameter after forward selection. However, we expect that using Dmax in the plan 
optimization will not sufficiently influence the dose distributions. Since grade 3 AET is 
clinically more relevant, and also for practical reasons, we also estimated the binary 
logistic regression parameters for grade 2 AET using the V50, which was also shown to 
be highly significant (p=0.012) (Table 3). Doing so, we establish one single parameter, 
which can be used to predict the probability of both grade ≥2 AET and grade ≥3 AET. 
The probability of developing acute esophagitis grade ≥3 can now be estimated using: 
 
and for grade 2 AET:
The sigmoid shaped relationship between AET grade ≥2 and ≥3 and the V50 is plotted 
in Figure 2, together with the actual incidences of AET.
To illustrate the need to replace our current V35-model for grade ≥2 AET, we have 
plotted the actual V35 data of the current study with respect to the model (Figure 3). 
The log-likelihood difference between the V35 data estimated with the old model and 
the V50 data estimated with the new model corresponded to a significant difference 
with a p-value of 0.011 (chi-square distribution with 3 degrees of freedom), indicating 
superiority of the V50 model. 
Using the Mann-Whitney test, patients experiencing grade 3 AET and receiving all 
planned doses of Cisplatin (26%) were compared to patients in whom Cisplatin was 
discontinued early (10%). This incidence was not significant different (p= 0.083).
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Table 1: Patients Characteristics (NSCLC = non-small cell lung carcinoma; WHO = World Health 
Organization)
























Weight loss ≥5% last 6 months
Yes 50 36.0
No 89 64.0
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Table 2: Spearman’s rank correlation coefficients of dose volume parameters and acute 
esophagus toxicity (AET). * correlation is significant at the 0.05 level;  **correlation is significant 
at the 0.01 level
Variables Correlation with AET  Correlation with V50
Dmax 0.237 ** 0.536 **
Dmean 0.220 ** 0.960 **
V5 0.104 0.665 **
V10 0.135 0.727 **
V15 0.149 0.764 **
V20 0.161 0.833 **
V25 0.174 * 0.876 **
V30 0.193 * 0.909 **
V35 0.222 ** 0.944 **
V40 0.231 ** 0.970 **
V45 0.250 ** 0.991 **
V50 0.250 **     --
V55 0.265 ** 0.989 **
V60 0.284 ** 0.938 **
V65 0.300 ** 0.856 **
V70 0.247 ** 0.708 **
Table 3: Results of the backward stepwise regression analysis; Volume of the esophagus 









Grade 2 V50 0.027 0.011 0.012 1.027
Constant -0.515 0.405 0.204 0.598
Grade 3 V50 0.032 0.013 0.012 1.033
Constant -2.486 0.561 <0.001 0.083
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▲Figure 1: Average esophageal dose-volume-histogram for the historical patients planned with 
conformal radiotherapy, and the current IMRT-dataset. The error bars denote the 95% standard 
error. Both groups were compared for each dose level using a 2-sided students T-test (*p<0.05, 
**p<0.01, ***p<0.001)
▲Figure 2: Probability of developing AET grade 2 (grey line) and grade 3 (black line) using the 
logistic model based on V50. The 95% confidence intervals are plotted in dash-dotted lines. The 
actual incidences, together with its 95% confidence intervals, are plotted in the vertical lines. 
CCRT = concurrent chemoradiotherapy.
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 6▲Figure 3: Probability of developing grade ≥2 AET using the current clinical model based on V35 (solid line). The datapoints illustrate the actual incidence of AET based on the V35, and their 
95% confidence intervals. 
Discussion
To the best of our knowledge, this is the first analysis of dosimetric predictors of AET 
performed within a large patient group treated with IMRT and the same concurrent 
chemotherapy-regimen. Several studies have shown that treatment with CCRT gives 
an increased risk of AET [2,3,5-7], as was also confirmed in the current study. We 
showed that in the setting of CCRT, the incidence of AET was not significantly changed 
by the introduction of IMRT compared to 3DCRT. Our current clinical AET prediction 
model, using V35, resulted in inadequate prediction of AET grade ≥2 when treating 
with CCRT. With increasing incidence of grade 3 AET, prediction of grade 3 is deemed 
to be clinically more relevant, and we therefore propose to use the V50. 
With the introduction of IMRT the volume of the esophagus receiving 5 to 40 Gy 
was significantly reduced, and simultaneously, the volume receiving 70 Gy was 
significantly increased (Figure 1). Using the historic prediction model based on V35 
[2], one would expect that the incidence of grade ≥2 AET would have been reduced 
with IMRT, which was actually not the case. The inability of predicting AET using the 
V35 model in CCRT was indicated by the discrepancies between the actual incidence 
and the V35 prediction model (Figure 3). With use of CCRT, there were a substantial 
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proportion of patients with more severe grade 3 AET, independent of use of IMRT, 
which was not addressed in the old V35 model. An update of the prediction model 
was therefore needed. 
For grade 3 AET, the V50 was shown to be the best predictor, and for grade 2 AET 
the V50 also showed to perform significantly better than the current V35 model. With 
no significant change in AET incidence compared to patients treated with 3DCRT, it 
is also logical to find the best predictor at a dosimetric level at which the volume of 
esophagus was not different between 3DCRT and IMRT (between V45 and V65, Figure 
1).   
Werner-Wasik et al. [7] described in their review that a higher dose, even on a 
small part of the esophagus, might be a risk factor for AET. They described several 
dosimetric parameters to be predictive in univariate analysis for grade 2 and 3 AET: 
V20 till V80. But most at risk for AET were esophagus volume doses receiving >40-50 
Gy. This data is consistent with our analysis, were V15 till V70 and Dmean and Dmax of the 
esophagus were all significantly correlated with AET. 
The systematic review of Rose et al. [6] demonstrated that the Dmean, V20, V30, V40, 
V45 and V50 were the most studied dosimetric predictors, showing high levels of 
association with AET. The dosimetric predictors of AET in Rose’s review are consistent 
with the most significant predictor we found, the V50.
Caglar et.al. published an analysis based on 3DCRT and concurrent chemotherapy with 
109 patients [4]. These patients were treated with or without induction chemotherapy 
followed by CCRT with different chemotherapy regimens. Radiotherapy dose varied 
between 50-68 Gy in 2 Gy fractions. V45 till V60 were indicated as most predictive 
dose-volume-parameters for AET. Besides the dose on the entire esophagus, Caglar 
et al. studied the region of the esophagus exposed to a high dose (esophagus infield). 
The V55 of the entire esophagus and esophagus infield was the most significant 
parameter to predict AET in multivariate analysis. They showed that when the Dmean of 
the esophagus infield was below 50 Gy, no grade 3 occured. In our analysis we did not 
specify between entire esophagus dose and esophagus infield, but the dose of 50 Gy 
is in agreement with our V50 for predicting grade 3 AET. 
In the current study RT was given with 2.75 Gy fractions. Despite the increased fraction 
dose, the incidence of grade 3 AET was not higher compared to Caglar et al. [4] (25%), 
where conventional 2 Gy fractions were used. The radiotherapy dose of our study 
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was converted into NTD equivalent to fraction doses of 2 Gy with α/β=10, for which 
the derived results may also be applied to other fractionation schemes providing 
the same α/β is used. Uitterhoeve et. al. reported in a phase I/II EORTC trial that 
this fractionation-scheme was safe using 3DCRT and an EORTC phase III multicenter 
trial confirmed this[13,14]. In 2005 the NKI-AVL introduced IMRT for all lung cancer 
patients treated with radical intent and to our clinical experience the safety of this 
treatment is well established. Uyterlinde et. al. analyzed that our CCRT regimen with 
IMRT is well tolerated in cohort of 188 patients [15].
For the treatment of stage III NSCLC patients, a certain risk of grade 3 AET is deemed 
acceptable because the toxicity is often temporary and manageable. Late esophagus 
toxicity (LET) like a fistula or stricture of the esophagus may however cause life-
threatening problems for the patient. For LET, proposed predictive parameters are 
Dmean and V50 [6], and V45 to V60 [4], but most studies analyzing LET were done 
in patient groups treated with heterogeneous radiotherapy and chemotherapy 
schedules. Belderbos et al. reported from the randomized trial comparing sequential 
(N=78) and concurrent (N=80) chemoradiation that a higher incidence of AET in the 
CCRT-arm did not result in a higher incidence of severe late toxicity (4 vs. 5 %). Follow-
up of the patients included in the current study is ongoing to report LET in the future.
Limitations of the study
Limitations in general were the difficulties encountered with the scoring of AET in 
patients treated with CCRT. Although we scored prospectively, sometimes it is difficult 
to differentiate between AET and side effects of chemotherapy (e.g. anorexia). 
The dose-volume-parameters were all based on the position of the esophagus during 
the midV-scan and were not corrected for movements of the esophagus during 
treatment. Motion analysis of the esophagus, and also the influence of length and 
circumference of the irradiated esophagus on AET is currently being investigated to 
further increase our knowledge on AET. 
Our CCRT treatment consists of daily low dose Cisplatin but different chemotherapy-
regimens are frequently used. Currently this radiotherapy scheme and full-dose 





For NSCLC patients treated with CCRT and IMRT, the V50 was identified as most 
accurate predictor of grade ≥3 AET. We advise to introduce the V50 model in clinical 
practice in order to reduce the risk of AET, and have a better prediction of severe 
acute esophageal toxicity. There is no difference in the incidence of grade ≥2 AET 
between 3DCRT and IMRT in patients treated with CCRT.
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CHAPTER 7
THE USE OF REAL-WORLD 
EVIDENCE TO AUDIT NTCP - 
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The aim of this work is to assess the validity of real world data (RWD) derived from 
an electronic toxicity registration (ETR). As a showcase, the NTCP-models of acute 
esophageal toxicity (AET) for concurrent chemoradiation (CCRT) for NSCLC patients 
were used to validate the ETR of AET before/after dose de-escalation to the mediastinal 
lymph nodes.
Material and Methods
One hundred and one patients received 24x2.75 Gy and 116 patients received 
de-escalated dose of 24x2.42 Gy to the mediastinal lymph nodes. The validity and 
completeness of the ETR was analyzed. The grade ≥2 AET probability was defined 
according the V50 Gy and V60 Gy NTCP-models from literature. Validity of the 
models was assessed by calibration and discrimination. Furthermore, sensitivity and 
specificity for different cut-off points were determined. 
Results
The compliance of ETR was 73-80%, with sensitivity and specificity rates of 83% and 
86% for grade ≥2 AET, respectively. Discrimination of both NTCP-models demonstrated 
a moderate accuracy (V50 model = AUC of 0.71; V60-model AUC= 0.69). Dose de-
escalation did not influence the accuracy of the V50-model; AUC before: 0.69, and 
AUC after: 0.71. For the V60-model the model-accuracy decreased after dose de-
escalation; before AUC= 0.72 and after AUC 0.62, respectively.
Conclusion
RWD is a useful method to audit NTCP models in clinical practice. The NTCP models to 
predict AET in NSCLC patients showed good predictive accuracy. For clinical practice, 
the V50 Gy seems to be most stable for dose de-escalation without compromising 
safety and efficacy.




Randomized clinical trials (RCTs) provide the highest level of evidence to prove 
treatment efficacy and safety. When evidence from RCTs is lacking, clinical decision-
making is typically supported by data from observational studies and clinical registries. 
Collectively, data obtained from sources outside RCTs are often referred to as ‘real 
world data’ (RWD), and the evidence derived from aggregation and analysis of such 
data as real world evidence (RWE) (1-5). RWE is often criticized due to its presumed 
lack of validity because of the broad patient heterogeneity and the vast amount of 
missing data compared to data derived from RCTs (1).  
With the introduction of electronic medical records, a more systematic and accurate 
recording of treatment related toxicity was implemented in clinical practice (6, 7). 
Such a toxicity registration, when consistently used for all patients, provides a large 
amount of data, possibly useful for the evaluation of treatment quality since this data 
can easily be associated with patient characteristics and/or treatment parameters. 
Nonetheless, the completeness and validity of this ‘big data’ remains uncertain. 
Therefore, validation is needed to define the accuracy of such a registration to provide 
RWE (1, 8, 9).
For patients with locally advanced non-small cell lung cancer (NSCLC), the treatment 
of choice is concurrent chemoradiation (CCRT)(10-12). The addition of chemotherapy 
provokes a radiosensitizing effect leading to an improved local tumor control and 
overall survival, compared to radiotherapy only or sequential chemoradiation. But 
this comes at the cost of an increase of acute esophageal toxicity (AET)(13). Several 
studies have reported (14-20) on different dosimetric and clinical parameters to 
predict the risk of AET with the use of Intensity Modulated Radiotherapy (IMRT). We 
previously investigated the dose-effect relation between dose volume parameters 
and AET (16)  and identified the V50 (volume of the esophagus receiving ≥ 50 Gy) as 
the most accurate predictor of AET. Palma et al. (17) performed an individual-patient-
data meta-analysis and concluded that the V60 (volume of the esophagus receiving 
≥60 Gy) was the most accurate predictor for AET.
The aim of this work is to assess the validity of a RWD toxicity registration and to 
show the feasibility of such an infrastructure to audit toxicity prediction models and 
dose constraints in daily clinical practice. Since June 2015 the dose to the irradiated 
mediastinal lymph nodes was de-escalated from 66 Gy to 58.08 Gy (60 Gy (EQD2)) 
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in 24 fractions) for NSCLC patient treated with CCRT (21, 22). As a showcase, the 
electronic registration of AET was used to validate the applicability of this RWD for the 
NTCP models of AET for CCRT for NSCLC-patients, for 2 sequential cohorts. 
Materials and Methods
Patient selection
A consecutive cohort of patients treated with CCRT for cytologically or histologically 
proven NSCLC in our institute between 2014 and 2016, were selected for this 
analysis. The clinical AET grades from the electronic toxicity registration as well as 
patient characteristics and dose-volume-parameters of the esophagus were available 
for all patients. Baseline characteristics are presented as mean (+standard deviation 
(SD)) or median (+ interquartile range) in case of a skewed distribution or proportions.
Treatment
The concurrent chemotherapy regimen consisted of daily low dose Cisplatin 
intravenous (6 mg/m²) 1-2h before irradiation. The patients treated between January 
2014 until June 2015 were treated with IMRT of 66 Gy to the primary tumor and 
mediastinal lymph nodes in 24 fractions, once daily, 5 times per week. Since the 1st 
of June 2015 the dose on the irradiated mediastinal lymph nodes was de-escalated 
from 66Gy to 58.08 Gy (60 Gy BED) in 24 fractions (21, 22). Therefore, this dose de-
escalation was used as a showcase to audit the quality of the NTCP-models before/
after this treatment adaptation with the use of RWD.  
Radiotherapy preparation
For all patients a 3D-midventilation-CT (MidV-CT) was selected out of a respiration 
correlated 4DCT, in which the moving tumor was closest to its time-averaged mean 
position (23). The gross tumor volume (GTV) and all pathological lymph nodes were 
delineated on the MidV-CT which was also registered with a recent fludeoxyglucose-
positron-emission-tomography-(FDG-PET)-scan. The GTV was expanded to a 
planning target volume (PTV) using a personalized margin protocol based upon the 
tumor and lymph node movement during breathing. Critical organs were delineated 
according to a written protocol: heart, spinal cord, lungs and esophagus (from cricoid 
to gastro-esophageal-junction). The planning-constraints used for the organs at 
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risk were; esophagus: Dmax ≤66 Gy and  V(50Gy) ≤50% (EQD210), mean lung-dose 
≤20 Gy (EQD23), spinal cord ≤52 Gy (EQD22), total heart ≤40 Gy and ⅔ of the heart 
≤50 Gy and ⅓ of the heart ≤66 Gy (EQD23). Equally spaced, 7-field IMRT-plans were 
calculated and optimized using 10 and/or 6 MV photons. Optimization was done 
using direct machine parameter optimization in Pinnacle version 9.0, (Philips, Best, 
The Netherlands). The prescription dose was specified at a representative point in the 
PTV. The dose inhomogeneity within the PTV was >90% and <115%.
Electronic toxicity registration method
From December 2012, a prospective, electronic toxicity (grade ≥2 toxicities (CTCAE 
v4.0)) registration was implemented within our department. Registration of toxicity is 
performed by the treating physician during each patient consultation. Simultaneously, 
a data management infrastructure was built to merge the toxicity data to patient 
characteristics and treatment parameters.  
AET was scored using the Common Toxicity Criteria 4.0 from start of treatment, till 
3 months after. Toxicity was scored at baseline and weekly during treatment, until 3 
weeks after treatment by the treating physician. Thereafter the patients were followed 
with 3 monthly intervals or more frequently if indicated. The toxicity was scored in 
the electronic patient file (Chipsoft, Amsterdam, The Netherlands). The physician first 
indicated whether or not any toxicity grade ≥2 was present. In case no or grade 1 
toxicity was present, ‘no toxicity’ was scored to distinguish between missing data and 
an explicit registration of ‘no toxicity’. When there was grade ≥2 toxicity, the type and 
grade of toxicity was registered. The highest AET grade was used for this analysis. The 
data from the first year of the toxicity registration (December 2012 until December 
2013) was not used for this study. This first year was used to illustrate the learning 
curve of the registration of the physicians. To assess the validity and completeness 
of the electronic registration, a sample test of N=77 (35%) was performed to check 
the accuracy of the registration. This was done separately by two individuals, by 
retrospectively reviewing the patients file and compare this to the electronic toxicity 
registration. For this sample test, a cross table was made and sensitivity and specificity 




The physical RT-dose was converted to Normalized Total Dose (NTD) for 2 Gy per 
fraction with an α/β-ratio of 10 Gy for AET. With the NTD corrected dose, esophageal 
dose-volume-histograms (DVH) were computed and dose-volume-parameters V50 
and V60 were derived. 
The grade ≥2 AET probability was calculated as (16, 17); 
V50-model:  
V60-model: 
The grade ≥3 AET probability was calculated as (16, 17); 
V50-model:  
V60-model:  
Validity of the model was assessed as the ability to predict the number of grade 
≥2 and grade ≥3 AET events (calibration). A receiver operating characteristic curve 
(ROC-curve) was used to analyze the predictive ability of the V50 and V60 prediction 
models. The area under the curve (AUC) was calculated to distinguish between those 
who develop grade ≥2 AET. For clinical use, the ability to identify the true positive 
(sensitivity) patients is more important than the false negative patients (specificity). 
Therefore, the optimal cut-off point of the model (probability to predict AET) was 
based on the highest sensitivity. 
The following sensitivity analyses for quality assurance were performed. A Mann 
Whitney test was used to compare the median V50 and V60 before and after 1st 
of June 2015 (Since 1st of June 2015 the dose on the irradiated mediastinal lymph 
nodes was de-escalated to 58.08 Gy in 24 fractions). Thereafter a ROC-curve was 
used to analyze the predictive ability between the 2 periods (before and after dose 
de-escalation) for grade ≥2 AET for both V50- and V60-models. The Delong-test was 
used to analyze the significance differences in AUCs (24, 25). All statistical analyses 
were performed using IBM SPSS (version 22). 




Two hundred and seventeen consecutive patients were included in this study (Table 
1). Mean age was 62 years (SD 8.9 year). One hundred and one patients were treated 
before 1st of June 2015 when the prescription dose was 66 Gy in 24 fractions on the 
primary tumor and pathological lymph nodes and 116 patients were treated after 
dose de-escalation with a prescription dose of 66 Gy in 24 fractions on the primary 
tumor and 58.08 Gy in 24 fractions on the pathological lymph nodes.  Ninety-five 
patients developed grade 2 AET (44%) and AET grade 3 was seen in 12 patients (6%) 
according to the electronic toxicity registration. No AET grade 4 and 5 were registered. 
Due to the low incidence of grade 3 AET (6%) and corresponding low power, further 
analyses on grade 3 AET were not possible. Therefore, validation of the V50- and V60 
NTCP-models for prediction was only performed for grade ≥2 AET.  
Validation of electronic toxicity registration
The period from December 2012 until December 2013 was considered a learning 
period for the physicians to get used to the toxicity registration in the electronic 
medical record. Compliance of toxicity registration in de the electronic medical 
record increased over this year from 48% to 60% of all appointments. After additional 
training, compliance increased further to an average of 73%, 80% and 80% for the 
years 2014, 2015 and 2016 respectively. This means that in 73% - 80% of the patients, 
the absence/presence of toxicities were registered. 
The results of the sample test to assess the validity of the electronic toxicity registration 
are shown in Table 2. For this sample test, the sensitivity of the electronic toxicity 
registration for grade ≥2 AET (when the independent validation is the gold standard) 
was 83%, with a specificity of 86%. 
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Table 1: Patients and tumor characteristics. WHO = world health organization, NOS: not 
otherwise specified. TNM 7th edition was used for staging. 





























Non-small-cell lung cancer NOS 48 (22%)
Table 2: Cross tabulation of the sample test of 77 patients.  AET = Acute Esophagus Toxicity, ETR 
= Electronic Toxicity Registration.
AET Grade 0-1 ETR Grade 2 ETR Grade 3 ETR Total
Grade 0-1 observer 31 5 0 36
Grade 2 observer 5 25 0 30
Grade 3 observer 2 4 5 11
Total 38 34 5 77
Validation of V50- and V60-model
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Median V50 was 22.9% (IQR 10.3% - 35.7%) and the median V60 was 5.1% (IQR 
0.0% - 20.96%). Discrimination of both algorithms demonstrated a similar moderate 
accuracy with an area under the curve (AUC) of 0.706 (95%CI 0.637 to 0.775) for the 
V50 model and an AUC of 0.685 (95% CI 0.614 to 0.757) for the V60 model, respectively 
(Figure 1).  Calibration showed that the V50-model slightly overestimated the risk of 
developing grade ≥2 AET in low-risk (predicted incidence <50%) patients while in high 
risk patients (predicted incidence >50%) the predicted incidence was in accordance 
with the observed incidence of grade ≥2 AET. The V60-model overestimated the 
risk of developing grade ≥2 AET in low-risk patients and underestimated the risk of 
developing grade ≥2 AET in high-risk patients (Figure 2&3). 
In both models, the sensitivity was higher for lower cut-off points and the specificity 
was higher for higher cut-off points. For the V50-model, a cut-off point of more than 
40% probability of developing grade AET resulted in the most favorable sensitivity of 
95.8% for grade ≥2 with specificity scores of 30.1%.  For the V60-model, this cut-off 
point resulted in a sensitivity of 68.3% for grade ≥2 with specificity scores of 58.8%.
Validation V50- and V60-model before and after dose de-escalation
The patient cohort was split into a population before and after dose de-escalation. 
The median V60 decreased significantly (p=0.001) after the dose de-escalation on the 
mediastinal lymph nodes from 12.7% (IQR 25.3%) to 1.3% (IQR 17.1%). The median 
V50 decreased as well (from 26.9% (IQR 23.5%) to 21.7% (IQR 24.6%)) but this was not 
significant (p=0.120). 
The incidence of grade ≥2 and grade ≥3 AET decreased after de-escalation of the 
mediastinal lymph nodes from 50.5% to 37.9% (p=0.032) and 7.9% to 3.4% (p=0.076) 
respectively.  We compared the accuracy of the V50- and V60-model for grade ≥2 AET 
between the 2 time periods (Figure 4).  For the V50-model, an almost similar model fit 
was found with an AUC of 0.690 (95%CI 0.585-0.795) before dose de-escalation and 
0.707 (95%CI 0.609 – 0.804) after. For the V60-model, the model fit decreased after 
dose de-escalation; AUC= 0.722 (95%CI 0.621 – 0.823) compared to 0.624 (95%CI 
0.518 – 0.729), respectively (Figure 2).  The Delong-test (24, 25) showed no significant 




▲Figure 1: ROC-curve of the V50 and V60 predictive models for acute esophagus toxicity grade 
≥ 2.  
▲Figure 2: Calibration plot of the observed incidence of grade ≥2 Acute Esophagus Toxicity 
(AET) versus the predicted incidence of grade ≥2 Acute Esophagus Toxicity for the V50 model.
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  7▲Figure 3: Calibration plot of the observed incidence of grade ≥2 Acute Esophagus Toxicity (AET) versus the predicted incidence of grade ≥2 Acute Esophagus Toxicity for the V60 model.
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▲Figure 4: ROC-curve of the V50 and V60 predictive AET models grade ≥2 for time periods 
before and from June 2015. (AET = Acute Esophagus Toxicity)




This study illustrates that real world data (RWD), gathered from an electronic toxicity 
registration (ETR), is a useful method to audit NTCP-models. The showcase, used in 
this study, exemplifies that with the use of RWD, the accuracy of the AET prediction 
models were influenced by the dose de-escalation of the involved mediastinal lymph 
nodes for CCRT in NSCLC patients. 
The use of digital toxicity registration in electronic medical records is becoming 
more common practice in many radiotherapy departments. With this approach, a 
more systematic and accurate recording of radiotherapy toxicity can be achieved 
(6, 7). With regular adaptations in radiotherapy treatment schedules, techniques or 
prescription doses it is necessary to assure and maintain treatment quality. The use 
of RWD simplifies and accelerates quality assurance and provides tools to validate 
NTCP models in current clinical practice. Of course, (randomized) clinical trials remain 
a powerful method for developing scientific evidence. Nonetheless, RWD can be used 
to complement or audit the knowledge gained from traditional clinical trials, and 
provides additional insights on generalizability of RCT outcomes to the real world 
population. But to interpret this RWD right, it is important to use adequate analytic 
approaches to analyze the data and to use the right data-sources to collect the data 
(1).
AET is a common and severe toxicity of CCRT which has a negative influence on quality 
of life. Therefore, it is important to predict AET to mitigate the risk and to improve 
the therapeutic ratio of CCRT. The literature available on prediction models for AET 
and IMRT concluded that the high dose volumes are more important than the low 
dose volumes (14-19). In our previous work, the V50 was identified as an accurate 
predictor of AET for IMRT (16). In our hospital, the V50 is currently used as predictor 
for AET and dose constraint for the treatment planning.  The meta-analysis of Palma 
et al. (17) analyzed the data of 1082 patients and concluded that the V60 has the best 
predictive ability (3D-CRT and IMRT). In the guidelines for radical radiotherapy from 
the Advisory Committee on Radiation Oncology Practice (ACROP) of the European 
Society for Radiotherapy and Oncology (ESTRO), the V60 is advised as dosimetric 
parameter to predict AET (26). We therefore decided to audit both parameters. AUCs 
for both the V50-model and the V60-model showed a moderate accuracy.  Palma et 
al. found a lower AUC of 0.583 for the V60-model for grade ≥2 AET compared to ours 
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(AUC = 0.685 respectively). Our data is only IMRT based, and the dose heterogeneity 
due to IMRT, makes the higher dose parameters a better predictor for AET (14-18) 
compared to IMRT and 3D-CRT data in the study of Palma et al.(17). 
 A significantly lower median V60 dose on the esophagus was found after the dose 
de-escalation on the pathological lymph nodes. This resulted also in a significantly 
lower incidence of AET grade ≥2. With the de-escalation of the prescription dose 
from 66 Gy to 58.08 Gy (60 Gy EQD2) in 24 fractions on the mediastinum (i.e., the 
esophagus area), we found that the model accuracy of the V50-model was equivalent 
but the model accuracy of the V60-model was declined (AUC= 0.722 compared to an 
AUC = 0.624), p=0.09).  Qualitatively this can be understood by the realization that the 
dose parameter that predicts AET is basically the volume of the esophagus receiving 
a high dose and less related to the specific value of V60. With a dose prescription 
of 58 Gy, it is expected that the V60 correlates less well with this volume, leading to 
a decline in model performance. Therefore, the V50-model is more robust in our 
clinical practice. Since radiation techniques and prescriptions doses differ in time the 
use of EUD models to predict AET, might be less amendable for these changes, but 
are not widely used in clinical practice (18). 
We performed a sample test (N=77) to validate the quality of the electronic toxicity 
registration. This test showed a sensitivity of 83% and a specificity of 86% for the 
electronic registration of grade ≥2 AET. The compliance of the toxicity registration was 
73-80%. This means that there is missing data.  A limitation of this study is this missing 
data and that the sensitivity and specificity of <100% could have influenced the model 
accuracy. Comparison with the incidence of AET in the study of Van diessen et. al (22), 
similar incidences are found. This substantiate that RWD for ETR is reliable.  
To conclude, the use of real world data provides a useful method for quality assurance 
and for validation of NTCP-models in clinical practice. Both V50 and V60 NTCP-models 
showed moderate accuracy to predict acute oesophageal toxicity in NSCLC patients. 
For clinical practice, the V50Gy seems to be the most stable to the dose de-escalation 
and sensitive without compromising safety and efficacy. 




1. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World 
Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016;375(23):2293-7.
2. Network for Exellence in Health Innovation. Real world evidence: a new era for health care 
innovation September 2015 [Available from: http://www.nehi.net/writable/publication_
files/file/rwe_issue_brief_final.pdf.
3. Booth CM, Tannock IF. Randomised controlled trials and population-based observational 
research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551-5.
4. Salathe M, Bengtsson L, Bodnar TJ, Brewer DD, Brownstein JS, Buckee C, et al. Digital 
epidemiology. PLoS Comput Biol. 2012;8(7):e1002616.
5. Califf RM. Pragmatic clinical trials: Emerging challenges and new roles for statisticians. Clin 
Trials. 2016;13(5):471-7.
6. Akbarov A, Williams R, Brown B, Mamas M, Peek N, Buchan I, et al. A Two-stage Dynamic 
Model to Enable Updating of Clinical Risk Prediction from Longitudinal Health Record 
Data: Illustrated with Kidney Function. Stud Health Technol Inform. 2015;216:696-700.
7. Tamblyn R, Girard N, Dixon WG, Haas J, Bates DW, Sheppard T, et al. Pharmacosurveillance 
without borders: electronic health records in different countries can be used to address 
important methodological issues in estimating the risk of adverse events. J Clin Epidemiol. 
2016;77:101-11.
8. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative 
Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific 
issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9.
9. Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, et al. The 
lessons of QUANTEC: recommendations for reporting and gathering data on dose-
volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 2010;76(3 
Suppl):S155-60.
10. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of 
concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung 
cancer. J Clin Oncol. 2010;28(13):2181-90.
11. O’Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in 
non-small cell lung cancer. Cochrane Database Syst Rev. 2010(6):CD002140.
12. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and 
locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1-iv21.
13. Choy H, LaPorte K, Knill-Selby E, Mohr P, Shyr Y. Esophagitis in combined modality therapy 
for locally advanced non-small cell lung cancer. Semin Radiat Oncol. 1999;9(2 Suppl 1):90-
6.
14. Wijsman R, Dankers F, Troost EG, Hoffmann AL, van der Heijden EH, de Geus-Oei LF, et 
al. Multivariable normal-tissue complication modeling of acute esophageal toxicity in 
advanced stage non-small cell lung cancer patients treated with intensity-modulated 
(chemo-)radiotherapy. Radiother Oncol. 2015;117(1):49-54.
15. Gomez DR, Tucker SL, Martel MK, Mohan R, Balter PA, Lopez Guerra JL, et al. Predictors 
of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-
modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J 
Radiat Oncol Biol Phys. 2012;84(4):1010-6.
 Chapter 7
144
16. Kwint M, Uyterlinde W, Nijkamp J, Chen C, de Bois J, Sonke JJ, et al. Acute esophagus 
toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent 
chemotherapy. Int J Radiat Oncol Biol Phys. 2012;84(2):e223-8.
17. Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, et al. Predicting 
esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual 
patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87(4):690-6.
18. Nijkamp J, Rossi M, Lebesque J, Belderbos J, van den Heuvel M, Kwint M, et al. Relating 
acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy 
for locally advanced non-small cell lung cancer. Radiother Oncol. 2013;106(1):118-23.
19. Chen C, Uyterlinde W, Sonke JJ, de Bois J, van den Heuvel M, Belderbos J. Severe late 
esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. 
Radiother Oncol. 2013;108(2):337-41.
20. Rose J, Rodrigues G, Yaremko B, Lock M, D’Souza D. Systematic review of dose-volume 
parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol. 
2009;91(3):282-7.
21. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose 
versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin 
plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-
cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet 
Oncol. 2015;16(2):187-99.
22. van Diessen JNA, Kwint M, Sonke JJ, Walraven I, Stam B, de Langen AJ, et al. Safety and 
efficacy of reduced dose and margins to involved lymph node metastases in locally 
advanced NSCLC patients. Radiother Oncol. 2019.
23. Wolthaus JW, Schneider C, Sonke JJ, van Herk M, Belderbos JS, Rossi MM, et al. Mid-
ventilation CT scan construction from four-dimensional respiration-correlated CT 
scans for radiotherapy planning of lung cancer patients. Int J Radiat Oncol Biol Phys. 
2006;65(5):1560-71.
24. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating 
characteristic (ROC) curve. Radiology. 1982;143(1):29-36.
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or 
more correlated receiver operating characteristic curves: a nonparametric approach. 
Biometrics. 1988;44(3):837-45.
26. Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pottgen C, et al. ESTRO ACROP 
guidelines for target volume definition in the treatment of locally advanced non-small cell 
lung cancer. Radiother Oncol. 2018;127(1):1-5.
27. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and using 
sensitivity, specificity and predictive values. Indian J Ophthalmol. 2008;56(1):45-50.









General discussion and future perspectives 
Main findings and summary of results
The aim of this thesis was to explore strategies to optimize radiotherapy for 
locally advanced non-small cell lung cancer patients (LA-NSCLC). In the first part 
we investigated if a modified dose prescription resulted in improved treatment 
outcomes for LA-NSCLC (Chapter 2) and for oligo-metastasized treatment 
(Chapter 3). In the second part, optimization of the radiotherapy with the use of 
image guided radiotherapy (IGRT) was studied (Chapter 4 & 5). In the last part, 
normal tissue complication probability (NTCP) models for acute esophagus toxicity 
(AET) in radically treated LA-NSCLC patients were investigated (Chapter 6 & 7). 
In this final chapter, the findings of this thesis are discussed and recommendations 
for future research are presented.
Part I Dose prescription and patient selection
Optimization of radiotherapy by dose alteration
The standard treatment of LA-NSCLC is concurrent chemoradiotherapy (CCRT) (1). In 
patients without progression, adjuvant immunotherapy is administered afterwards 
and part of the current standard of care (2, 3). In the past, different treatment 
strategies have been tested to improve local control and overall survival (OS) for LA-
NSCLC patients. One of these strategies is dose escalation. Recently, an unexpected 
poor OS was associated with dose escalation in two randomized trials (RTOG 0617 
and the trial of Hallqvist et.al.) (4, 5). In those studies, dose-escalation with prolonged 
overall treatment time was given in the experimental arm (74 and 84 Gy versus 60 
Gy in 2 Gy). Other factors associated with poor OS in these studies were, tumor 
location, institution accrual volume, esophagitis, PTV and heart dose (V5). It has been 
suggested that the extended overall treatment time contributed to the poor OS in 
the experimental arm. Therefore, new interest is growing in dose-escalation using 
hypofractionation. In the Netherlands Cancer Institute, patients are treated with a 
mildly hypofractionated radiotherapy schedule of 24x2.75 Gy, combined with daily 
low dose Cisplatin, which is different from the international standard of 30x2 Gy 
and has been shown to have favorable outcomes compared to dose-escalation with 
extended treatment time (6-8).
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The incidence of regional failures (lymph node metastases) after radiotherapy for 
LA-NSCLC is generally lower than local failures (primary tumor), around 10% versus 
30% after 2 years (9-11). Tumor volume is a significant factor for predicting these 
regional and local failures (9). Since involved mediastinal lymph nodes have a smaller 
volume, compared to the primary tumor in the majority of patients, we hypothesized 
that the dose needed to control lymph node metastases might be lower than the 
dose needed to control the primary tumor. A consequence of a lower dose to the 
mediastinum might also induce an efficient reduction of the pulmonary, esophageal 
and cardiac toxicity rates.
In Chapter 2, an observational study of 308 locally advanced non-small cell lung 
cancer patients, compared 2 sequential cohorts, treated with a different radiation 
dose to involved mediastinal lymph nodes with or without concurrent or sequential 
chemotherapy. This study demonstrated that a differentiated dose prescription 
to the primary tumor (24x2.75 Gy) and the involved mediastinal lymph nodes 
(24x2.42 Gy), as well as a margin reduction of the primary tumor and lymph nodes, 
led to decreased radiotherapy induced pulmonary and esophageal toxicities and 
improved OS compared to the reference cohort (24x2.75 Gy to the primary tumor 
and lymph nodes). This study demonstrated that hypofractionated radiotherapy 
with a differentiated dose is a safe strategy with low toxicity risk and good OS (12). 
Recently, it was reported that the risk of heart disease in breast cancer patients, 
increased significantly within 5 years after treatment (13). Since the results of the 
RTOG 0617 (4), more awareness has arisen that heart dose is associated with a 
reduced OS in lung cancer patients. Lately, in a systematic review of Zhang et al. 
(14) it was concluded that 20 different cardiac dose-volume parameters were 
significantly associated with OS in NSCLC patients. However, no consistency in these 
heart dose volume parameters was found. We demonstrated that dose de-escalation 
to the mediastinal lymph nodes and PTV-margin reduction resulted in lower 
heart, esophageal and lung dose, reduced toxicities, and improved OS. To further 
enhance treatment outcomes, improvements of radiation dose distributions and/or 
escalation to the primary tumor are crucial. A potential approach which facilitates 
dose escalation to the primary tumor, while not exceeding the dose constraints of the 
organs at risk (OAR), is isotoxic treatment planning. This is a personalized treatment 
planning method in which the maximum achievable biologically effective dose (BED) 
to the tumor is given, until predefined dose constraints on the OAR are reached. 
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Several trials investigated dose escalation using such isotoxic planning strategy 
without extending the overall treatment time (15-19). An overview is given in Table 
1. The reported acute and late toxicity rates of these trials are classified ‘acceptable’. 
Altogether, these studies indicate that dose escalation with reduced overall treatment 
time by increasing the dose per fraction or twice daily irradiation, is a promising 
method.
Several (randomized) trials are ongoing in which isotoxic hypofractionated dose 
escalation with the use of an FDG-PET scan are investigated (16, 20-24). The results 
regarding treatment outcomes are pending. The phase II PET boost trial (NCT01024829) 
(21) toxicity outcomes were recently reported (22). In this international trial, LA-NSCLC 
patients were randomized between dose escalation to the entire primary tumor (arm 
A) or to the high FDG-uptake region inside the primary tumor (>50% SUVmax, arm 
B), whilst giving 66 Gy in 24 fractions to the involved lymph nodes. Grade≥3 toxicity 
were reported in 41% (acute) and 25% (late) of the patients. In 9 patients (8%) fatal 
pulmonary hemorrhages and esophageal fistulas were observed (22). This is a higher 
incidence compared to our cohort results (acute & late toxicity combined grade≥3 
was 29% and 10% for the reference- and reduction cohort respectively). In the PET 
boost trial, the same dose as our reference cohort (24x2.75 Gy) was given to the 
involved lymph nodes, however in patients selected with large primary tumors (> 4 
cm). Combining these findings we can conclude that a differentiated dose prescription 
to the involved lymph nodes combined with dose escalation to the primary tumor 
with restricted overall treatment time, is a promising option for further testing.
To summarize, many recent studies revealed that the paradigm ‘the higher the dose, 
the better the outcome’ is not always true. Caution is required in dose escalation trials 
especially when dose-escalation is combined with a prolonged overall treatment time. 
Currently, new strategies for dose escalation are investigated, such as personalized 
isotoxic planning. These promising strategies will hopefully lead to further improved 
local control without compromising the dose to organs at risk. 
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Patient selection for oligometastatic disease 
Patients with stage IV NSCLC are considered incurable and are mainly treated with 
a palliative intent (25). However, when a patient presents with a limited number of 
metastases (oligometastatic disease), a more radical treatment regime instead of 
palliative treatment may be beneficial with respect to PFS and/or OS (26-29).  Chapter 
3 describes the results of a retrospective cohort study of stage IV NSCLC patients 
(N=91) with ≤5 synchronous oligometastatic disease with a good performance 
status, who were treated with a radical treatment at the NKI (either with surgery or 
radiotherapy after systemic treatment). Favorable long-term PFS and OS (14 and 32 
months, respectively) was found in this selected group of patients, compared to stage 
IV NSCLC patients who were treated with palliative chemotherapy only (1-year OS of 
29% and a median OS of 6 months) (25).
Ideally, the benefits of a radical treatment for oligometastatic NSCLC are investigated 
within randomized phase III trials. Several randomized phase II trials showed 
improved treatment outcomes for an additional local consolidative treatment of 
the oligometastases compared to systemic treatment only as the standard of care 
(27-31). Two of these randomized studies were prematurely closed after interim 
analysis, due to a significant PFS benefit in the local consolidative therapy arm (27, 31). 
To learn more about the outcome of a radical local treatment for oligometastatic disease 
and the different states of oligometastatic disease, it is crucial that internationally, the 
same definitions are used. ESTRO and EORTC recently published a consensus report 
on the different states of oligometastatic disease (29). They distinguish 9 different 
states of oligometastatic disease as shown in Figure 1 (29). Consequently, the 
committee set up the OligoCare prospective multi-cohort trial with the aim to assess 
the prognostic value of the defined oligo states and the acceptance and compliance of 
these states within clinical practice (NCT03818503) (32). Besides uniform definitions 
of the different states of oligometastatic disease, another important knowledge gap 
is the number of metastases present to be considered for oligometastatic state. 
Currently, a maximum of 3-5 metastases is most often called oligometastatic disease 
(29, 33, 34). In our study, most patients had 1 metastasis (85%), with a maximum of 4 
metastases. The SABR-COMET study (28) was a randomized phase II study in which 99 
patients with a maximum of 5 synchronous metastases were randomized between 
either palliative standard of care or standard of care + SABR to all metastatic lesions. 
In this study, SABR was associated with improved OS compared to palliative care (me-
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▶Figure 1: Illustration of the oligometastatic disease classification system   
(A) De-novo oligometastatic disease. (B) Repeat oligometastatic disease. (C) Induced 
oligometastatic disease. In repeat and induced oligometastatic disease the primary tumor is 
assumed to be controlled by ongoing or previous treatment. Oligometastases are confirmed 
by imaging or biopsy to exclude simultaneous or secondary primary tumors. T0=at this current 
point of time. T-x=any previous point in time. (Figure from Guckenberger et al. (29) published with 
copyright permission of The Lancet Oncology)
dian OS: 41 months versus 28 months). However, only 18% of the included patients 
had NSCLC. Therefore, the impressive OS might be an overestimation for NSCLC 
patients, due to the overall better prognosis of prostate, colorectal and breast cancer 
patients compared to NSCLC. The outcome of the SABR-COMET study prompted 
the initiation of the randomized phase III study SABR-COMET-10 (NCT03721341) 
(35). This study is at the moment enrolling patients to assess the impact of SABR 
in patients with 4-10 metastatic lesions. Randomization is stratified by two factors: 
histology (Group 1: prostate, breast, or renal; Group 2: all others), and type of pre-
specified systemic therapy (Group 1: immunotherapy/targeted; Group 2: cytotoxic; 
Group 3: observation). Hopefully these results will contribute to answer the clinical 
relevant question if patients with ≥4 metastatic lesions are indicated and safe for 
ablative therapies (35). 
To conclude, consensus on the definition of oligometastatic disease is growing, but 
further research is necessary to investigate the association between the number of 
metastases, treatment options and overall survival in oligometastatic stage IV NSCLC 
patients.
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Part II Image Guided Radiotherapy
Image guided radiotherapy and adaptive radiotherapy
Nowadays, image guided radiotherapy (IGRT) using CBCT for position verification and 
dosimetric quality assurance, is widely adopted in radiotherapy departments around 
the world (36). Repeated CBCT’s made us aware of intra thoracic anatomical changes 
(ITAC) during the treatment course of lung cancer patients. In the Netherlands, 
CBCT’s are typically analyzed by radiation therapy technologists (RTTs); the radiation 
oncologist is informed only when a change is observed. It is important that the RTT 
knows how to act on these detected ITACs. Therefore, a practical decision support 
system: “the traffic-light protocol”, was developed in our institute to guide the RTT. 
Chapter 4 describes the quantity of ITACs during the course of a radical radiotherapy 
treatment for LA-NSCLC patients. The traffic-light protocol has three urgency levels: 
red (considerable impact on dose distribution), orange (moderate impact on dose 
distribution) and green (negligible impact on dose distribution). The traffic-light 
protocol was retrospectively applied to all CBCT-scans of 177 patients. In the majority 
of the patients (72%) ITAC’s were observed and 8% of the patients required a new 
planning CT-scan and an adapted treatment plan to account for anatomical changes. 
This study illustrated that ITACs indeed frequently occur and that it is important to 
have a practical decision support system in daily clinical practice to adequately react 
to these ITACs. Several studies reported on the dosimetric consequences of ITACs 
during treatment (37-39). A strategy to adjust for these ITACs is adaptive radiotherapy 
by performing a re-planning (40). Adaptive radiotherapy has the unique ability to 
prevent under dosing of the primary tumor or increased dose to the OARs when e.g. a 
tumor baseline shift or atelectasis occurs. Another advantage of adaptive radiotherapy 
is the possibility to reduce the dose to the OAR while maintaining the dose to the 
primary tumor after tumor regression is seen on a CBCT. This adaptive strategy raised 
the concern of local failure due to under dosing of microscopic disease in the new 
treatment plan. The LARTIA study (41) investigated the failure pattern of LA-NSCLC 
patients with an adaptive approach. A re-planning was performed in 50 out of 217 
patients (23%). The decision of re-planning was based on regression seen on weekly CT-
scans during treatment, visualized by 2 radiation oncologist, without a predetermined 
classification criteria. A local failure rate of 30% was reported (median follow-up of 
25.8 months) in this trial which is comparable to the 25%-40% local failure rate in 
published literature (4, 9, 42, 43). Local failures were in-field (20%), marginal (6%), and 
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out-of-field (4%), respectively. The low incidence (6%) of marginal failures in this trial, 
supports an adaptive radiotherapy strategy to adjust for primary tumor regression. 
In chapter 5 tumor volume regression during CCRT was investigated. In more than a 
third (35%) of the patients objective tumor regression during treatment was observed 
on CBCT. Three distinct subgroups of tumor volume change trajectories seen on a 
CBCT during CCRT for LA-NSCLC patients were identified in this study. Previously 
published studies indicated that tumor volume changes during treatment might 
be predictive for treatment outcomes (44-46). Surprisingly, no association between 
these subgroups and treatment outcome was found, whereas baseline volume of the 
primary tumor was significantly associated with OS. Our results were confirmed by 
the recent study of Amugongo et al. (47). Similarly to our study, 3 distinct subgroups 
of tumor volume change trajectories seen on CBCT were reported, but no significant 
association between these subgroups and OS was found. These findings demonstrate 
that tumor regression during treatment frequently occurs, and this has led to a new 
initiative in our institute, to analyze an adaptive radiotherapy re-planning approach 
based on tumor regression seen on the CBCT compared to non-adaptive radiotherapy 
for LA-NSCLC. This will be subject of future research in lung cancer patients irradiated 
with radical intent.
Part III Acute esophagus toxicity
NTCP-modelling of acute esophagus toxicity
As previously mentioned, for patients with LA-NSCLC, the treatment of choice is CCRT 
(1, 48, 49). The addition of chemotherapy provokes a radiosensitizing effect leading 
to improved local control and OS, compared to radiotherapy only or sequential 
chemoradiation. However, this comes at the cost of an increase of acute esophageal 
toxicity (AET) (50). In chapter 6, the V50 (volume of the esophagus receiving ≥50 Gy) 
was identified as an accurate predictor of AET with IMRT for NSCLC patients treated 
with CCRT. Nowadays, IMRT and Volumetric Modulated Arc Radiotherapy (VMAT) 
are commonly used techniques. These techniques have the ability to modulate the 
beam intensity during dose delivery, which leads to an increased dose conformality 
compared to 3DCRT (51, 52). In a retrospective study (N=188), a higher incidence of 
AET grade ≥2 was reported with VMAT compared to IMRT (51). This study also reported 
a not statistically significant higher rate of late pulmonary toxicity in VMAT patients. 
Since VMAT and IMRT have a different dose delivery and distribution, it is important 
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to verify and adjust the current 3DCRT-based NTCP-models for these new treatment 
techniques. A method to validate current NTCP-models is the use of real-world data. 
With the introduction of an electronic toxicity scoring registration (based on the 
CTCAE), a more systematic recording of treatment related toxicity was implemented 
at the NKI in 2012 (53, 54). In chapter 7, data from the electronic registration of AET 
was used to validate the applicability of real-world data for the NTCP-models for AET 
of CCRT for NSCLC-patients, for the 2 sequential cohorts as described in chapter 2. 
We found that real-world data is a useful method to audit NTCP-models in clinical 
practice. This model should ideally be tested in several institutions. To further optimize 
NTCP models, patient reported outcomes (PROs) can be used, since PROs have shown 
to be an useful complement to improve precision and accuracy when comparing 
these to clinician reported outcomes alone (55, 56). To conclude, due to continuous 
improvement of radiotherapy techniques and schedules, a constant update of NTCP-
models is crucial to adequately predict radiotherapy induced toxicities. The use of 
real-world data and PROs simplifies and accelerates quality assurance and provide 
tools to validate these NTCP-models. 
Future Perspectives
Adaptive radiotherapy and artificial intelligence 
The studies in chapter 4 and 5 showed that tumor regression is frequently seen 
during treatment on CBCT. As already described in a previous paragraph, adaptive 
radiotherapy is a promising approach to account for tumor volume regression 
and other intra thoracic anatomical changes during treatment. Currently, adaptive 
radiotherapy is a time-consuming strategy due to the manual clinical effort needed 
to produce an adaptive plan in a short time period. Besides, in current clinical 
practice, the decision to make an adapted plan usually relies on the decision of 
the radiation oncologist and physicist, which is inherently subjective (57). Adaptive 
radiotherapy may benefit from the advances of artificial intelligence (AI). With the use 
of AI, sophisticated predictive models can be developed with observational data by 
a computer. Then, these models can assess complex relationships between data. 
Automatic segmentation based on deep learning is an example of a frequently used 
application developed by AI in radiotherapy treatment planning with the use of the 
RT-planning CT. With automatic segmentation, the delineation of OAR is accelerated 
since it is done automatically instead of manually. Besides, it decreases inter- and 
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intra-observer variability (58). The challenge is to make this automatic segmentation 
suitable for CBCT’s, so that a new RT-planning CT is not mandatory to adapt 
radiotherapy treatment planning.  Moreover, the use of AI in automated treatment 
planning is rapidly developing (59), which enables the opportunity to implement 
adaptive radiotherapy in clinical practice in the broader radiotherapy community, 
since for some departments the time consuming (manually) procedure of re-planning 
is currently a limiting factor for routine clinical implementation.
The introduction of magnetic resonance-guided radiation therapy (MRgRT) enables 
the use of imaging with superior soft tissue contrast without the use of ionizing 
radiation. This allows real-time imaging of the tumor and OAR before and during 
treatment, and combined with an online-adaptive workflow, online adaptation of the 
RT-planning is possible (60-62). MR-guided online adaptive radiotherapy (MRgART) 
improves visualization for image guided and adaptive radiotherapy compared to the 
image quality of CBCT. Further research to develop AI techniques in IGRT and MRgRT 
should be embraced to improve efficiency of adaptive radiotherapy in daily clinic.
Prediction modelling and radiomics
TNM-staging is the cornerstone in the classification of lung cancer, based on 
comprehensive evidence from (randomized) clinical studies and observational data 
(63). However, there is still a considerable variation in the treatment response among 
patients with identical lung cancer stages. The search for new biomarkers to improve 
current prediction models for a better patient selection is therefore essential. In 
recent years, knowledge on tumor heterogeneity is increasing (64), both between 
and within tumors, urging the need for further developing treatment options that 
can operate on an individual level rather than on a population level. One of the 
new promising fields that uses this tumor heterogeneity in prediction modelling, 
is radiomics. Radiomics is a method that extracts large amounts of features from 
radiographic medical images using data-characterization algorithms. These features 
are subsequently correlated with tumor characteristics and/or prognostic endpoints 
using advanced machine learning algorithms to develop computational prediction 
models (65, 66). All lung cancer patients undergo medical imaging, especially CT-
imaging, subsequently making CT-based biomarkers attractive to optimize current 
prediction models for NSCLC-patients. Fornacon et al. (67) found 43 CT-image 
based articles in which the prognostic or predictive role of radiomics signatures in 
NSCLC-patients were described. The conclusion of this review was, that generally the 
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studies present a positive view of the potential for radiomics signatures to deliver 
personalized medicine. However, there are some limitations. The radiomics signatures 
associated with treatment outcome vary substantially between the different studies 
reported. There is not one specific radiomic signature identified to evaluate in larger 
multicenter studies. Besides, radiomics studies suffer from several technical and 
methodological limitation such as lack of biological and technical validation (67). This 
is illustrated by the external validation (68-70) of the radiomics signature of Aerts et 
al. (71). The subsequently performed study of Welch et al.(72) demonstrated that this 
radiomics signature was highly correlated with tumor volume rather than reflecting 
tumor heterogeneity. In recent years several studies on the limitation of radiomics 
studies were performed (67), and the awareness increases that standardization 
and transparency of technical and methodological aspects of radiomics studies are 
necessary to establish true progress in this research field. Finally, it is important that 
radiomics signatures are tested for clinical relevance at a multi institutional level. 
Incorporating radiomics signatures into clinical models, should improve the accuracy 
of these existing models for patients risk stratification. 
Radiotherapy and the immune system
How can we further optimize treatment outcome? The immune system has an 
important role in tumor response and treatment outcome. It is well established 
that radiotherapy can activate the immune system by different mechanisms 
like immunogenic cell death, leading to host immune responses as well as local 
inflammatory responses. This is illustrated by the abscopal effect of radiotherapy (73). 
Besides its immune activating effect, radiotherapy can also suppress the immune 
system (74). This is, amongst other mechanisms, explained by destruction of mature 
circulating lymphocytes in the blood-flow or lymphocytes in the tumor-draining 
lymph nodes. This cell type exhibits DNA fragmentation already at low doses of 
radiation (<1 Gy) (75). The heart and many large blood vessels are situated within the 
thoracic region, subsequently leading to irradiation of the blood flow (and thus with 
mature lymphocytes) during lung cancer irradiation. Several studies identified that 
lymphocyte count is associated with treatment outcome in different solid cancers 
including NSCLC (76-81). The study of Contreras (78) found a worse OS in patients 
with a neutrophil to lymphocyte ratio (NLR) >10.5, four months post radiotherapy. An 
expected association between heart dose and NLR >10.5 was found in multivariate 
analysis. This substantiates that larger radiation fields expose more circulating 
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lymphocytes and neutrophils to a radiation dose and that this plausibly leads to more 
immune suppression leading consecutive to a worse treatment outcome. In addition, 
larger radiation fields include more often lymph nodes, leading to an increased 
radiation dose to lymphocytes as well. The effect of larger thoracic radiation fields 
is illustrated for example by the study of Tang (82). Tang et al. reported that larger 
GTV’s were correlated with lower lymphocytes nadirs in NSCLC patients who were 
treated with definitive radiotherapy, regardless whether concurrent chemotherapy 
was administered. Moreover, a lower lymphocyte nadir and larger GTV volume were 
associated with worse OS in this study. These blood biomarkers (total lymphocyte 
count and neutrophil to lymphocyte ratio) have the advantage of being cheap and 
easily repeatable during treatment since they can be calculated using routine blood 
analysis. Since the first results are promising, ongoing research is needed to unravel 
the exact mechanism of immunosuppression during radiotherapy and to validate 
the value of lymphocyte count as predictive biomarker in LA-NSCLC. Hopefully in 
the future these blood biomarkers can refine current treatment outcome prediction 
models. 
Optimizing radiotherapy by adding immunotherapy
As described in the previous paragraph, radiotherapy could, besides suppress, also 
stimulate the immune system (73). This immune stimulating effect nourished the 
theory that the combination of radiotherapy and immunotherapy might improve 
treatment outcome. Pre-clinical evidence showed that radiotherapy up-regulates 
death ligand 1 (PD-L1) expression in tumor cells (83). Durvalumab is a selective, 
high affinity, human immunoglobulin-G1 (IgG1) monoclonal antibody that blocks 
programmed PD-L1 binding to programmed death 1 (PD-1)  and CD80, allowing T-cells 
to recognize and kill tumor cells (84). In the phase III Pacific study, randomization 
occurred between placebo and Durvalumab as consolidation therapy after CCRT in 
NSCLC patients (2, 3). Because of the improved OS and PFS in the Durvalumab-arm, 
Durvalumab is now standard of care after CCRT in responding patients. The results 
of the Pacific study generated new research questions and trials. One of these trials 
was the phase 1 study that addressed whether immunotherapy (Pembrolizumab) 
could be given concurrently with chemoradiation (85).  The trial concluded that it 
was tolerable (no dose limiting toxic-effects) with a promising PFS of 69.7% at 1 year. 
Pembrolizumab is another monoclonal antibody that blocks PD-1. The Pembro-trial 
(86) investigated the effect of stereotactic radiotherapy (SBRT) on the response to 
 Chapter 8
162
PD-1 blockade in patients with metastatic NSCLC by analyzing tumor response in 
non-irradiated lung cancer lesions. In this phase II study, metastatic NSCLC patients 
(unselected for PD-L1 status) with progression after chemotherapy, were randomized 
to receive treatment with Pembrolizumab, either after SBRT (3 x 8 Gy) to a single 
tumor site or without SBRT. Improvement of overall response was seen (18% vs 
36%, p <0.10) in the experimental arm. However, the results did not meet the study 
predefined endpoints for meaningful clinical benefit. Other trials (87, 88) reported that 
the response rate of Pembrolizumab is dependent on the PD-L1 expression levels of 
the tumor. Therefore, the PD-L1 negative subgroup is expected to have influenced 
the results of the Pembro-trial (86). A currently ongoing multicenter study examining 
the activity of immunotherapy (L19-IL2) and SBRT in metastatic NSCLC is the phase 
II ImmunoSABR study (89). The expected activity is a systemic immune response 
preventing disease progression and resulting in an improvement of PFS. The ability 
that SBRT in combination with immunotherapy might provoke a systemic immune 
response to improve PFS is auspicious. These studies illustrate that radiotherapy 
and immunotherapy are a very promising combination with the potential to further 
improve treatment outcome for lung cancer patients. 
Proton therapy and NTCP-modelling 
Predicting the risk of AET enables us to take appropriate precautions, such as 
individualized patient information, hydration, tube feeding or dietary guidance and 
supplements. Accurate NTCP-models will help to select the ideal patients who might 
benefit from novel radiotherapy techniques such as proton therapy (90, 91). A phase 
III study (92) randomizing between IMRT and passive scattering proton therapy 
(PSPT), reported a significantly lower mean heart dose in the PSPT-arm. However, 
no significant differences in the mean lung dose and mean esophagus dose were 
achieved. In spite of the similar mean lung dose, PSPT reduced the low-dose bath 
(lung V5-10), but exposed significantly larger volumes to higher doses (lung V20-80). The 
primary end points of this study were radiation pneumonitis grade 3 and local failure. 
No significant differences in grade 3 radiation pneumonitis (IMRT 6.5%; PSPT 10.5%, 
p=0.537) and in local failure was reported (IMRT 10.9%; PSPT 10.5%, p=1.0). Intensity 
Modulated Proton Therapy (IMPT) is a new and more advanced technique compared 
to PSPT. IMPT has the ability to deliver a more conformal dose to the tumor and 
spare the nearby organs at risk even more compared to PSPT. But this can make 
IMPT more sensitive for patient and tumor movements and anatomical changes. The 
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currently ongoing RTOG 1308 phase III trial has as primary objective to compare OS, 
lymphopenia and cardiac toxicity of LA-NSCLC patients, who are randomized between 
IMRT and proton beam therapy (93). Secondary endpoints of this trial are 2-year PFS, 
grade ≥3 adverse events, quality of life and cost effectiveness. In this trial IMPT and 
isotoxic dose escalation (60 to 70 Gy) are allowed. This is important, because the 
potentially improved local control of dosimetric advantages in the proton-arm due to 
dose escalation by OAR sparing can be assessed. Hopefully this trial will contribute to 
our knowledge on the clinical benefit of IMPT compared to the widely used IMRT. The 
use of NTCP-models supports personalized radiotherapy. For example in patients 
with a low toxicity risk, dose escalation can be applied, and patient with a high toxicity 
risk can be selected for more conformal radiation techniques such as IMPT. Because 
of the limited availability of proton therapy in the Netherlands and high costs, it is 
important to select those patients that will benefit the most from this treatment. 
Therefore, in the Netherlands a so called “model based approach” is implemented, to 
decide which lung cancer patients should be selected for proton therapy (91). In this 
approach, NTCP models of radiation pneumonitis, acute esophagitis and mortality 
are used to estimate what the expected difference (ΔNTCP) in complication risk is 
between photons and protons. If this comparison reveals a considerable decrease of 
this complication risk, proton therapy is indicated. These NTCP-models are based on 
photon radiotherapy data, hence validation with proton radiotherapy data is essential 
in the future. In summary, new radiotherapy techniques such as IMPT might lead to 
an improved sparing of OAR and are therefore potentially suitable for dose escalation 
with improved outcome for the patient. 
Conclusions
In the last decades big steps have been made in the treatment for LA-NSCLC. The 
studies presented in this thesis all contribute to the optimization of radiotherapy for 
LA-NSCLC patients to reduce toxicity while improving locoregional control. Several 
improvements in the personalized treatment of lung cancer patients are expected 
to be implemented within clinical practice in the coming years. Cooperation between 
different research areas such as pharmacology, biostatistics, artificial intelligence, 
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Over 13,000 patients are yearly diagnosed with lung cancer in the Netherlands. Surgery 
is treatment of choice, but only 20% of patients qualify for a curative resection. About 
25% of the patients are diagnosed with locally advanced non-small cell lung cancer 
(LA-NSCLC). The standard treatment of this stage is concurrent chemoradiotherapy 
(CCRT) with adjuvant immunotherapy in patients without progression after CCRT. This 
is an intensive treatment and associated with toxicities, such as dysphagia. Despite 
the curative intent of CCRT for LA-NSCLC patients, overall survival (OS) is still poor. 
More personalized treatment is needed, in which treatment outcomes can hopefully 
be improved and toxicity can be more accurately predicted and reduced. 
The purpose of this thesis was to evaluate strategies to improve the radiotherapy 
for LA-NSCLC patients. Focus was on different aspects of the treatment. The specific 
dose prescription for LA-NSCLC patients was optimized by differentiating the dose 
to the primary tumor and involved mediastinal lymph nodes to improve treatment 
outcome and to reduce toxicities. Further, the patient selection for the treatment of 
oligometastatic disease was analyzed. A clear and practical decision support system 
was introduced in the clinical practice to optimize the workflow for image guided 
radiotherapy with ConeBeam-CT (CBCT). Besides, the imaging data of tumor volume 
regression during treatment detected on CBCT was associated with treatment 
outcome. Finally, the normal tissue complication probability (NTCP) model to predict 
the risk of acute esophagus toxicity was optimized. 
Part I Dose prescription and patient selection
In the Netherlands Cancer Institute patients with LA-NSCLC are treated with a (mild) 
hypofractionated radiotherapy schedule (24x2.75 Gy) compared to a conventional 
schedule of 60 Gy in 30 fractions. This hypofractionated schedule shortens the 
overall treatment time from 6 till 5 weeks reducing tumor cell repopulation during 
the course of treatment. Recent studies showed that dose escalation with prolonged 
overall treatment time might lead to a worse overall survival (OS) and increased 
toxicity compared to the conventional scheme. Possible causes of this poorer OS 
are dose to the heart, extended overall treatment time and higher grade ≥3 toxicities 
(e.g. dysphagia). Concurrent chemoradiation for LA-NSCLC causes severe dysphagia 
due to the radiation dose to the mediastinal lymphadenopathy and the proximity of 
the esophagus. Previous research showed that the regional failure rate is lower than 
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local failure, due to the lower tumor volume of the involved mediastinal lymph nodes. 
Reducing the dose to the mediastinum might reduce these severe toxicity rates. Due to 
improved position verification methods with image guidance radiotherapy techniques, 
the margins for the primary tumor and involved lymph nodes were reduced in our 
institute, which can also decrease the toxicity. In chapter 2 an observational study is 
described where dose-reduction to the lymph nodes as well as a margin reduction in 
2 consecutive cohorts of LA-NSCLC patients treated with (chemo) radiotherapy were 
analyzed. The reference-cohort (N=170) received the same dose of 70 Gy (24x2.75Gy, 
EQD210) to the involved lymph nodes and primary tumor, while the reduction-cohort 
(N=138) received 24x2.42Gy (which is 60Gy; EQD210) to the involved lymph nodes. 
With 60 Gy instead of 70 Gy to the involved mediastinal lymph nodes, the acute grade 
3 dysphagia and grade 3 pulmonary toxicity decreased significantly from 12.9% to 
3.6% and 4.1% versus 0%, respectively. The regional failure rates were comparable. 
The median OS was significantly different: 26 months for the reference-cohort versus 
35 months for the dose reduction-cohort. The conclusions of this study were that a 
differentiated dose to primary tumour and lymph nodes using a hypofractionated 
regimen is a safe treatment strategy with very low toxicity for LA-NSCLC patients. 
Nowadays these inhomogeneous dose prescriptions for the primary tumor and 
lymph nodes, as well as the reduced margins due to the daily online CBCT position 
verification, are standard care in current clinical practice in the Netherlands Cancer 
Institute. 
In current practice patients with ≤ 5 metastases are considered as having 
oligometastatic disease. Evidence is growing that a radical treatment of the primary 
tumor as well all the metastases, leads to an improved progression free survival 
(PFS) and OS for these oligometastatic NSCLC patients. In chapter 3 the PFS and 
OS is described of a cohort study of 91 patients with synchronous oligometastatic 
NSCLC who were treated with a radical intent. The PFS of this cohort was 14 months 
and the OS 32 months. The 1- and 2-year OS rates were 85% and 58% and the 1- 
and 2-year PFS rates were 55% and 27%, respectively. The conclusion of this study 
was that a radical local treatment of a selected group of NSCLC patients with good 
performance status presenting with synchronous oligometastatic disease resulted in 
favorable long-term PFS and OS. In current clinical practice in our institute, patients 
with oligometastatic disease are discussed in a multidisciplinary tumor board, and 
when feasible, a radical treatment is advised. 
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Part II Image Guided Radiotherapy
The overall treatment time of concurrent chemoradiation is about 5 to 6 weeks. In 
radiotherapy, it is generally assumed that the anatomy of the patient is stable during 
this treatment course. However, during the 5-6 weeks course of lung radiotherapy 
several anatomical changes may occur, such as increasing/decreasing atelectasis, 
infiltrative changes, tumor progression or regression and pleural effusion. With the 
introduction of advanced image-guided systems like kilo voltage (kV) CBCT, we have 
the ability to visualize the tumor and organs at risk in three dimensions just before, 
during and/or after each fraction. These CBCT is primarily used to minimize target 
misalignment and setup error. In clinical practice repetitive CBCT’s during treatment 
have made us aware of intra thoracic anatomical changes (ITACs) during the course 
of a radical treatment. The aim of the study described in chapter 4 was to quantify 
the ITAC’s during the radiotherapy course. A total of 1500 CBCT’s of 177 patients were 
analyzed. Our decision support system: “the traffic-light protocol”, was retrospectively 
applied to all of these CBCT-scans. The traffic-light protocol has three urgency 
levels: red (considerable impact on dose distribution), orange (moderate impact on 
dose distribution) and green (negligible impact on dose distribution).  In 72% of the 
patients ITAC’s were observed with a maximum level of red, orange and green in 
12%, 36% and 24% respectively. Fourteen patients (8%) required a new planning CT-
scan and an adapted treatment plan to account for anatomical changes. Types of 
observed ITACs were, evident tumor regression (35%), considerable tumor baseline 
shift (27%), changes in atelectasis (19%), tumor progression (10%), pleural effusion 
(6%) and infiltrative changes (3%). This decision support system is currently used in 
our institute by the RTT’s who analyze the CBCT’s during treatment. 
Although concurrent chemoradiotherapy of NSCLC patients has a curative intent, OS 
remains poor. To distinguish between patients with better or worse OS, prediction 
models are used. Current prediction models mainly use baseline characteristics to 
predict treatment outcomes. An important step to improve these prediction models 
is to incorporate longitudinal data. The use of CBCT’s during treatment resulted in 
an increase of available imaging data of tumor volume change during radiotherapy 
treatment. The aim of the study in chapter 5 was to identify subgroups of LA-NSCLC 
patients showing tumor volume changes during CCRT and to investigate whether 
the identified subgroups are associated with treatment outcomes. In this study 
of 394 patients, 3 different subgroups of tumor volume change during treatment 
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were identified. Surprisingly, these subgroups did not differ in their risk of treatment 
outcomes, whereas baseline volume of the primary tumor was significantly associated 
with OS. Therefore, risk stratification at baseline might already be accurate enough in 
identifying the best treatment strategy for most patients. However, further research 
is needed to optimize current prediction models. 
Part III Acute esophagus toxicity
Intensity Modulated Radiotherapy (IMRT) results in a more conformal dose distribution 
leading to increased organ sparing compared to 3D-conformal-radiotherapy (3DCRT). 
The change of radiotherapy technique from 3D-CRT to IMRT can influence the 
accuracy of dose volume parameters to predict toxicity. In chapter 6 the dose-effect-
relation between acute esophageal toxicity (AET) and dose-volume-parameters of the 
esophagus after IMRT and concurrent chemotherapy in 139 NSCLC patients were 
investigated. The outcome was compared to the clinically (at that time in our institute) 
used esophagus V35 (volume of the esophagus receiving ≥35 Gy) prediction model 
for grade ≥2 after radical 3D-CRT treatment. The conclusion of this study was that 
the incidence of AET did not differ between patients treated with IMRT or 3D-CRT. 
The V50 (volume of the esophagus receiving ≥50 Gy) turned out to predict grade 
≥2 significantly better compared to the clinical V35-model. At present the V50 of 
the esophagus is used as planningsconstraint in clinical practice in the Netherlands 
Cancer Institute.
Data obtained from sources outside of randomized clinical trials are often referred 
to as ‘real world data’ (RWD). By introducing electronic toxicity registration within our 
institute, a more systematic and accurate recording of toxicity was implemented 
in clinical practice. The RWD collected from this electronic toxicity registration, can 
be used to audit normal tissue complication probability (NTCP) models. The dose 
reduction of the involved mediastinal lymph nodes as described in chapter 2 might 
have impact on the NTCP-model to predict AET. The aim of the study described in 
chapter 7 was to assess the validity of the RWD derived from the electronic toxicity 
registration and to show the feasibility of this registration to audit toxicity prediction 
models and dose constraints used in daily clinical practice. As a showcase, 2 NTCP-
models (V50 and V60; volume of the esophagus receiving ≥50 Gy and ≥60 Gy) of AET 
for CCRT for NSCLC patients were used to validate the electronic toxicity registration of 
AET before/after dose de-escalation of the prescribed dose to the mediastinal lymph 
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nodes (chapter 2). Data of 217 patients were analyzed. The conclusions of this study 
were that the use of real world data provides a useful method for quality assurance 
and for validation of NTCP-models in clinical practice. Both V50 and V60 NTCP-models 
showed moderate accuracy to predict acute esophageal toxicity in NSCLC patients. 
For clinical practice, the V50 seems to be the most stable dose volume parameter 
without compromising safety and efficacy after dose de-escalation. 




In Nederland worden jaarlijks meer dan 13000 patiënten gediagnosticeerd met 
longkanker. De voorkeursbehandeling voor longkanker is een operatie, echter in de 
praktijk komt slechts ongeveer 20% van de longkankerpatiënten in aanmerking voor 
een operatieve behandeling. Rond de 25% van de patiënten wordt gediagnosticeerd 
met een lokaal gevorderd niet kleincellige vorm van longkanker (LA-NSCLC). De 
standaardbehandeling voor dit stadium van ziekte is gelijktijdige chemotherapie en 
radiotherapie (chemoradiatie), met aansluitend immunotherapie indien de patiënt 
goed reageert op de gelijktijdige chemoradiatie. Dit is een hele intensieve behandeling 
die gepaard gaat met bijwerkingen zoals vermoeidheid en pijn met slikken (dysfagie). 
Hoewel het doel van deze behandeling genezing is, blijkt de overleving vaak slecht. 
Meer gepersonaliseerde zorg is nodig, waarbij bijwerkingen nauwkeuriger voorspeld 
kunnen worden en de behandeluitkomsten hopelijk verbeterd kunnen worden.
Het doel van het onderzoek, beschreven in dit proefschrift, was het evalueren van 
verschillende strategieën om de bestralingsbehandeling voor LA-NSCLC-patiënten te 
optimaliseren.
De nadruk lag op verschillende aspecten van deze behandeling. Het dosisvoorschrift 
voor de radiotherapie behandeling van LA-NSCLC-patiënten werd geoptimaliseerd 
door de dosis op de aangedane lymfeklieren en de primaire tumor te differentiëren 
teneinde de bijwerkingen te verminderen en de behandeluitkomst te verbeteren. 
Tevens werd de selectie voor patiënten met oligometastatische ziekte (beperkt aantal 
uitzaaiingen) die in aanmerking komen voor een radicale behandeling geanalyseerd. 
Om de werkwijze van beeld gestuurde radiotherapie met ConeBeam-CT (CBCT) te 
optimaliseren, werd er een praktisch en duidelijk beslissingsprotocol geïntroduceerd 
in de klinische praktijk. Daarnaast werd de beeldvormende data van tumor volume 
afname tijdens de behandeling, gedetecteerd op de CBCT, geassocieerd met 
behandeluitkomst. Als laatste werd het normale weefsel complicatie risico-model 
(normal tissue complication probability model: NTCP-model) voor radiatie oesophagitis 
(door bestraling geïnduceerde ontsteking van de slokdarm) geoptimaliseerd.
In hoofdstuk 1 is een algemene introductie van de epidemiologie, stadiering 
en behandeling van longkanker beschreven. Verder worden in dit hoofdstuk de 
verschillende onderwerpen van dit proefschrift uitgelegd; radiotherapie technieken, 




Deel I. Dosis voorschriften en patiënten selectie
In het Antoni van Leeuwenhoek ziekenhuis worden patiënten met LA-NSCLC behandeld 
met een mild gehypofractioneerd bestralingsschema (24x2.75 Gy), in vergelijking met 
het conventionele schema van 30x2 Gy. Dit gehypofractioneerde bestralingsschema 
verkort de totale behandelduur van 6 naar 5 weken. Uit recente studies kan worden 
opgemaakt dat dosis escalatie in combinatie met een verlengde behandelduur, 
mogelijk leidt tot een slechtere overleving en meer toxiciteit, in vergelijking met 
het conventionele schema. Mogelijke verklaringen voor dit overlevingsverschil zijn 
bestralingsdosis op het hart, verlenging van de behandelduur en meer ernstige 
bijwerkingen (zoals slikklachten). Gelijktijdige chemo- en radiotherapie voor LA-NSCLC 
kan ernstige slikklachten geven door een bestraling geïnduceerde ontsteking van het 
slijmvlies van de slokdarm. Dit is het gevolg van de bestralingsdosis op de aangedane 
lymfeklieren in het gebied tussen de longen (mediastinum) en de nabijheid van 
de slokdarm. Voorafgaand onderzoek heeft uitgewezen dat regionale (lymfklier) 
recidieven minder vaak voorkomen dan recidieven van de primaire tumor, doordat 
het tumor volume van deze lymfeklieren vaak kleiner is dan dat van de primaire 
tumor. Door de dosis op deze aangedane lymfeklieren in het mediastinum te 
verlagen, wordt de dosis op de slokdarm ook verlaagd en kan daarmee mogelijk het 
risico op deze slikklachten verminderd worden. Door verbeterde positie verificatie 
methoden met beeld gestuurde radiotherapie zijn recentelijk de bestralingsmarges 
voor de primaire tumor en de aangedane lymfeklieren verkleind in ons instituut. Deze 
marge verkleining kan ook zorgen voor afname van toxiciteit. In hoofdstuk 2 wordt 
een observationele studie beschreven waarin de dosis op de aangedane lymfeklieren 
is verlaagd alsmede de marges voor het planning-doelvolume (PTV) werden verkleind 
in 2 opeenvolgende cohorten voor LA-NSCLC-patiënten, die werden behandeld met 
(chemo)radiotherapie. Het referentie cohort (N=170) ontving dezelfde dosis van 
24x2.75Gy (70 Gy; EQD210) op de aangedane lymfeklieren en de primaire tumor, 
terwijl het dosis reductie cohort (N=138) 24x2.42Gy (60Gy; EQD210) ontving op de 
aangedane lymfeklieren. De graad 3 slikklachten en long bijwerkingen (hoesten, 
kortademigheid en bestralingslongontsteking) namen significant af in het dosis 
reductie cohort van 12.9% naar 3.6% en 4.1% naar 0%, respectievelijk. Het aantal 
regionale recidieven was vergelijkbaar. De mediane overleving was significant beter in 
het dosis reductie cohort; 26 maanden in het referentie cohort i.v.m. 35 maanden in het 
dosis reductie cohort. De conclusie van deze studie was dat een dosis reductie op de 
aangedane lymfeklieren met een gehypofractioneerd bestralingsschema veilig is met 
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beperkte toxiciteit voor LA-NSCLC-patiënten. Tegenwoordig is dit gedifferentieerde 
dosisschema voor de primaire tumor en lymfeklieren, de standaardbehandeling in 
het Antoni van Leeuwenhoek ziekenhuis. 
In de huidige klinische praktijk worden patiënten met ≤ 5 uitzaaiingen beschouwd als 
oligometastatische ziekte. Er komt steeds meer bewijs dat een radicale behandeling 
van de primaire tumor en alle uitzaaiingen een betere ziektevrije overleving en 
betere overleving geven voor deze oligo-gemetastaseerde NSCLC-patiënten. In 
hoofdstuk 3 worden de resultaten van een cohortstudie van 91 patiënten met 
oligo-gemetastaseerd NSCLC  beschreven. In deze studie is de ziektevrije overleving 
en totale overleving geanalyseerd van patiënten die met een radicale intentie zijn 
behandeld. De ziektevrije overleving van dit cohort was 14 maanden en de totale 
overleving was 32 maanden. De 1- en 2-jaar overleving was 85% en 58% en de 1- 
en 2-jaar ziektevrije overleving was 55% en 27%. De conclusie van deze studie was 
dat een radicale behandeling in een selecte groep van NSCLC  patiënten met een 
goede conditie en die zich presenteren met synchrone oligometastatische ziekte een 
gunstige ziektevrije overleving en totale overleving geeft. In de huidige klinische praktijk 
worden in ons instituut patiënten met oligo-gemetastaseerde ziekte besproken in 
een multidisciplinair overleg en wordt, wanneer haalbaar, een radicale behandeling 
geadviseerd. 
Deel II. Beeld gestuurde radiotherapie 
De behandelduur van gelijktijdige chemoradiatie ligt gemiddeld tussen de 5 en 6 
weken. In het algemeen wordt aangenomen dat de anatomie van de patiënt niet 
verandert gedurende deze behandelperiode. Regelmatig treden er tijdens deze 
5-6 weken van behandeling toch anatomische veranderingen op, zoals toename/
afname van atelectase, infiltratieve veranderingen, pleuravocht, tumorgroei of juist 
tumorafname. Met de komst van geavanceerde beeld gestuurde technieken zoals 
kilo voltage (KV) ConeBeam computer tomografie (CBCT), werd het mogelijk om de 
tumor en de organen rondom de tumor in beeld te brengen in 3 dimensies vlak voor, 
tijdens en/of na elke bestralingsfractie. Het primaire doel van deze CBCT is om de 
inwendige positie van de tumor te controleren en zo nodig de patiënt positie hierop 
aan te passen. In de praktijk zorgden deze herhaaldelijke CBCT’s er tevens voor 
dat meer anatomische intra thoracale veranderingen werden geobserveerd (intra 
thoracic anatomical changes = ITAC) tijdens de bestralingsbehandeling. Het doel van 
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de studie, beschreven in hoofdstuk 4 was om te kwantificeren hoe vaak deze ITAC’s 
plaatsvinden tijdens de bestralingsbehandeling. In totaal werden 1500 CBCT’s van 177 
patiënten beoordeeld. Het beslissingsprotocol van ons instituut ‘het Stoplichtprotocol’, 
werd retrospectief toegepast op al deze CBCT’s. Dit stoplichtprotocol heeft 3 niveaus: 
rood (grote invloed op dosisverdeling), oranje (matige invloed op dosisverdeling) en 
groen (verwaarloosbare invloed op dosisverdeling). In 72% van de patiënten werd 
een ITAC geobserveerd, met een maximaal niveau van rood, oranje of groen in 
respectievelijk 12%, 36% en 24% van de gevallen. Veertien patiënten (8%) hadden een 
nieuwe planningsCT en een aangepast bestralingsplan nodig om te corrigeren voor 
deze anatomische veranderingen. De verschillende ITAC’s die werden waargenomen 
zijn: evidente tumor afname (35%), tumor baseline shift (27%), veranderingen in 
atelectase (19%), tumor progressie (10%), pleuravocht (6%) en ontstekingsbeeld 
(3%). Dit stoplichtprotocol wordt momenteel in de klinische praktijk gebruikt in ons 
instituut door de radiotherapeutisch laboranten die de CBCT beoordelen tijdens de 
bestralingsbehandeling. 
Hoewel het doel van gelijktijdige chemoradiotherapie voor NSCLC-patiënten genezing 
is, blijft de overleving slecht. Om onderscheid te kunnen maken tussen patiënten 
met betere of slechtere overleving, worden predictiemodellen gebruikt. De huidige 
predictiemodellen gebruiken hoofdzakelijk tumor- en patiënt-karakteristieken voor 
start van de behandeling om behandeluitkomsten te voorspellen. Een belangrijke 
stap voorwaarts om deze modellen te verbeteren, is het hierbij betrekken van 
longitudinale data. Het gebruik van CBCT’s tijdens de behandeling heeft geleid tot 
een enorme toename van beeldvorming van tumorvolume veranderingen tijdens 
de bestralingsbehandeling. Het doel van de studie beschreven in hoofdstuk 5 
was om subgroepen van LA-NSCLC-patiënten te identificeren die tumorvolume 
veranderingen tijdens gelijktijdige chemoradiotherapie lieten zien, en vervolgens te 
analyseren of deze subgroepen geassocieerd zijn met behandeluitkomsten. In deze 
studie van 394 patiënten, werden drie verschillende subgroepen van tumorvolume 
veranderingen geïdentificeerd. Er bleek geen significant verschil in behandeluitkomst 
te bestaan tussen deze groepen. Het tumorvolume bij start van de behandeling 
was wel significant voorspellend voor een slechtere overleving. Derhalve is risico 
stratificatie bij start van behandeling mogelijk al nauwkeurig genoeg om voor de 
meeste patiënten de beste behandelstrategie te bepalen. Het is evident dat verder 
onderzoek nodig is om de huidige predictiemodellen verder te verbeteren.
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Deel III. Acute slokdarm toxiciteit
Intensiteit gemoduleerde radiotherapie (IMRT) zorgt voor een meer conformele 
dosis verdeling en daardoor betere sparing van gezonde organen in vergelijking 
met 3D conformele radiotherapie (3D-CRT). Door de verandering van radiotherapie 
techniek van 3D-CRT naar IMRT kunnen de dosis volume parameters die het risico 
op bijwerkingen voorspellen, beïnvloed worden. In hoofdstuk 6 werd onderzocht 
wat de dosis effect relatie is voor acute slokdarm toxiciteit bij IMRT in 139 LA-NSCLC-
patiënten die behandeld werden met gelijktijdige chemoradiotherapie. De uitkomst 
werd vergeleken met het (op dat moment) in de kliniek gebruikte V35 predictie model 
van de slokdarm (volume van de slokdarm dat ≥35 Gy ontvangt) om graad ≥2 acute 
slokdarm toxiciteit te kunnen voorspellen met radicale radiotherapie middels 3D-CRT. 
De conclusie van deze studie was, dat de incidentie van acute slokdarm bijwerkingen 
niet verschilde tussen patiënten die behandeld waren met IMRT of 3D-CRT. De 
V50 (volume van de slokdarm dat ≥50 Gy ontvangt) bleek de beste dosimetrische 
voorspeller voor graad ≥3 acute slokdarm toxiciteit. Het V50 model was significant 
beter om graad ≥2 acute slokdarm toxiciteit te voorspellen dan het oude V35 model. 
Momenteel wordt het V50-model van de slokdarm gebruikt als planningsrestrictie in 
het Antoni van Leeuwenhoek ziekenhuis. 
Data die niet uit gerandomiseerde studies afkomstig zijn, worden regelmatig 
geclassificeerd als ‘real world data’ (RWD). Door de introductie van het elektronische 
patiëntendossier in ons instituut, werd een nauwkeuriger en meer systematische 
manier van toxiciteitregistratie geïmplementeerd in de klinische praktijk. De RWD 
verkregen uit deze registratie, kunnen gebruikt worden voor het valideren van NTCP-
modellen. De dosis reductie zoals beschreven in hoofdstuk 2 voor de behandeling 
van NSCLC-patiënten, kan de NTCP-modellen voor acute slokdarm toxiciteit hebben 
beïnvloed. Het doel van de studie in hoofdstuk 7 was om te toetsen of de RWD, 
verkregen uit de elektronische toxiciteit registratie, gebruikt kunnen worden om 
NTCP-modellen te toetsen die in de dagelijkse klinische praktijk worden gebruikt. Als 
een showcase werd het NTCP-model voor acute slokdarm toxiciteit bij gelijktijdige 
chemoradiatie voor NSCLC-patiënten gebruikt om de validiteit van de elektronische 
toxiciteit registratie van acute slokdarm toxiciteit voor/na de de-escalatie van de 
radiotherapie dosis op de aangedane lymfeklieren (hoofdstuk 2) te analyseren. In 
deze studie werden data van 217 patiënten geanalyseerd. De conclusie van deze studie 
was dat het gebruik van RWD een geschikte methode is voor kwaliteitsdoeleinden en 
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voor validatie van NTCP-modellen in de klinische praktijk. Zowel de V50 als de V60 
(volume van de slokdarm dat ≥50 Gy en ≥60 Gy ontvangt) NTCP-modellen lieten een 
redelijke nauwkeurigheid zien om acute slokdarm toxiciteit te voorspellen in NSCLC-
patiënten. Voor de klinische praktijk kwam de V50 er als meest robuuste voorspeller 
uit na de dosis de-escalatie.
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Ja, en dan nu het dankwoord, het hoofdstuk van het proefschrift dat het meest 
gelezen wordt. Dit proefschrift was nooit tot stand gekomen zonder de hulp van velen. 
Graag wil ik iedereen die indirect of direct heeft bijgedragen aan het volbrengen van 
dit proefschrift heel erg bedanken. Een aantal mensen wil ik graag in het bijzonder 
bedanken.
Alle onderzoeken in dit proefschrift zijn gebaseerd op gegevens van patiënten. Ik wil 
alle patiënten heel erg bedanken voor het geven van toestemming voor het gebruik 
van de behandelgegevens. Zonder deze gegevens is er geen onderzoek mogelijk.
Mijn promotoren, prof dr. Verheij en prof. dr. Ir. Sonke. 
Beste Marcel, doordat jij als hoofd van de afdeling het aandurfde om als een van de 
eerste radiotherapie afdelingen in Nederland met PA’s te starten kreeg ik daarmee de 
kans om mijzelf verder te ontwikkelen binnen het AvL. Daarnaast wil ik je bedanken 
dat je mij de kans hebt gegeven om een PhD-traject te starten gecombineerd met 
patiënten zorg, zodat ik mij als onderzoeker verder kon ontwikkelen.
Beste Jan-Jakob, jou wil ik ook bedanken voor het geven van de mogelijkheid om een 
PhD-traject te starten. Daarnaast vond ik de research overleggen en commentaren 
op mijn manuscripten altijd erg leerzaam en inspirerend door jouw precieze blik. Dit 
heeft zeker bijgedragen aan mijn persoonlijke ontwikkeling als onderzoeker. 
Mijn co-promotoren, dr. Belderbos en dr. Walraven, 
Lieve Jose, in 2007 kwam in onder jouw vleugels terecht als PA. Jij hebt mij de klinische 
kant van het vak geleerd. Maar ook kwam ik via jou in aanraking met het doen van 
onderzoek. Het moment dat mijn afstudeeronderzoek een ‘oral’ presentatie werd op 
een internationaal congres, was achteraf gezien nog maar het begin. Ik vond dat toen 
hartstikke spannend maar ook heel erg leuk. Ik wil je heel erg bedanken voor het 
vertrouwen dat je in mij hebt en alle mogelijkheden die je me hebt gegeven. 
Lieve Iris, nadat onze emigratie naar Zuid-Afrika toch niet door ging, ben jij 
epidemioloog geworden en ik PA. In 2015 kwam je weer terug in het AvL. En i.p.v. 
gesprekken over de uitspraak van Digestives op B1, gingen onze gesprekken nu vaak 
over onderzoek. Ik wil je bedanken voor de inspiratie die je hebt gegeven, waardoor 
we onder andere op R-vontuur gingen in Bordeaux om ons in LCMM te verdiepen. 
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Daarnaast heeft jouw goede kritische blik en begeleiding gezorgd dat ik veel geleerd 
heb. 
Geachte leden van promotiecommissie, prof.dr. Slotman,  prof.dr. Guckenberger, 
prof.dr. Bussink, prof.dr. Dingemans, prof.dr. Hoogeman, dr De Langen, dr. Peulen 
bedankt voor het beoordelen van mijn proefschrift. Thank you very much for assessing 
my dissertation. 
Graag wil ik alle coauteurs danken voor hun waardevolle bijdragen aan de verschillende 
manuscripten. 
Beste collega’s van de afdeling radiotherapie; laboranten, afsprakenbureau, 
doktersassistenten, moulagemedewerkers, secretariaat, studie-ondersteuners, trial 
medewerkers, radiotherapeuten AIOS, fysica, PA’s en alle overige medewerkers 
zonder jullie hadden we nooit alle data voor deze onderzoeken kunnen verzamelen. 
Door Corona spreken we elkaar allemaal wat minder op de werkvloer, maar wil ik 
graag toch de collegiale en prettige samenwerking met iedereen even benoemen. 
De long research groep: Thanks everyone for the weekly meetings, in which we helped 
each other when we were stuck or needed motivation. 
Maddalena, met jouw enorme energie en secure werkwijze ben jij een rots in de 
branding van de long research groep. Maar daarnaast ben je ook een hele fijne 
collega en heb ik genoten tijdens onze hike in Zwitserland. 
Barbara, als ik advies nodig had kon ik altijd bij jou terecht om even te sparren. En 
dankzij jouw is Fogo de Chao nu een van mijn favoriete restaurants.
Beste collega’s van het longteam (Joost, Rick, Judi, Jose, Renske, Monique en Saar), 
ik ben blij in zo’n fijn team te werken. Jullie wisten gelukkig af en toe op mijn rem 
te trappen als ik te veel hooi op mijn vork nam met de combinatie van een 
tweelingzwangerschap, promoveren en kliniek. Als team staan we voor elkaar klaar 
en daarnaast is gezelligheid ook belangrijk. 
Lieve Heike, ik mis nog steeds jouw lach hier door de gangen van AvL. Helaas woon je 
nu wat verder weg dat we elkaar niet meer zo vaak spreken. We moeten post-Corona 
maar weer een congres afstemmen zodat we weer in een Cabrio kunnen cruisen of 
van Kaiseki kunnen genieten. 
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Lieve Judi, jij bent een hele fijne collega, die altijd goed de rust weet te bewaren. 
En daarnaast is het altijd leuk en gezellig om samen op culinaire ontdekkingstocht 
in Amsterdam te gaan. Geniet van je Indonesië avontuur maar zodra je terug bent 
kiezen we weer een goed restaurant uit om bij te kletsen.
Graag wil alle longartsen, thoraxchirurgen, radiologen, nucleair geneeskundigen, 
pathologen en verpleegkundig specialisten binnen de thorax oncologie werkgroep 
van het AvL bedanken voor de prettige samenwerking. Behalve samenwerking op het 
gebied van longkanker en onderzoek, komen de tweeling adviezen van Wieneke en 
Wanda ook goed van pas.
Lieve Wilma, hoeveel presentaties hebben we wel niet samen gegeven over CCRT. 
Dat jij een PhD ging doen was zeker een inspiratie voor mij. Ik vind het nog steeds 
jammer dat we niet meer samenwerken, maar gelukkig kom ik je nog af en toe in de 
gangen tegen. 
Robin, samen zijn we in 2007 het PA-avontuur begonnen. Ik denk dat we mogen 
terugkijken op een geslaagd avontuur waarbij de ontdekking van de CheeseCake 
Factory ook zeker een hoogte punt was.
Lieve PA’s (Robin, Barry, Sandra, Marcel, Gerbert, Corine, Hester en Cherita), ik ben 
heel dankbaar met jullie als PA-collega’s. Een nieuwe functie en taakherschikking in 
de zorg is niet altijd even makkelijk, maar als PA-team weten we elkaar hierin elkaar te 
ondersteunen en motiveren. Daarnaast is het ook heel gezellig nu we met zijn allen 
(Corona-proof) op een kamer zitten. 
Pink Ladies (Lilian, Marieke, Jeanette, Kati, Sabrina, Mariëlle, Margarita, Jitske, Linda 
en Viviënne) ondanks dat we (bijna) allemaal niet meer basketballen blijven we een 
hecht team. En zijn we naast basketballen nog beter in gezelligheid. Dit heeft geregeld 
gezorgd voor hilarische momenten en de nodige ontspanning.
Lieve sportvrienden, gelukkig kon ik bij jullie mijn passie voor sport en mijn energie 
kwijt.Phanos loopmaatjes (Gerard, Gadiza, Ritsert, Cindy, Kim, Sybren, Tjalling, Lieke, 
Lisa en Patricia) de ontelbare rondjes op de baan zorgden na een drukke werkdag vaak 
voor de broodnodige ontspanning. Maar ook van de duurloopjes en wielrenrondjes 
kan ik altijd erg genieten. Wanneer staat de volgende marathon op de planning? 
(gezien ik nu weer meer tijd heb ⅔ )
Evert, je woont nu ook niet meer om de hoek maar we dan moeten we de provincie 
Utrecht maar eens op de racefiets verkennen (of met de bakfiets).
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Lieve vrienden, ook al kan ik door onze drukke levens jullie niet altijd zo vaak zien als 
ik zou willen. 
Angela en Goziëm, de gezellige etentjes houden we erin, inclusief de beruchte 
whiskyfles aan het einde. 
Lydia, inmiddels allang geen huisgenootjes meer, en nu ook geen stadsgenootjes 
meer. Maar als ik je weer zie kletsen we gewoon weer verder. 
Linda en Mariette, na de Corona toestand moeten we echt een vakantie in Andalusië 
plannen!
Judith, via Mom in Balance bleken we dezelfde passie voor hardlopen te delen, en het 
is ook prachtig om te zien hoe onze kinderen samen spelen en de wereld ontdekken.
Lieve Iris, Lilian, Annikki en Pip, bedankt voor alle broodnodige afleiding. Gelukkig is 
Haarlem om de hoek en lukt het nog regelmatig om spontane borrels/etentjes in te 
plannen. 
Lieve schoonfamilie (Marelva, Gilbert, Yuli en Luis), dank jullie wel voor jullie interesse 
en steun en natuurlijk ook voor alle oppasuurtjes.
Jessica en Chris, wat toevallig allebei tegelijk een eeneiige tweeling, superfijn om met 
jullie dit avontuur te delen. 
Lieve Eva, jij bent een aanwinst voor onze familie, op naar een mooie toekomst samen!
Lieve Sander en Wellington, door dezelfde combi van business en medisch is het 
altijd vruchtbaar om met jullie te sparren over onze en jullie toekomstplannen. Nu 
jullie nieuwe huis en mijn proefschrift eindelijk af zijn, komen we vaker richting het 
‘Grunnens Laand’ om van jullie kookkunsten en rust daar te genieten. 
Lieve pap en mam, dank voor jullie onvoorwaardelijke liefde. Mijn onbezorgde jeugd 
heeft gezorgd dat ik nu ben wie ik ben. Jullie steun was de afgelopen jaren onmisbaar, 
bedankt voor alle op en neertjes Assen – Amsterdam.
Lindo, mijn allerliefste, samen staan we sterk. Door jou positieve en opportunistische 
levensstijl denk jij altijd in mogelijkheden. Met Norah en Elaine is ons gezin compleet 
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